Chimeric glycoproteins and pseudotyped lentiviral vectors

ABSTRACT

A method is provided for producing a recombinant pseudotyped viral vector particle wherein a cell is transfecting with (i) at least one vector construct; (ii) at least one packaging construct; and (iii) an expression construct encoding a chimeric glycoprotein encoded by a nucleic acid comprising the sequence of SEQ ID NO: 1 to yield a producer cell, followed by culturing the producer cell in a medium; and separating the producer cell from the medium to recover the recombinant viral vector particle from the medium. Vectors obtained in this manner have significantly higher titers than vectors coated with the parental non-chimeric glycoprotein.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of U.S. application Ser.No. 10/512,474, having a filing date of Mar. 9, 2006, which is a 371application of PCT/IB03/01597, filed Apr. 25, 2003, which claimed thebenefit of U.S. Provisional Application No. 60/375,654, filed Apr. 26,2002, all of said applications hereby incorporated by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to chimeric glycoproteins and improvedlentiviral vectors pseudotyped with those glycoproteins, methods andcompositions for making such glycoproteins and vectors, and methods ofin vitro and in vivo transduction of cells with such vectors. Theimproved compositions and vectors are of particular utility for in vivogene transfer applications.

2. Description of Related Art

Vectors derived from retroviruses offer particularly flexible propertiesin gene transfer applications given the numerous possible associationsof various viral surface glycoproteins (determining cell tropism) withdifferent types of viral cores (determining genome replication andintegration)¹. For example, association of the VSN-G glycoprotein withviral cores derived from lentiviruses results in vector pseudotypes thathave broad tropism and can integrate into non-prohferatmg target cells².They have proved useful for the transduction of several cell types exvivo and in vivo³⁻⁷. Yet there is considerable interest in exploring theproperties of lentiviral vectors pseudotyped with alternative viralglycoproteins⁸⁻¹⁵. This parameter is likely to modulate thephysico-chemical properties of the vectors, their interaction with thehost immune system and their host-range. Several studies have indeedshown that the transduction efficiency of target cells is dependent onthe type of glycoprotein used to coat retroviral vectors¹⁶⁻²¹.Additionally, some in vivo gene transfer applications will requirevectors that are targeted for specific cell entry and/or gene expressionafter systemic administration²². Due to the wide distribution of itsreceptor, a lipid component of the plasma membrane²³, NSN-G pseudotypesmay bind to the surface of all cells encountered after inoculationbefore reaching the target cells. Moreover, NSV-G-pseudotyped vectorsare rapidly inactivated by human serum²⁴ and this might impose alimitation on the use of NSN-G as a glycoprotein to pseudotype vectorsfor systemic gene delivery.

Lentiviral vectors derived from simian immunodeficiency virus (SIV) havebeen generated in several laboratories¹, including our own²⁵.Characterization of these vectors has indicated that they are similar tothose derived from human immunodeficiency virus (HIV-1) with respect tothe insertion of trans genes in non-proliferating cells, although SIVvectors perform better than HTV-1 vectors in simian cells²⁵.

SUMMARY OF THE INVENTION

The present invention is directed to chimeric and mutant glycoproteinsfor use in making pseudotyped viral vector particles. In particularembodiments, the chimeric glycoprotein comprises a cytoplasmic taildomain derived from MLV-A and a transmembrane and extracellular domainderived from feline endogenous virus RD114.

In additional embodiments, the glycoproteins incorporate minimalmodifications that allow efficient pseudotype formation withlentivirus-based vectors. Specific embodiments include glycoproteinscomprising cleavage sites within the cytoplasmic tail domain compatiblewith the retroviral core protease of the retroviral vector that is to bepseudotyped with the altered glycoprotein. In particular embodiments,modifications are introduced into a stretch of 8 amino-acids, whichencompass a substrate for the viral core protease and whose cleavage iscritical for the fusogenicity of the viral glycoprotein. Thesemodifications allow pseudotyping with either oncoretro viral or withdifferent lentiviral cores.

In conjunction with these embodiments, a further embodiment of theinvention is a method for matching the amino acid sequence of thecytoplasmic tail of chimeric and mutant glycoproteins with the proteasesof retroviral cores, resulting in dramatically improved glycoproteinassembly on those cores.

The invention also encompasses nucleic acid constructs encoding suchglycoproteins. In a preferred embodiment, the nucleic acid comprises thesequence of SEQ ID NO: 1. In additional aspect, the construct is anexpression construct suitable for expression the glycoproteins such thatthey are incorporated into recombinant viral vector particles. In anadditional aspect, the invention comprises a cell transfected with suchnucleic acid constructs.

One embodiment of the invention comprises a vector particle comprising achimeric glycoprotein wherein the chimeric glycoprotein comprises acytoplasmic tail domain derived from MLV-A and a transmembrane andextracellular domain derived from feline endogenous virus RD114. In anadditional aspect, the vector particle is a pseudotyped vector particle.In a further aspect, the vector particle further comprises a recombinantviral vector construct.

In another embodiment, the vector particle comprises a vector constructwherein the vector construct is derived from a retrovirus or lentivirus.In one aspect, the vector construct is derived from SIV or HIV.

In another embodiment the vector particle comprises a vector construct,which further comprises a transgene. In one aspect, the transgene is amarker or reporter gene. In a particular embodiment, the transgene is agreen fluorescent protein (GFP). In another aspect, the transgene is atherapeutic gene. In particular embodiments, the transgene is anoncogene or a protooncogene. In another particular embodiment, thetransgene is a drug susceptibilty gene.

An additional embodiment of the present invention is a method oftransducing cells comprising:

a) obtaining cells to be transduced;

b) obtaining a pseudotyped vector particle in accordance with claim 8,and

c) contacting the cells with the vector particle of (b) under conditionssufficient to result in transduction. In an additional embodiment, themethod further comprises the step of providing retronectin in an amountsufficient to enhance transduction. In one aspect of the method thecells are transduced in vitro. In another, the cells are transduced invivo. In further embodiment s, the cells are vertebrate cells, primatecells, or human cells. The cells are also contemplated to be CD34+ orPBL cells. Another embodiment of the method encompasses a celltransduced by the method.

Yet another embodiment is a method for producing a recombinantpseudotyped viral vector particle comprising:

(a) transfecting a cell with:

(i) at least one vector construct;

(ii) at least one packaging construct; and

(iii) an expression construct encoding a chimeric glycoprotein of claim1 to yield a producer cell;

(c) culturing the producer cell in a medium; and

(d) separating the producer cell from the medium to recover therecombinant viral vector particle from the medium.

Another embodiment comprises contacting the cell with a vector particlemade in accordance with the methods of the invention and underconditions to effect the transduction of the cell by the recombinantvector. The cell is specifically contemplated to be a human cell, whichincludes a hematopoietic stem cell or a human CD34+ cell. In anadditional embodiment, the cell is treated to stimulate cellproliferation without substantial loss of stem cell pluripotency. Inadditional aspects, the cell is transduced in vivo or in vitro. Infurther embodiments, the transduced cell is introduced into an animalsubject. The animal subject is a human subject in a preferredembodiment.

A typical example of ex vivo gene therapy encompassed by the inventionis a patient suffering from chronic granulatous disease (CGD), whoseCD34⁺ cells can be isolated from the bone marrow or the peripheral bloodand transduced ex vivo with a lentivector expressing the gp91phox genebefore reimplantation. In the case of patients suffering from severecombined immunodeficiency (SCID), the inventors contemplate a similarapproach, using vector constructs of the invention expressing the genedefective in the patient, for example, the gene encoding the commongamma chain of the Interleukin receptor. For the genetic treatment ofHIV infection, the present inventors contemplate intracellularimmunization, wherein cells are rendered resistant to the HIV virusthrough the introduction of antiviral genes. In embodiments of theintracellular immunization for HIV, targets of the vectors of theinvention include hematopoietic progenitors, peripheral blood CD4⁺ Tcells, and monocytes. As will be recognized by the skilled artisan,similar intracellular immunization methods can be used for other viralinfections as well. For the immunotherapy of cancers, tumor cells orantigen presenting cells such as dendritic cells will be geneticallyengineered with the lentivectors of the invention. For cancer therapiessome transgenes that may be used in the lentivector constructs of theinvention are those that can inhibit, and/or kill, and/or prevent theproliferation, and/or mediate the apoptosis of, the cancer/tumor celland/or genes such as TNF.

The vector particles described herein may also be used in vivo, bydirect injection into the blood or into a specific organ. For example,in one embodiment intracerebral injection of lentivectors expressing theGlial Cell Derived Nerve Growth Factor (GDNF), can be used for thetreatment of Parkinson's disease. In another example, intraportalinjection of a lentivector expressing coagulation factor VIII for thecorrection of hemophilia A is envisioned. In yet another example,intravenous or intramuscular injection of a lentivector of the presentinvention expressing the dystrophin gene for the treatment of DuchenneMuscular Dystrophy is envisioned. Thus, one of ordinary skill in the artwill appreciate the extensive use of the vector constructs and particlesof the present invention in terms of gene therapies.

As used herein the specification or claim(s) when used in conjunctionwith the word “comprising”, the words “a” or “an” may mean one or morethan one. As used herein “another” may mean at least a second or more.

Other objects, features and advantages of the present invention willbecome apparent from the following detailed description. It should beunderstood, however, that the detailed description and the specificexamples, while indicating preferred embodiments of the invention, aregiven by way of illustration only, since various changes andmodifications within the spirit and scope of the invention will becomeapparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and areincluded to further demonstrate certain aspects of the presentinvention. The invention may be better understood by reference to one ormore of these drawings in combination with the detailed description ofspecific embodiments presented herein.

FIG. 1A. Generation of SIVmac251-derived vectors. The genome of aninfectious molecular clone of SIVmac (SIVmac251).

FIG. 1B. SIVmac251 was used to derive constructs encoding the packagingfunctions and constructs carrying the transfer vector. Expressionconstructs expressing various viral glycoproteins (GP) were alsodesigned. The filled boxes represent the viral genes. The open boxesshow the cis-acting sequences. LTR, long terminal repeat; CMV, humancytomegalovirus immediate-early promoter; PBS, primer binding site; MSD,major splice donor site; Ψ, packaging sequence; RRE, Rev-responsiveelement; P_(HMG), 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG)promoter; polyA, polyadenylation site; SD, splice donor site; SA, spliceacceptor site; SV40, simian virus 40 early promoter. Vector particleswere produced by co-transfection of plasmids harboring the packagingfunctions, the viral glycoproteins and the transfer vector into 293Tcells. The supernatants of transfected cells were collected duringtransient expression, concentrated by ultracentrifugation, and used fortarget cell transduction.

FIG. 2A. Infectious titers of SIVmac-derived vectors pseudotyped withdifferent viral glycoproteins. Vectors carrying the GFP marker gene weregenerated with the indicated GPs of retroviral or non-retroviral (stars)origins. EboV, Ebola virus; FPV-HA, hemagglutinin of fowl plague virus;GALV, gibbon ape leukemia virus; MLV-A, amphotropic murine leukemiavirus; LCMV, lymphocytic choriomeningitis virus; VSV, vesicularstomatitis virus. TE671 target cells were infected with dilutions ofnon-concentrated vector preparations and the percentage of GFP-positivecells was determined 3 days post-infection. Infectious titers werecalculated as GFP i.u./ml. In duplicate experiments, vector producercells expressing the FPV-HA were treated with 2 U of Clostridiumperfringens neuraminidase (Sigma-Aldrich, France) for 24 hrs to inducethe release of HA-pseudotyped particles from the surface of producercells (FPV-HA+NA).

FIG. 2B. Schematic representation of the RD114/TR chimeric GP in whichthe cytoplasmic domain of the RD114 glycoprotein was replaced with thatof the MLV-A GP. The sequences of the three topological domains,ectodomain, transmembrane and cytoplasmic tail, are shown for MLV-A,RD114 and RD114/TR (SEQ ID NOS: 23, 24 and 25, respectively). TheGALV/TR chimeric GP was modified in a similar manner.

FIG. 2C. Incorporation of RD114 and RD1 14/TR GPs in virions wasassessed in immunoblots of SIV vector particles pelleted through 20%sucrose cushions, using anti-RD114 SU and anti-CA antibodies. Theposition of the molecular weight markers is shown (kDa)

FIG. 3A. Characterization of pseudotyped SIV-based vector stocks.Infectious titers of SIVmac-based vector stocks pseudotyped with theindicated GPs and concentrated by ultracentrifugation. The meantiters±SD from nine individual experiments performed on TE671 targetcells are shown.

FIG. 3B. (B) Detection of physical particles was performed byimmunoblotting of representative purified vector stocks usinganti-SIV-CA (capsid) antibodies.

FIG. 4A. Stability of pseudotyped SIV-vector virions in human sera.Infectious pseudotyped SIV-vector particles (50,000 GFP i.u. in 50 μl ofsuspension buffer) were mixed with 50 μl of fresh (dashed bars) orheat-inactivated (black bars) human sera. As a reference, virions weremixed with 50 μl of heat-inactivated fetal calf serum (FCS). Virion/seramixtures were incubated at 37° C. for one hr and then used to transduceTE671 target cells. Values show the titers of primate sera-incubatedvirions relative to the titers of the same virions incubated in FCS (%).The results of experiments performed with sera of three differentindividual donors are shown. The experiments with human serum #659 wereperformed in triplicate and are displayed as mean values±SD.

FIG. 4B. Stability of pseudotyped SIV-vector virions in macaque sera.Infectious pseudotyped SIV-vector particles (50,000 GFP i.u. in 50 μl,of suspension buffer) were mixed with 50 μl of fresh (dashed bars) orheat-inactivated (black bars) macaque sera. As a reference, virions weremixed with 50 μl of heat-inactivated fetal calf serum (FCS). Virion/seramixtures were incubated at 37° C. for one hr and then used to transduceTE671 target cells. Values show the titers of primate sera-incubatedvirions relative to the titers of the same virions incubated in FCS (%).The results of experiments performed with sera of three differentindividual donors are shown. The experiments with human serum #659 wereperformed in triplicate and are displayed as mean values±SD.

FIG. 5A. Transduction of human and macaque CD34⁺ cells. CD34⁺ cells,derived from human mobilized blood were pre-stimulated by overnightincubation with TPO and were transduced for 16 hrs at differentmultiplicities of infection (MOIs) with SIV-vectors pseudotyped withVSV-G (triangles), MLV-A GP (closed circles), GALV/TR GP (open circles)or RD114/TR GP (closed squares). For each sample of CD34⁺ cells,transductions were performed in duplicate: in the absence or in thepresence of CH-296 retronectin polypeptides coated on the plates. Afterinfection, cells were washed in PBS and cultured in the presence ofFlt3-L, TPO, and SCF for an additional 3 days until transductionefficiency was assessed. The dose-response curves of representativeexperiments are shown for the same batches of CD34⁺ cells as well as thestatistical analyses of the maximal transduction efficiencies of atleast four experiments performed with CD34⁺ cells derived from differentdonors and stocks of pseudotyped vectors.

FIG. 5B. Transduction of human and macaque CD34⁺ cells. CD34⁺ cells,derived from cynomolgus macaque bone marrow were pre-stimulated byovernight incubation with TPO and were transduced for 16 hrs atdifferent multiplicities of infection (MOIs) with SIV-vectorspseudotyped with VSV-G (triangles), MLV-A GP (closed circles), GALV/TRGP (open circles) or RD114/TR GP (closed squares). For each sample ofCD34⁺ cells, transductions were performed in duplicate: in the absenceor in the presence of CH-296 retronectin polypeptides coated on theplates. After infection, cells were washed in PBS and cultured in thepresence of Flt3-L, TPO, and SCF for an additional 3 days untiltransduction efficiency was assessed. The dose-response curves ofrepresentative experiments are shown for the same batches of CD34⁺ cellsas well as the statistical analyses of the maximal transductionefficiencies of at least four experiments performed with CD34⁺ cellsderived from different donors and stocks of pseudotyped vectors.

FIG. 6A. Transduction of human peripheral blood lymphocytes. Peripheralblood lymphocytes (PBLs) of human origins were transduced with theindicated SIV-vector pseudotypes at different multiplicities ofinfection (MOIs). Human PBLs were activated with soluble anti-CD3 andanti-CD28 antibodies for 24 hours. Macaque PBLs were activated withconcanavalin A and rhIL2 for 2 days prior to infection. Activated PBLswere infected for 4 hrs with STV vectors pseudotyped with VSV-G(triangles), MLV-A GP (closed circles), GALV/TR GP (open circles) or RD114/TR GP (closed squares). Infected cells were washed in PBS, grown inPBL culture medium and transduction efficiency was assessed five dayspost-infection. The results of experiments performed with PBLs fromdifferent donors are shown, as well as the statistical analyses of themaximal transduction efficiencies of at least four experiments performedwith PBLs derived from different donors and stocks of pseudotypedvectors.

FIG. 6B. Transduction of macaque peripheral blood lymphocytes.Peripheral blood lymphocytes (PBLs) of cynomolgus macaque origins weretransduced with the indicated SIN-vector pseudotypes at differentmultiplicities of infection (MOIs). Human PBLs were activated withsoluble anti-CD3 and anti-CD28 antibodies for 24 hours. Macaque PBLswere activated with concanavalin A and rhIL2 for 2 days prior toinfection. Activated PBLs were infected for 4 hrs with SIN vectorspseudotyped with NSN-G (triangles), MLN-A GP (closed circles), GALN/TRGP (open circles) or RD1 14/TR GP (closed squares). Infected cells werewashed in PBS, grown in PBL culture medium and transduction efficiencywas assessed five days post-infection. The results of experimentsperformed with PBLs from different donors are shown, as well as thestatistical analyses of the maximal transduction efficiencies of atleast four experiments performed with PBLs derived from different donorsand stocks of pseudotyped vectors.

FIG. 7A. Representation of RD114 GP cytoplasmic-tail mutants. Alignmentof the TM subunits of the RD114 GP with the TMs of type C (MLV-A) ortype D (Mason-Pfizer monkey virus-MPMV) mammalian retrovirus Envglycoproteins. (SEQ ID NOS: 28-43, respectively) shows the identicalamino-acids in the TMs of MLV-A and MPMV relative to that of RD114.Conserved amino-acids such as I, L or V for aliphatic residues; K or Rfor positively charged residues and D or E for negatively chargedresidues are highlighted. The transmembrane domain (M) of the differentGPs is boxed. The cytoplasmic tail is formed of two segments: the tail(T) of the mature GP found on virions after removal of the GPcarboxy-terminal end (R) by the viral core protease. The proteasecleavage sites (boxed) and the YXXL (SEQ ID NO: 26) endocytosis motif(underlined) are shown in the different GPs.

FIG. 7B. Sequences of the carboxy-terminal ends that were modified inRD1 14 GP are underlined for each mutant. Only the transmembrane domainsof the different chimeric GPs is boxed. (*) shows the position of thepremature stop codon inserted in the RDRless chimeric GP. (′) representsthe position of cleavage mediated by the viral core protease.

FIG. 8. Results of syncytia assays. Cell-cell fusogenicity of the GPchimeras determined by counting the number of syncytia in transfectedcells seeded in 2 cm2 wells. Mock-transfected cells (no GP) were used todetermine the background number of syncytia (substracted here). The datarepresent the results of three independent experiments.

FIG. 9A. Infectivity of vector pseudotypes. Infectivity of MLV vectorspseudotyped with the indicated GP mutants as GFP i.u./ml. The graphshows the mean±SD of four independent experiments. Results obtained withvectors pseudotyped with either the MLV-A GP or with VSV-G are alsoshown, for comparison.

FIG. 9B. Infectivity of vector pseudotypes. Infectivity of SIV vectorspseudotyped with the indicated GP mutants as GFP i.u/ml. The graph showsthe mean±SD of four independent experiments. Results obtained withvectors pseudotyped with either the MLV-A GP or with VSV-G are alsoshown, for comparison.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

We have made chimeric GPs encoding the extracellular and transmembranedomains of GALV or RD1 14 GPs fused to the cytoplasmic tail (designatedTR) of MLV-A GP. Surprisingly, STV-derived vectors pseudotyped withthese GALV/TR and RD1 14/TR GP chimeras have significantly higher titersthan vectors coated with the parental GPs. Additionally, RD114/TR-pseudotyped vectors are efficiently concentrated and are resistantto inactivation induced by the complement of both human and macaquesera. Modified RD1 14 GP-pseudotyped lentiviral vectors are therefore ofparticular value for in vivo gene transfer applications. Furthermore, ascompared to vectors pseudotyped with other retroviral GPs or with VSV-G,RD114/TR-pseudotyped vectors show augmented transduction of human andmacaque primary blood lymphocytes and CD34+ cells.

Furthermore, RD1 14 GP mutants that bear alterations in theirtransmembrane domains and/or cytoplasmic tails can modulate pseudotypeformation either with MLV, SIV or HIV-1 viral core particles. Wedemonstrate that a cleavage site compatible with the retroviral coreprotease must be present in the cytoplasmic tail of the RD114 GP toenable efficient pseudotyping. While incompatibility of the cleavagesite with the MLV protease alters infectivity of pseudotyped virions butnot GP incorporation on MLV cores, compatibility of the cleavage sitewith the lentiviral protease conditions both GP incorporation andinfectivity of pseudotyped lentiviral cores. There is therefore a novelpathway of viral assembly whereby determinants harboured by thecytoplasmic tail of a GP that restrict its incorporation on lentiviralcores should be removed by the viral protease to allow GP incorporationand infectivity of pseudotyped virions.

1. THE CYTOPLASMIC TAIL OF THE RD1 14 GP CONTROLS CELL-CELL ANDVIRUS-CELL FUSOGENICITY

For type C and type D mammalian retrovirus GPs, the cytoplasmic tail isof central importance in the processes that regulate both viral assemblyand fusogenicity. Several evidences establish its influence onglycoprotein localisation, cell surface density, cell-cell fusion,interaction/incorporation with heterologous or homologous viral coresand infectivity of the virions. The cytoplasmic tail of these GPs is astructural motif that contains a carboxy-terminal peptide, named R,which harbours a tyrosine endocytosis signal—YXXL—(5), and whosecleavage by the viral protease strongly modulates the properties of theGP. In the native form of the GP, before cleavage, the R peptide isthought to interact i) with the adaptin complex of the cellularendocytosis machinery, ii) with the carboxy-terminal end of the matureGP found in virions (domain T of the cytoplasmic tail in FIG. 1A) andiii) with virion internal proteins (1, 8, 13, 14, 17, 19, 43).Characterisation of mutants of the RD1 14 glycoprotein (this report)indicates the existence of related signals carried by its cytoplasmictail. Thus, the RDΔYXXL mutant GPs, in which the YXXL motif wasdisrupted by point mutagenesis, leads to increased cell-cell fusion mostlikely via increased cell surface expression, as suggested by studies ofothers using distinct onco-retroviral and lentiviral glycoproteins (1,8, 13). However mutations that increased cell-cell fusogenicity and/orcell-surface expression may not necessarily enhance viral incorporationand/or viral infectivity, as inferred by the characterisation of theRDRless, RDPrMLV, RDPrSIV_(RQAG), RDPrHIV and RDΔYXXL mutant GPs.Additionally, our data indicate that the infectivity of pseudotypedvectors depends on the compatibility between the—modified—cytoplasmictails of RD1 14 GP and the type of viral core.

Several genetic evidences obtained with other type C and D mammalianretrovirus GPs indicate that the cytoplasmic tail in itsuncleaved—cellular—form acts both as an intrinsic negative regulator ofGP fusogenicity (2, 14, 17, 30, 33, 43) and as a partner of the matrixprotein during virion assembly (2, 3). Results obtained with the CTmutants of the RD1 14 glycoprotein indicate that the fusion control ofthe latter GP is modulated by its cytoplasmic tail in a manner similarto that of type C and D glycoproteins. Indeed cleavage of thecytoplasmic tail was found essential to activate the fusion potentialfor several type C and D glycoproteins (2, 14, 30, 33), through a notyet defined mechanism. Lack of cleavage of the CT results in poorlyfusogenic glycoproteins. Also, premature cleavage, achieved through theinsertion of a stop codon at the position of cleavage, strongly enhancessyncytia formation (2, 30, 33). Moreover our data directly confirm thatthe carboxy-terminal end of the RD1 14 GP must be cleaved during orafter virion assembly to allow infectivity (FIG. 5). Additionallymutations in either the region that forms the mature cytoplasmic tail(domain T—FIG. 1B) or in the R peptide alter the control of cell-cellfusion (14, 17, 43), most likely as a result of disruption of thestructure and/or integrity of this cytoplasmic tail. Likewise RD1 14 GPmutants that bear several mutations in the cytoplasmic tail, e.g.,RDPrMLV, RDPrSIV_(RQAG) and RDPrHIV mutants may have enhancedcytotoxicity because of the loss of fusion inhibitory control by theirmutated cytoplasmic tails.

2. A NOVEL PATHWAY OF PSEUDOTYPE FORMATION WITH LENTIVIRAL CORES

Modifications of the cytoplasmic tail of the RD114 GP had little effecton the incorporation of the RD114 GP chimeras on MLV cores, in contrastto lentiviral cores (FIG. 4). This indicated that onco-retroviral coresare more permissive than lentiviral cores for GP incorporation, or,alternatively, that determinants of incompatibility carried by the RD114GP were restricted to lentiviral cores. However the infectivity of thepseudotyped MLV vector particles was greatly influenced by the type ofcleavage site introduced in the cytoplasmic tail of the RD114 GPchimeras (FIG. 3). While the replacement of the RD114 GP cleavage sitewith that of MLV had not effect on infectivity, the insertion oflentiviral cleavage sites dramatically decreased infection. Consistentwith the deficient processing of the cytoplasmic tails of the TMproteins of these latter mutants when incorporated on MLV core particles(FIG. 5A), these results suggested that the poor infectivity of thelatter vector pseudotypes was due to lack of activation of fusionpotential of the incorporated GP chimeras. For MLV GP, abolishingcleavage of the cytoplasmic tail, achieved through mutations of thecleavage site itself or of the viral protease, resulted in mutants thatincorporated normal levels of GP but which were not infectious (33).

Interestingly, the low infectivity of SIV vectors pseudotyped withwild-type RD114 GP could not only be explained by incompatibility of thecleavage site of its cytoplasmic tail with the lentiviral core protease.Indeed, our data suggest that, in constrast to the MLN-A GP, thecytoplasmic tail of the unmodified RD114 glycoprotein may not allowoptimal interactions with the lentiviral core, preventing an efficientincorporation of the latter GP (FIG. 4). Examination of the propertiesof the RD114 GP chimeras may provide a molecular basis for this negativeinteraction. Indeed replacement of the cytoplasmic tail of the RD114glycoprotein with that of the incorporation-competent MLV-A GP, resultedin up to 10 fold increased viral incorporation (FIG. 4), demonstratingthat the cytoplasmic tail of the RD114 GP contains determinants ofincompatibility with the lentiviral core. Interestingly, compatibilitycould be restored by introducing changes in the specificity of thecleavage site of its cytoplasmic tail. One possibility is that suchchanges may have induced structural modifications of the cytoplasmictail that resulted in optimised interactions with SIV core, for example,by reducing steric incompatibilities with the SIV matrix proteins. Yet,our data also suggest the alternative, nonexclusive, possibility thatcleavage of the cytoplasmic tail could be associated to GPincorporation. Substitutions of the RD114 GP cleavage site with cleavagesites derived either from the cytoplasmic tail of thepseudotyping-conipetent MLV-A GP (mutant RDPrMLV) or from SIV Gagproteins (mutant RDPrSIV_(RQAG)) resulted in the enhancement of bothincorporation on SIV core particles and of viral titers, with theexception of the RDPrSIV_(ARLM) GP mutant. In a recent related study,Cannon et al. found that the unmodified GALV GP was excluded fromincorporation on HIV-1 cores (4). Truncation of the R peptide as well asreplacement of either the GALV CT or of its cleavage site with thecorresponding sequences derived from MLV-A resulted in both increased GPincorporation and viral titers (4), in good agreement with our dataobtained with a distinct type of retroviral glycoprotein. Collectivelythese data therefore suggest that the infectivity of pseudotypedlentiviral vectors is the result of compatibility of the CT of thepseudotyping glycoprotein with the viral core and can be modulatedthrough its cleavage by the viral core protease. While these assumptionsshould be confirmed by the direct assessment for cleavage of thecytoplasmic tail, we envisage the possibility of a link between cleavageof the cytoplasmic tail and GP incorporation on non-permissive cores.Despite the localisation of onto-retro virus glycoproteins in plasmamembrane lipid rafts (29), where lentiviruses have been shown to imitatebudding (25), it is possible that the cytoplasmic tails of theseuncleaved GPs are not compatible with the network of matrix proteins.The presence of few active lentiviral protease in the vicinity of theviral assembly site may then cleave the cytoplasmic tails of these GP ina manner dependent on their compatibility with the cleavage siteharboured by their CT. This would result in removal of the R peptide andthus in elimination of incompatibility determinants that preventedincorporation on the lentiviral cores. The tailored GPs may then beincorporated on lentiviral particles possibly following a passivemechanism of incorporation.

3. VIRAL VECTORS

Viruses of many types have formed the basis for vectors. Virus infectioninvolves the introduction of the viral genome into the host cell. Thatproperty is co-opted for use as a gene delivery vehicle in viral basedvectors. The viruses used are often derived from pathogenic viralspecies that already have many of the necessary traits and abilities totransfect cells. However, not all viruses will successfully transfectall cell types at all stages of the cell cycle. Thus, in the developmentof viral vectors, viral genomes are often modified to enhance theirutility and effectiveness for introducing foreign gene constructs(transgenes) or other nucleic acids. At the same time, modifications maybe introduced that reduce or eliminate their ability to cause disease.

Lentiviruses are a subgroup of retroviruses that can infect nondividingcells owing to the karyophilic properties of their preintegrationcomplex, which allow for its active import through the nucleopore.Correspondingly, lentiviral vectors derived from human immunodeficiencyvirus type 1 (HIV-1) can mediate the efficient delivery, integration andlong-term expression of transgenes into non-mitotic cells both in vitroand in vivo (Naldini et al, 1996a; Naldini et al, 1996b; Blomer et al,1997). For example, HIV-based vectors can efficiently transduce humanCD34⁺ hematopoietic cells in the absence of cytokine stimulation (Akkinaet al, 1996; Sutton et al, 1998; Uchida et al, 1998; Miyoshi et al,1999; Case et al, 1999), and these cells are capable of long-termengraftment in NOD/SCID mice (Miyoshi et al, 1999). Furthermore, bonemarrow from these primary recipients can repopulate secondary mice withtransduced cells, confirming the lentivector-mediated geneticmodification of very primitive hematopoietic precursors, most probablybona fide stem cells. Since none of the other currently available genedelivery systems has such an ability, lentiviral vectors provide apreviously unexplored basis for the study of hematopoiesis and similarphenomena, and for the gene therapy of inherited and acquired disordersvia the genetic modification of human stem cells (HCLs).

This important capability is subject to significant biosafety concerns(Akkina et al, 1996; Sutton et al, 1998; Uchida et al, 1998). Theaccidental generation of replication-competent recombinants (RCRs)during the production of lentiviral vector stocks represents one of themajor problems to be solved before lentiviral vectors can be consideredfor human gene therapy.

In the retroviral genome, a single RNA molecule that also contains allthe necessary cis-acting elements carries all the coding sequences.Biosafety of a vector production system is therefore best achieved bydistributing the sequences encoding its various components over as manyindependent units as possible, to maximize the number of crossovers thatwould be required to re-create an RCR. Lentivector particles aregenerated by co-expressing the virion packaging elements and the vectorgenome in host producer cells, e.g. 293 human embryonic kidney cells. Inthe case of HIV-1-based vectors, the core and enzymatic components ofthe virion come from HIV-1, while the envelope protein is derived from aheterologous virus, most often VSV. The genomic complexity of HIV, wherea whole set of genes encodes virulence factors essential forpathogenesis but dispensable for transferring the virus genetic cargo,substantially aids the development of clinically acceptable vectorsystems.

Multiply attentuated packaging systems typically now comprise only threeof the nine genes of HIV-1: gag, encoding the virion main structuralproteins, pol, responsible for the retrovirus-specific enzymes, and rev,which encodes a post-transcriptional regulator necessary for efficientgag and pol expression (Dull, et al, 1998). From such an extensivelydeleted packaging system, the parental virus cannot be reconstituted,since some 60% of its genome has been completely eliminated. In oneversion of an HIV-based packaging system, Gag/Pol, Rev, VSV G and thevector are produced from four separate DNA units. Also, the overlapbetween vector and helper sequences has been reduced to a few tens ofnucleotides so that opportunities for homologous recombination areminimized.

HIV type 1 (HIV-1) based vector particles may be generated byco-expressing the virion packaging elements and the vector genome in aso-called producer cell, e.g. 293T human embryonic kidney cells. Thesecells may be transiently transfected with a number of plasmids.Typically from three to four plasmids are employed, but the number maybe greater depending upon the degree to which the lentiviral componentsare broken up into separate units. Generally, one plasmid encodes thecore and enzymatic components of the virion, derived from HIV-1. T hisplasmid is termed the packaging plasmid. Another plasmid encodes theenvelope protein(s), most commonly the G protein of vesicular stomatitisvirus (VSV G) because of its high stability and broad tropism. Thisplasmid may be termed the envelope expression plasmid. Yet anotherplasmid encodes the genome to be transferred to the target cell, thatis, the vector itself, and is called the transfer vector. Recombinantviruses with titers of several millions of transducing units permilliliter (TU/ml) can be generated by this technique and variantsthereof. After ultracentrifugation concentrated stocks of approximately10⁹ TU/ml can be obtained.

The vector itself is the only genetic material transferred to the targetcells. It typically comprises the transgene cassette flanked bycis-acting elements necessary for its encapsidation, reversetranscription, nuclear import and integration. As has been previouslydone with oncoretroviral vectors, lentiviral vectors have been made thatare “self-inactivating” in that they lose the transcriptional capacityof the viral long terminal repeat (LTR) once transferred to target cells(Zufferey, et al. 1998). This modification further reduces the risk ofemergence of replication competent recombinants (RCR) and avoidsproblems linked to promoter interference.

4. PSEUDOTYPING VIRAL VECTORS

Protein incorporation on retroviruses is not specific to the homologousviral glycoproteins. Over 40 different host cell-derived proteins havebeen identified on the exterior of HIV-1 viral particles, includingmajor histocompatibility complex class I (MHC-I) and MHC-II molecules,adhesion molecules, co-stimulation molecules and complement controlproteins⁴⁸. Additionally, many heterologous viral glycoproteins can beincorporated into retrovirus particles and mediate infectivity⁴⁹. Thisprocess, known as pseudotyping, allows retroviral vectors to transduce abroader range of cells and tissues. Engineering of lentiviral vectorswith the NSN-G glycoprotein exemplifies the ability of a heterologousglycoprotein to extend the tropism of a vector2. However, co-expressionof a given glycoprotein (GPs) with a heterologous viral core will notnecessarily give rise to highly infectious viral particles^(8′14′15′50).

The env gene can be derived from any virus, including retroviruses.Examples of retro viral-derived env genes include, but are not limitedto: Moloney murine leukemia virus (MoMuLN or MMLN), Harvey murinesarcoma virus (HaMuSN or HSN), murine mammary tumor virus (MuMTN orMMTN), gibbon ape leukemia virus (GaLV or GALV), human immunodeficiencyvirus (HIV) and Rous sarcoma virus (RSV). Other env genes such asVesicular stomatitis virus (VSV) protein G (VSV G), that of hepatitisviruses and of influenza also can be used.

While VSV G protein is a desirable env gene because VSV G confers broadhost range on the recombinant virus, VSV G can be deleterious to thehost cell, e.g. the packaging cell. Thus, when a gene such as that forVSV G is used, an inducible promoter system may be employed so that VSVG expression can be regulated to minimize host toxicity when VSV G isexpression is not required. For example, the tetracycline-regulated geneexpression system of Gossen & Bujard, (1992) can be employed to providefor inducible expression of VSV G when tetracycline is withdrawn fromthe transferred cell. Thus, the tet/VP16 transactivator is present on afirst vector and the VSV G coding sequence is cloned downstream from apromoter controlled by tet operator sequences on another vector.

The vector providing the viral env nucleic acid sequence is associatedoperably with regulatory sequences, e.g., a promoter or enhancer. Theregulatory sequence can be any eukaryotic promoter or enhancer,including for example, EF1α, PGK, the Moloney murine leukemia viruspromoter-enhancer element, the human cytomegalovirus enhancer, thevaccinia P7.5 promoter or the like (also see examples listed in Tables 1and 2 below). In some cases, such as the Moloney murine leukemia viruspromoter-enhancer element, the promoter-enhancer elements are locatedwithin or adjacent to the LTR sequences. Preferably, the regulatorysequence is one which is not endogenous to the lentivirus from which thevector is being constructed. Thus, if the vector is being made from SIN,the SIV regulatory sequence found in the SIV LTR would be replaced by aregulatory element which does not originate from SIN.

One may further target the recombinant virus by linkage of the envelopeprotein with an antibody or a particular ligand for targeting to areceptor of a particular cell-type. By inserting a sequence (including aregulatory region) of interest into the viral vector, along with anothergene which encodes the ligand for a receptor on a specific target cell,for example, the vector is now target-specific. Retroviral vectors canbe made target-specific by inserting, for example, a glycolipid or aprotein. Targeting often is accomplished by using an antigen-bindingportion of an antibody or a recombinant antibody-type molecule, such asa single chain antibody, to target the retroviral vector.

Two types of mechanisms are thought to lead to assembly of homologousand heterologous, viral or cellular, glycoproteins on viral particles.The passive model of GP incorporation implies non-obligatoryinteractions between the pseudotyping glycoprotein and the viral core,provided that the former is sufficiently abundant at the site of virusbudding⁵¹ and that its cytoplasmic tail does not bear determinants thatare sterically incompatible with viral assembly or virion morphology⁴⁹,in this respect, heterologous GPs harboring short cytoplasmic tails suchas those of FPV, LCMV and VSV (FIG. 2) are likely to be incorporated onlentiviral particles via a passive mechanism. On the other hand, in theactive model of GP incorporation, interactions between the cytoplasmictail of the pseudotyping glycoprotein and components of the virion coredictate assembly of viral particles. There is ample evidence in theliterature to support the critical role of such interactions in viralassembly (reviewed in^(39′49)), at least for lentiviruses⁵²⁻⁵⁵.

In a recent study we proposed that pseudotyping of lentiviral coreparticles with the glycoproteins of type C and D mammalian retrovirusesinvolves an alternative pathway of assembly¹⁴. The GPs of some of theseretroviruses, like the GALV and the RD114 viruses, have been shown toharbor in their cytoplasmic tail a determinant that restrictsincorporation on lentiviral cores^(8,14). The relatively shortcytoplasmic tails of type C/D mammalian retrovirus GPs, of about 30-40amino-acid-long, harbor a 15-20 amino-acid-long carboxy-terminalpeptide, named R for MLVs, whose cleavage by the homologous viral coreprotease is required to activate the fusion potential of theglycoprotein⁵⁶⁻⁵⁸. For pseudotype formation with homologous type C/Dviral cores, lack of cleavage of the R peptide by the viral proteasealters infectivity of pseudotyped virions but not GPincorporation^(14′56′58). In contrast, the compatibility of the cleavagesite with the lentiviral protease affects both GP incorporation andinfectivity of pseudotyped lentiviral cores particles¹⁴. Thus, apossible pathway of incorporation of these GPs on lentiviral cores mayinvolve cleavage of the R peptide by active core protease at the site ofvirion assembly, resulting in removal of the cytoplasmic taildeterminant that impaired pseudotyping. Based on these observations, wehave generated efficient SIV-derived vectors pseudotyped with chimericGPs derived from GALV⁸ and RD114 (FIG. 2). These mutant glycoproteins,named GALV/TR and RD114/TR (FIG. 2), respectively, harbor thecytoplasmic tail of the MLV-A GP whose cleavage site is compatible withthe HIV-1 and SIV proteases. It is likely due to this property that theyare efficiently incorporated on lentiviral particles (FIG. 2C).

5. STABILITY OF LENTIVIRAL VECTOR PSEUDOTYPES IN PRIMATE SERA

VSV-G-pseudotyped lentiviral vectors have proved useful to transduceseveral cell types in vivo or in vitro^(3′7). Y et their highsensitivity to human24 and non-human primate (FIG. 4) complement maypreclude their utility for in vivo systemic administration. In contrastto VSV-G pseudotypes, vectors generated with retroviral glycoproteinswere stable in human and macaque sera, with RD114/TR-pseudotyped SIVvectors being constantly resistant to human sera, suggesting that thelatter vectors could be particularly suitable for systemic gene delivery(FIG. 4). Several factors contribute in determining complementsensitivity and depend on: i) sera from different individuals, ii) typeof producer cells^(34′36), iii) presence of α(1-3)galactose sugarepitope in glycoproteins⁵⁹⁻⁶¹ or iv) type of pseudotyping GP^(34,36,62).Retroviruses produced by human cells are usually resistant in humanserum^(34′36), with the exception of VSV-G-pseudotyped vectors²⁴.However, in a recent study, it was found that onco-retroviral vectorscoated with MLV GPs and produced by human cells were differentiallysensitive to complement inactivation in sera from non-human Old Worldprimates in a manner that correlated with increasing evolutionarydistance from humans⁶³. Sensitivity to macaque sera resulted in morethan 99% vector degradation⁶³. Thus, in apparent disagreement with theselatter results obtained with onco-retroviral vectors, here we found thatlentiviral vectors pseudotyped with retroviral GPs are relatively stablein macaque sera (FIG. 4B). A factor that could modulate response to seraand explain the discrepancy between onco-retroviral and lentiviralparticles may be the incorporation of the CD46, CD55, and CD59complement inhibitory molecules into lentiviral particles, as reportedfor HIV and SIV^(48′64).

6. TRANSDUCTION OF PRIMARY CELLS WITH PSEUDOTYPED SIV VECTORS

The broad tropism of VSV-G-pseudotyped lentiviral vectors may not besuitable for particular gene transfer applications where celltype-specific gene delivery would be required. More selective tropismscould be achieved by taking advantage of the natural tropisms ofglycoproteins derived from some membrane-enveloped viruses or,alternatively, by engineering the host-range of incorporation-competentGPs (e.g., MLV, GALV/TR or FPV-HA)^(65′66). For instance, the use ofsurface glycoproteins derived from viruses that cause lung infection andinfect via the airway epithelia, like Ebola virus or Influenza virus,may prove useful for gene therapy of the human airway¹⁰. Nevertheless,it should be noted that lentiviral vector pseudotypes might not alwaysretain the host range of the parental viruses from which thepseudotyping glycoproteins were derived. For example, although theglycoprotein of the Mokola virus, a neurotropic lyssavirus, efficientlypseudotypes HIV-1 vectors¹², the pseudotyped vectors do not reproducethe specific neurotropism of the parental virus⁹.

Recent reports have demonstrated that onco-retroviral vectorspseudotyped with the RD114 GP efficiently transduce human and canineCD34⁺ cells^(16-18′21). Transduced cells could repopulate NOD/SCID miceand dogs with an efficiency similar to that of non-transduced cells anddisplayed multilineage expression¹⁶⁻¹⁸. From these studies, it wassuggested that, in human CD34+ cells, the “major barrier to genetransfer is at the receptor level and is not due to the quiescence ofthe target cells”¹⁸. We attempted to test this hypothesis withlentiviral vectors pseudotyped with the MLV-A, GALV/TR, RD114/TR andVSV-G glycoproteins. In contrast to the former studies, we usedconditions of infection that would minimize the influence of factorsthat may affect virus/receptor interactions and/or transduction, i.e.,no reiterated infections, absence of retronectin or stromal cells andonly minimal cytokine treatment. Thus, human CD34⁺ cells were transducedby a single and short virus/cell exposure under cytokine treatment thatwould not allow MLV vectors to transduce the CD34⁺ cells²⁶. Because ofthese sub-optimal conditions, the maximal levels of gene transfer wererelatively low; yet they allowed reliable comparison of the specificinfluence of the pseudotyping GPs in CD34 cells transduction. The bestglycoproteins under these conditions were clearly the VSV-G and GALV/TRGPs (FIG. 5A). Compared to VSV-G, much lower transduction levels wereachieved with vectors pseudotyped with the MLV-A and RD114/TR GPs. Theseresults may reflect differences in the pattern of receptor expression onthe CD34⁺ cells for the different GPs and seem to contradict thosepreviously reported with onco-retroviral vectors¹⁸. However, inagreement with the previous studies¹⁶⁻¹⁸, the combined use of theRD114/TR GP and retronectin strongly increased transduction of humancells, allowing RD114/TR-pseudotyped lentiviral vectors to surpass thosepseudotyped with VSV-G (FIG. 5). The mechanisms by which CH-296retronectin fragment enhances infection may involve the co-localizationof retroviral particles and target cells⁴³, owing to the property ofCH-296 to bind both the cell surface, through its attachment toα4/5β{umlaut over (ι)} integrins, and the viral glycoprotein, through ahigh-affinity hep arm II domain⁴². Although alternative explanations,involving inhibition of apoptosis and stimulation of cell division, havebeen proposed⁶⁷, our results are in favor of the former mechanism sincedifferential effects of CH-296 were detected according to the type ofglycoprotein used to pseudotype the lentiviral core particles. Proteinsof the extra-cellular matrix, such as heparan sulfate proteoglycans,play a major role in the initial steps of infection and perhaps are moreimportant to mediate viral/cell attachment⁶⁸ than the viral receptorsthemselves, that primarily serve to trigger membrane fusion^(69,70).Motifs that differentially influence binding to extra-cellular matrixproteins have been identified in glycoproteins of several envelopedviruses^(71,72). They may be particularly efficient in the RD114glycoprotein and stimulate CH-296-mediated attachment to cells.

RD114/TR-pseudotyped SIV vectors very efficiently transduced human andmacaque PBLs (FIG. 6), in the absence of retronectin. Indeed, in thesecells, there was a striking difference in the transduction efficienciesobserved with vectors pseudotyped with either VSV-G or MLV-A GP andthose coated with RD114/TR GP. The reasons for this discrepancy may liein difference in expression of the receptors for these GPs.Alternatively these results may not necessarily involve differences inreceptor density and/or initial virus/receptor interaction parameters.Several reports have shown that transduction efficiency does notcorrelate with the level of receptor expression^(17,73) but ratherestablish the importance of post-binding events such as receptorclustering, membrane fusion mechanism, site of fusion, uncoating andmigration of the viral particle from the site of uncoating and thenucleus^(74,75). It can therefore be surmised that, for transduction ofPBLs with SIV vectors, the RD114 receptor modulates post-binding eventsin a more efficient fashion than the VSV-G or MLV-A receptors.

Cells may be transduced in vivo or in vitro, depending on the ultimateapplication. Even in the context of human gene therapy, such as genetherapy of human stem cells, one may transduce the stem cell in vivo or,alternatively, transduce in vitro followed by infusion of the transducedstem cell into a human subject. In one aspect of this embodiment, thehuman stem cell can be removed from a human, e.g., a human patient,using methods well known to those of skill in the art and transduced asnoted above. The transduced stem cells are then reintroduced into thesame or a different human.

Where a human subject is treated directly by introduction of the vectorinto the subject, the treatment is typically carried out by intravenousadministration of the vector. When cells, for instance CD34⁺ cells,dendritic cells, peripheral blood cells or tumor cells are transduced exvivo, the vector particles are incubated with the cells using a dosegenerally in the order of between 1 to 50 multiplicities of infection(MOI) which also corresponds to 1×10⁵ to 50×10⁵ transducing units of theviral vector per 10⁵ cells. This of course includes amount of vectorcorresponding to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40,45, and 50 MOI. Typically, the amount of vector may be expressed interms of HeLa transducing units (TU). Other routes for vectoradministration include intrarterially, endoscopically, intralesionally,percutaneously, subcutaneously, intramuscular, intrathecally,intraorbitally, intradermally, intraperitoneally, transtracheally,subcuticularly, by intrastemal injection, by inhalation or intranasalspraying, by endotracheal route and the like. In embodiments concerningtumor/cancer therapies with the vectors of the invention the expressionvector can be delivered by direct injection into the tumor or into thetumor vasculature.

7. HOST CELLS

As used herein, the terms “cell,” “cell line,” and “cell culture” may beused interchangeably. All of these terms also include their progeny,which is any and all subsequent generations. It is understood that allprogeny may not be identical due to deliberate or inadvertent mutations.In the context of expressing a heterologous nucleic acid sequence, “hostcell” refers to a prokaryotic or eukaryotic cell, and it includes anytransformable organisms that is capable of replicating a vector and/orexpressing a heterologous nucleic acid encoded by the vectors of thisinvention. A host cell can, and has been, used as a recipient forvectors. A host cell may be “transfected” or “transformed,” which refersto a process by which exogenous nucleic acid is transferred orintroduced into the host cell. A transformed cell includes the primarysubject cell and its progeny. As used herein, the terms “engineered” and“recombinant” cells or host cells are intended to refer to a cell intowhich an exogenous nucleic acid sequence, such as, for example, alentivector of the invention bearing a therapeutic gene construct, hasbeen introduced. Therefore, recombinant cells are distinguishable fromnaturally occurring cells which do not contain a recombinantlyintroduced nucleic acid.

In certain embodiments, it is contemplated that RNAs or proteinaceoussequences may be co-expressed with other selected RNAs or proteinaceoussequences in the same host cell. Co-expression may be achieved byco-transfecting the host cell with two or more distinct recombinantvectors. Alternatively, a single recombinant vector may be constructedto include multiple distinct coding regions for RNAs, which could thenbe expressed in host cells transfected with the single vector.

Host cells may be derived from prokaryotes or eukaryotes, depending uponwhether the desired result is replication of the vector or expression ofpart or all of the vector-encoded nucleic acid sequences. Numerous celllines and cultures are available for use as a host cell, and they can beobtained through the American Type Culture Collection (ATCC), which isan organization that serves as an archive for living cultures andgenetic materials. Some examples of host cells used in this inventioninclude but are not limited to virus packaging cells, virus producercells, 293T cells, human hematopoietic progenitor cells, humanhematopoietic stem cells, CD34⁺ cells CD4⁺ cells, and the like.

A. Tissues and Cells

It will be understood by the skilled artisan that the invention is notlimited to any one particular cell type and that one may use thelentiviral vectors and methods of the invention for the expression oftransgenes in many cell types. Some examples of cell types contemplatedinclude terminally differentiated cells such as neurons, lung cells,muscle cells, liver cells, pancreatic cells, endothelial cells, cardiaccells, skin cells, bone marrow stromal cells, ear and eye cells.Additionally, stem cells and progenitor cells such as pancreatic ductalcells, neural precursors, and mesodermal stem cells are alsocontemplated. Most notably, however, the more preferred lentivectors ofthe present invention have highly desirable features that permit thehigh level expression of transgenes in human progenitor cells whilemeeting human biosafety requirements.

For the production of virus particles, one may employ any cell that iscompatible with the expression of lentiviral Gag and Pol genes, or anycell that can be engineered to support such expression. For example,producer cells such as 293T cells, TE 671 and HT1080 cells may be used.

Of course, as noted, the lentivectors of the invention will beparticularly useful in the transduction of human hematopoieticprogenitor cell or a hematopoietic stem cell, obtained either from thebone marrow, the peripheral blood or the umbilical cord blood, as wellas in the tranduction of a CD4⁺ T cell, a peripheral blood B or Tlymphocyte cell, a peripheral blood mononuclear cell, a dendritic cell,and a monocytic cell. Particularly preferred targets are CD34⁺ cells.

A tissue may comprise a host cell or cells to be transformed orcontacted with a nucleic acid delivery composition and/or an additionalagent. The tissue may be part or separated from an organism. In certainembodiments, a tissue and its constituent cells may comprise, but is notlimited to, blood (e.g., hematopoietic cells (such as humanhematopoietic progenitor cells, human hematopoietic stem cells, CD34⁺cells CD4⁺ cells), lymphocytes and other blood lineage cells), bonemarrow, brain, stem cells, blood vessel, liver, lung, bone, breast,cartilage, cervix, colon, cornea, embryonic, endometrium, endothelial,epithelial, esophagus, facia, fibroblast, follicular, ganglion cells,glial cells, goblet cells, kidney, lymph node, muscle, neuron, ovaries,pancreas, peripheral blood, prostate, skin, skin, small intestine,spleen, stomach, testes.

B. Organisms

In certain embodiments, the host cell or tissue may be comprised in atleast one organism. In certain embodiments, the organism may be, human,primate or murine. In other embodiments the organism may be anyeukaryote or even a prokayote (e.g., a eubacteria, an archaea), as wouldbe understood by one of ordinary skill in the art. Some lentivectors ofthe invention may employ control sequences that allow them to bereplicated and/or expressed in both prokaryotic and eukaryotic cells.One of skill in the art would further understand the conditions underwhich to incubate all of the above described host cells to maintain themand to permit replication of a vector. Also understood and known aretechniques and conditions that would allow large-scale production of thelentivectors of the invention, as well as production of the nucleicacids encoded by the lentivectors and their cognate polypeptides,proteins, or peptides some of which are therapeutic genes or proteinswhich will be used for gene therapies.

C. Injectable Compositions and Pharmaceutical Formulations

To achieve gene-therapy using the lentiviral vector compositions of thepresent invention, one would generally contact a cell in need thereofwith a lentiviral vector comprising a therapeutic gene. The cell willfurther be in an organism such as a human in need of the gene therapy.The routes of administration will vary, naturally, with the location andnature of the disease, and include, e.g., intravenous, intrarterial,intradermal, transdermal, intramuscular, intranasal, subcutaneous,percutaneous, intratracheal, intraperitoneal, intratumoral, perfusionand lavage. The cells will also sometimes be isolated from theorganisms, exposed to the lentivector ex vivo, and reimplantedafterwards.

Injection of lentiviral nucleic acid constructs of the invention may bedelivered by syringe or any other method used for injection of asolution, as long as the expression construct can pass through theparticular gauge of needle required for injection. A novel needlelessinjection system has recently been described (U.S. Pat. No. 5,846,233)having a nozzle defining an ampule chamber for holding the solution andan energy device for pushing the solution out of the nozzle to the siteof delivery. A syringe system has also been described for use in genetherapy that permits multiple injections of predetermined quantities ofa solution precisely at any depth (U.S. Pat. No. 5,846,225).

Solutions of the nucleic acids as free base or pharmacologicallyacceptable salts may be prepared in water suitably mixed with asurfactant, such as hydroxypropylcellulose. Dispersions may also beprepared in glycerol, liquid polyethylene glycols, and mixtures thereofand in oils. Under ordinary conditions of storage and use, thesepreparations contain a preservative to prevent the growth ofmicroorganisms. The pharmaceutical forms suitable for injectable useinclude sterile aqueous solutions or dispersions and sterile powders forthe extemporaneous preparation of sterile injectable solutions ordispersions (U.S. Pat. No. 5,466,468). h all cases the form must besterile and must be fluid to the extent that easy syringability exists.It must be stable under the conditions of manufacture and storage andmust be preserved against the contaminating action of microorganisms,such as bacteria and fungi. The carrier can be a solvent or dispersionmedium containing, for example, water, ethanol, polyol (e.g., glycerol,propylene glycol, and liquid polyethylene glycol, and the like),suitable mixtures thereof, and/or vegetable oils. Proper fluidity may bemaintained, for example, by the use of a coating, such as lecithin, bythe maintenance of the required particle size in the case of dispersionand by the use of surfactants. The prevention of the action ofmicroorganisms can be brought about by various antibacterial andantifungal agents, for example, parabens, chlorobutanol, phenol, sorbicacid, thimerosal, and the like. In many cases, it will be preferable toinclude isotonic agents, for example, sugars or sodium chloride.Prolonged absorption of the injectable compositions can be brought aboutby the use in the compositions of agents delaying absorption, forexample, aluminum monostearate and gelatin.

For parenteral administration in an aqueous solution, for example, thesolution should be suitably buffered if necessary and the liquid diluentfirst rendered isotonic with sufficient saline or glucose. Theseparticular aqueous solutions are especially suitable for intravenous,intraarterial, intramuscular, subcutaneous, intratumoral andintraperitoneal administration, hi this connection, sterile aqueousmedia that can be employed will be known to those of skill in the art inlight of the present disclosure. For example, one dosage may bedissolved in 1 ml of isotonic NaCl solution and either added to 1000 mlof hypodermoclysis fluid or injected at the proposed site of infusion,(see for example, “Remington's Pharmaceutical Sciences” 15th Edition,pages 1035-1038 and 1570-1580). Some variation in dosage willnecessarily occur depending on the condition of the subject beingtreated. The person responsible for administration will, in any event,determine the appropriate dose for the individual subject. Moreover, forhuman administration, preparations should meet sterility, pyrogenicity,general safety and purity standards as required by FDA Office ofBiologies standards.

Sterile injectable solutions are prepared by incorporating the activecompounds in the required amount in the appropriate solvent with variousof the other ingredients enumerated above, as required, followed byfiltered sterilization. Generally, dispersions are prepared byincorporating the various sterilized active ingredients into a sterilevehicle which contains the basic dispersion medium and the requiredother ingredients from those enumerated above. In the case of sterilepowders for the preparation of sterile injectable solutions, thepreferred methods of preparation are vacuum-drying and freeze-dryingtechniques which yield a powder of the active ingredient plus anyadditional desired ingredient from a previously sterile-filteredsolution thereof.

The compositions disclosed herein may be formulated in a neutral or saltform. Pharmaceutically-acceptable salts, include the acid addition saltsand which are formed with inorganic acids such as, for example,hydrochloric or phosphoric acids, or such organic acids as acetic,oxalic, tartaric, mandelic, and the like. Salts formed with the freecarboxyl groups can also be derived from inorganic bases such as, forexample, sodium, potassium, ammonium, calcium, or ferric hydroxides, andsuch organic bases as isopropylamine, trimethylamine, histidine,procaine and the like. Upon formulation, solutions will be administeredin a manner compatible with the dosage formulation and in such amount asis therapeutically effective. The formulations are easily administeredin a variety of dosage forms such as injectable solutions, drug releasecapsules and the like.

As used herein, “carrier” includes any and all solvents, dispersionmedia, vehicles, coatings, diluents, antibacterial and antifungalagents, isotonic and absorption delaying agents, buffers, carriersolutions, suspensions, colloids, and the like. The use of such mediaand agents for pharmaceutical active substances is well known in theart. Except insofar as any conventional media or agent is incompatiblewith the active ingredient, its use in the therapeutic compositions iscontemplated. Supplementary active ingredients can also be incorporatedinto the compositions.

The phrase “pharmaceutically-acceptable” or“pharmacologically-acceptable” refers to molecular entities andcompositions that do not produce an allergic or similar untowardreaction when administered to a human. The preparation of an aqueouscomposition that contains a protein as an active ingredient is wellunderstood in the art. Typically, such compositions are prepared asinjectables, either as liquid solutions or suspensions; solid formssuitable for solution in, or suspension in, liquid prior to injectioncan also be prepared.

The terms “contacted” and “exposed,” when applied to a cell, are usedherein to describe the process by which a therapeutic lentiviral vectoris delivered to a target cell.

For gene-therapy to discrete, solid, accessible tumors, intratumoralinjection, or injection into the tumor vasculature is specificallycontemplated. Local, regional or systemic administration also may beappropriate. For tumors of >4 cm, the volume to be administered will beabout 4-10 ml (preferably 10 ml), while for tumors of <4 cm, a volume ofabout 1-3 ml will be used (preferably 3 ml). Multiple injectionsdelivered as single dose comprise about 0.1 to about 0.5 ml volumes. Theviral particles may advantageously be contacted by administeringmultiple injections to the tumor, spaced at approximately 1 cmintervals. Systemic administration is preferred for conditions such ashematological malignancies.

Continuous administration also may be applied where appropriate.Delivery via syringe or catherization is preferred. Such continuousperfusion may take place for a period from about 1-2 hours, to about 2-6hours, to about 6-12 hours, to about 12-24 hours, to about 1-2 days, toabout 1-2 wk or longer following the initiation of treatment. Generally,the dose of the therapeutic composition via continuous perfusion will beequivalent to that given by a single or multiple injections, adjustedover a period of time during which the perfusion occurs.

Treatment regimens may vary as well, and often depend on type of diseaseand location of diseased tissue, and factors such as the health and theage of the patient. The clinician will be best suited to make suchdecisions based on the known efficacy and toxicity (if any) of thetherapeutic formulations based on lentiviral vectors of the presentinvention.

The treatments may include various “unit doses.” A unit dose is definedas containing a predetermined-quantity of the therapeutic compositioncomprising a lentiviral vector of the present invention. The quantity tobe administered, and the particular route and formulation, are withinthe skill of those in the clinical arts. A unit dose need not beadministered as a single injection but may comprise continuous infusionover a set period of time. Unit dose of the present invention mayconveniently be described in terms of transducing units (T.U.) oflentivector, as defined by tittering the vector on a cell line such asHeLa or 293. Unit doses range from 10³, 10⁴, 10⁵, 10⁶, 10⁷, 10⁸, 10⁹,10¹⁰, 10¹¹, 10¹², 10¹³ T.U. and higher.

8. NUCLEIC ACIDS A. Transgenes and Disease Treatments

One embodiment of the present invention is to transfer nucleic acidsencoding a therapeutic gene, especially a gene that provides therapy forhematopoietic and lympho-hematopoietic disorders, such as the inheritedor acquired disorders described above. In one embodiment the nucleicacids encode a full-length, substantially full-length, or functionalequivalent form of such a gene. These genes may be known as transgenes.

It is believed that the lentivectors of the present invention may beemployed to deliver any transgene that one desires, depending on theapplication. In the case of delivery to hematopoietic progenitor cells,one will typically select a transgene that will confer a desirablefunction on such cells, including, for example, globin genes,hematopoietic growth factors, which include erythropoietin (EPO), theinterleukins (such as hιterleukin-1 (IL-1), hιterleukin-2 (IL-2),Interleukin-3 (IL-3), Interleukin-6 (IL-6), Interleukin-12 (IL-12),etc.) and the colony-stimulating factors (such as granulocytecolony-stimulating factor, granulocyte/macrophage colony-stimulatingfactor, or stem-cell colony-stimulating factor), the platelet-specificintegrin αllbβ, multidrug resistance genes, the gp91 or gp 47 genes thatare defective in patients with chronic granulomatous disease (CGD),antiviral genes rendering cells resistant to infections with pathogenssuch as human immunodeficiency virus, genes coding for blood coagulationfactors VIII or IX which are mutated in hemophiliacs, ligands involvedin T cell-mediated immune responses such as T cell antigen receptors, Bcell antigen receptors (immunoglobulins), the interleukin receptorcommon γ chain, as well as combination of T and B cell antigen receptorsalone or in combination with single chain antibodies such as ScFv, tumornecrosis factor (TNF), IL-2, IL-12, gamma interferon, CTLA4, B7 and thelike, genes expressed in tumor cells such as Melana, MAGE genes (such asMAGE-1, MAGE-3), P198, P1A, gp100 etc.

A principal application of the present invention will be to provide forvectors that deliver desired transgenes to hematopoietic cells for anumber of possible reasons. This might include, but of course not belimited to, the treatment of myelosupression and neutropenias which maybe caused as a result of chemotherapy or immunosupressive therapy orinfections such as AIDS, genetic disorders, cancers and the like.

Exemplary genetic disorders of hematopoietic cells that are contemplatedinclude sickle cell anemia, thalassemias, hemaglobinopathies, Glanzmannthrombasthenia, rysosomal storage disorders (such as Fabry disease,Gaucher disease, Niemann-Pick disease, and Wiskott-Aldrich syndrome),severe combined immunodeficiency syndromes (SCID), as well as diseasesresulting from the lack of systemic production of a secreted protein,for example, coagulation factor VIII and/or IX. In such cases, one woulddesire to introduce transgenes such as globin genes, hematopoieticgrowth factors, which include erythropoietin (EPO), the interleukins(especially Interleukin-1, Interleukin-2, hιterleukin-3, Interleukin-6,Interleukin-12, etc.) and the colony-stimulating factors (such asgranulocyte colony-stimulating factor, granulocyte/macrophagecolony-stimulating factor, or stem-cell colony-stimulating factor), theplatelet-specific integrin llbβ, multidrug resistance genes, the gp91 orgp 47 genes which are defective in patients with chronic granulomatousdisease (CGD), antiviral genes rendering cells resistant to infectionswith pathogens such as human immunodeficiency virus, genes coding forblood coagulation factors VIII or IX which are mutated in hemophiliacs,ligands involved in T cell-mediated immune responses such as T cellantigen receptors, B cell antigen receptors (immunoglobulins), theinterleukin receptor common γ chain, a combination of both T and B cellantigen receptors alone and/or in combination with single chainantibodies (ScFv), IL2, IL12, TNF, gamma interferon, CTLA4, B7 and thelike, genes expressed in tumor cells such as Melana, MAGE genes (such asMAGE-1, MAGE-3), P198, P1A, gp100 etc.

Exemplary cancers are those of hematopoietic origin, for example,arising from myeloid, lymphoid or erythroid lineages, or precursor cellsthereof. Exemplary myeloid disorders include, but are not limited to,acute promyeloid leukemia (APML), acute myelogenous leukemia (AML) andchronic myelogenous leukemia (CML). Lymphoid malignancies which may betreated utilizing the lentivectors of the present invention include, butare not limited to acute lymphoblastic leukemia (ALL) which includesB-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia (CLL),prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) andWaldenstrom's macroglobulinemia (WM). Additional forms of malignantlymphomas contemplated as candidates for treatment utilizing thelentiviral vectors of the present invention include, but are not limitedto non-Hodgkin lymphoma and variants thereof, peripheral T-celllymphomas, adult T-cell leukemia/lymphoma (ATL), cutaneous T-celllymphoma (CTCL), large granular lymphocytic leukemia (LGF) and Hodgkin'sdisease.

Thus, in some embodiments of the present invention, the treatment of ahematopoietic and lympho-hematopoietic disorder involves theadministration of a lentiviral vector of the invention comprising atherapeutic nucleic acid expression construct to a cell of hematopoieticorigin. The use of a lentiviral vector of the invention comprising atherapeutic nucleic acid expression construct for the manufacture of amedicament intended for the treatment of a hematopoietic andlympho-hematopoietic disorder is also within the scope of the invention.It is contemplated that the hematopoietic cells take up the constructand express the therapeutic polypeptide encoded by nucleic acid, therebyrestoring the cells normal phenotype.

A nucleic acid may be made by any technique known to one of ordinaryskill in the art. Non-limiting examples of synthetic nucleic acid,particularly a synthetic oligonucleotide, include a nucleic acid made byin vitro chemical synthesis using phosphotriester, phosphite orphosphoramidite chemistry and solid phase techniques such as describedin EP 266,032, or via deoxynucleoside H-phosphonate intermediates asdescribed by Froehler et al, 1986, and U.S. Pat. No. 5,705,629. Anon-limiting example of enzymatically produced nucleic acid include oneproduced by enzymes in amplification reactions such as PCR™ (see forexample, U.S. Pat. No. 4,683,202 and U.S. Pat. No. 4,682,195) or thesynthesis of oligonucleotides described in U.S. Pat. No. 5,645,897. Anon-limiting example of a biologically produced nucleic acid includesrecombinant nucleic acid production in living cells (see for example,Sambrook et al. 2000).

A nucleic acid may be purified on polyacrylamide gels, cesium chloridecentrifugation gradients, or by any other means known to one of ordinaryskill in the art (see for example, Sambrook et al. 2000).

The term “nucleic acid” will generally refer to at least one molecule orstrand of DNA, RNA or a derivative or mimic thereof, comprising at leastone nucleobase, such as, for example, a naturally occurring purine orpyrimidine base found in DNA (e.g., adenine “A,” guanine “G,” thymine“T,” and cytosine “C”) or RNA (e.g. A, G, uracil “U,” and C). The term“nucleic acid” encompasses the terms “oligonucleotide” and“polynucleotide.” The term “oligonucleotide” refers to at least onemolecule of between about 3 and about 100 nucleobases in length. Theterm “polynucleotide” refers to at least one molecule of greater thanabout 100 nucleobases in length. These definitions generally refer to atleast one single-stranded molecule, but in specific embodiments willalso encompass at least one additional strand that is partially,substantially or fully complementary to the at least one single-strandedmolecule. Thus, a nucleic acid may encompass at least onedouble-stranded molecule or at least one triple-stranded molecule thatcomprises one or more complementary strand(s) or “complement(s)” of aparticular sequence comprising a strand of the molecule.

In certain embodiments, a “gene” refers to a nucleic acid that istranscribed. As used herein, a “gene segment” is a nucleic acid segmentof a gene. In certain aspects, the gene includes regulatory sequencesinvolved in transcription, or message production or composition. Inparticular embodiments, the gene comprises transcribed sequences thatencode for a protein, polypeptide or peptide. In other particularaspects, the gene comprises a nucleic acid, and/or encodes a polypeptideor peptide-coding sequences of a gene that is defective or mutated in ahematopoietic and lympho-hematopoietic disorder. In keeping with theterminology described herein, an “isolated gene” may comprisetranscribed nucleic acid(s), regulatory sequences, coding sequences, orthe like, isolated substantially away from other such sequences, such asother naturally occurring genes, regulatory sequences, polypeptide orpeptide encoding sequences, etc. In this respect, the term “gene” isused for simplicity to refer to a nucleic acid comprising a nucleotidesequence that is transcribed, and the complement thereof. In particularaspects, the transcribed nucleotide sequence comprises at least onefunctional protein, polypeptide and/or peptide encoding unit. As will beunderstood by those in the art, this functional term “gene” includesboth genomic sequences, RNA or cDNA sequences, or smaller engineerednucleic acid segments, including nucleic acid segments of anon-transcribed part of a gene, including but not limited to thenon-transcribed promoter or enhancer regions of a gene. Smallerengineered gene nucleic acid segments may express, or may be adapted toexpress using nucleic acid manipulation technology, proteins,polypeptides, domains, peptides, fusion proteins, mutants and/or suchlike. Thus, a “truncated gene” refers to a nucleic acid sequence that ismissing a stretch of contiguous nucleic acid residues.

Various nucleic acid segments may be designed based on a particularnucleic acid sequence, and maybe of any length. By assigning numericvalues to a sequence, for example, the first residue is 1, the secondresidue is 2, etc., an algorithm defining all nucleic acid segments canbe created:n to n+y

where n is an integer from 1 to the last number of the sequence and y isthe length of the nucleic acid segment minus one, where n+y does notexceed the last number of the sequence. Thus, for a 10-mer, the nucleicacid segments correspond to bases 1 to 10, 2 to 11, 3 to 12 . . . and/orso on. For a 15-mer, the nucleic acid segments correspond to bases 1 to15, 2 to 16, 3 to 17 . . . and/or so on. For a 20-mer, the nucleicsegments correspond to bases 1 to 20, 2 to 21, 3 to 22 . . . and/or soon.

The nucleic acid(s) of the present invention, regardless of the lengthof the sequence itself, may be combined with other nucleic acidsequences, including but not limited to, promoters, enhancers,polyadenylation signals, restriction enzyme sites, multiple cloningsites, coding segments, and the like, to create one or more nucleic acidconstruct(s). The overall length may vary considerably between nucleicacid constructs. Thus, a nucleic acid segment of almost any length maybe employed, with the total length preferably being limited by the easeof preparation or use in the intended recombinant nucleic acid protocol.

The term “vector” is used to refer to a carrier nucleic acid moleculeinto which a nucleic acid sequence can be inserted for introduction intoa cell where it can be replicated. Vectors of the present invention arelentivirus based as described above and in other parts of thespecification. The nucleic acid molecules carried by the vectors of theinvention encode therapeutic genes and will be used for carrying outgene-therapies. One of skill in the art would be well equipped toconstruct such a therapeutic vector through standard recombinanttechniques (see, for example, Maniatis et al, 1988 and Ausubel et al,1994).

The term “expression vector” refers to any type of genetic constructcomprising a nucleic acid coding for a RNA capable of being transcribed.In some cases, RNA molecules are then translated into a protein,polypeptide, or peptide. In other cases, these sequences are nottranslated, for example, in the production of antisense molecules orribozymes. Expression vectors can contain a variety of “controlsequences,” which refer to nucleic acid sequences necessary for thetranscription and possibly translation of an operably linked codingsequence in a particular host cell. In addition to control sequencesthat govern transcription and translation, vectors and expressionvectors may contain nucleic acid sequences that serve other functions aswell and are described below.

B. Multiple Cloning Sites

Vectors of the present invention can include a multiple cloning site(MCS), which is a nucleic acid region that contains multiple restrictionenzyme sites, any of which can be used in conjunction with standardrecombinant technology to digest the vector (see, for example,Carbonelli et al, 1999, Levenson et al, 1998, and Cocea, 1997)“Restriction enzyme digestion” refers to catalytic cleavage of a nucleicacid molecule with an enzyme that functions only at specific locationsin a nucleic acid molecule. Many of these restriction enzymes arecommercially available. Use of such enzymes is widely understood bythose of skill in the art. Frequently, a vector is linearized orfragmented using a restriction enzyme that cuts within the MCS to enableexogenous sequences to be ligated to the vector. “Ligation” refers tothe process of forming phosphodiester bonds between two nucleic acidfragments, which may or may not be contiguous with each other.Techniques involving restriction enzymes and ligation reactions are wellknown to those of skill in the art of recombinant technology.

C. Splicing Sites

Most transcribed eukaryotic RNA molecules will undergo RNA splicing toremove introns from the primary transcripts. Vectors containing genomiceukaryotic sequences may require donor and/or acceptor splicing sites toensure proper processing of the transcript for protein expression (see,for example, Chandler et al, 1997)

D. Termination Signals

The vectors or constructs of the present invention will generallycomprise at least one termination signal. A “termination signal” or“terminator” is comprised of the DNA sequences involved in specifictermination of an RNA transcript by an RNA polymerase. Thus, in certainembodiments a termination signal that ends the production of an RNAtranscript is contemplated. A terminator may be necessary in vivo toachieve desirable message levels.

In eukaryotic systems, the terminator region may also comprise specificDNA sequences that permit site-specific cleavage of the new transcriptso as to expose a polyadenylation site. This signals a specializedendogenous polymerase to add a stretch of about 200 A residues (poly A)to the 3′ end of the transcript. RNA molecules modified with this polyAtail appear to more stable and are translated more efficiently. Thus, inother embodiments involving eukaryotes, it is preferred that thatterminator comprises a signal for the cleavage of the RNA, and it ismore preferred that the terminator signal promotes polyadenylation ofthe message. The terminator and/or polyadenylation site elements canserve to enhance message levels and to minimize read through from thecassette into other sequences.

Terminators contemplated for use in the invention include any knownterminator of transcription described herein or known to one of ordinaryskill in the art, including but not limited to, for example, thetermination sequences of genes, such as for example the bovine growthhormone terminator or viral termination sequences, such as for examplethe SV40 terminator. In certain embodiments, the termination signal maybe a lack of transcribable or translatable sequence, such as due to asequence truncation.

E. Polyadenylation Signals

In eukaryotic gene expression, one will typically include apolyadenylation signal to effect proper polyadenylation of thetranscript. The nature of the polyadenylation signal is not believed tobe crucial to the successful practice of the invention, and any suchsequence may be employed. Some examples include the SV40 polyadenylationsignal or the bovine growth hormone polyadenylation signal, convenientand known to function well in various target cells. Polyadenylation mayincrease the stability of the transcript or may facilitate cytoplasmictransport.

F. Origins of Replication

In order to propagate a vector of the invention in a host cell, it maycontain one or more origins of replication sites (often termed “ori”),which is a specific nucleic acid sequence at which replication isinitiated. Alternatively an autonomously replicating sequence (ARS) canbe employed if the host cell is yeast.

G. Selectable and Screenable Markers

In certain embodiments of the invention, cells transduced with thelentivectors of the present invention may be identified in vitro or invivo by including a marker in the expression vector. Such markers wouldconfer an identifiable change to the transduced cell permitting easyidentification of cells containing the expression vector. Generally, aselectable marker is one that confers a property that allows forselection. A positive selectable marker is one in which the presence ofthe marker allows for its selection, while a negative selectable markeris one in which its presence prevents its selection. An example of apositive selectable marker is a drug resistance marker.

Usually the inclusion of a drug selection marker aids in the cloning andidentification of transformants, for example, genetic constructs thatconfer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocinand histidinol are useful selectable markers. In addition to markersconferring a phenotype that allows for the discrimination oftransformants based on the implementation of conditions, other types ofmarkers including screenable markers such as GFP, whose basis iscolorimetric analysis, are also contemplated. Alternatively, screenableenzymes such as herpes simplex virus thymidine kinase (tk) orchloramphenicol acetyltransferase (CAT) may be utilized. One of skill inthe art would also know how to employ immunologic markers, possibly inconjunction with FACS analysis. The marker used is not believed to beimportant, so long as it is capable of being expressed simultaneouslywith the nucleic acid encoding a gene product. Further examples ofselectable and screenable markers are well known to one of skill in theart.

9. PROMOTERS AND ENHANCERS

A “promoter” is a control sequence that is a region of a nucleic acidsequence at which initiation and rate of transcription are controlled.It may contain genetic elements at which regulatory proteins andmolecules may bind, such as RNA polymerase and other transcriptionfactors, to initiate the specific transcription a nucleic acid sequence.The phrases “operatively positioned,” “operatively linked,” “undercontrol,” and “under transcriptional control” mean that a promoter is ina correct functional location and/or orientation in relation to anucleic acid sequence to control transcriptional initiation and/orexpression of that sequence.

A promoter generally comprises a sequence that functions to position thestart site for RNA synthesis. The best known example of this is the TATAbox, but in some promoters lacking a TATA box, such as, for example, thepromoter for the mammalian terminal deoxynucleotidyl transferase geneand the promoter for the SV40 late genes, a discrete element overlyingthe start site itself helps to fix the place of initiation. Additionalpromoter elements regulate the frequency of transcriptional initiation.Typically, these are located in the region 30-110 bp upstream of thestart site, although a number of promoters have been shown to containfunctional elements downstream of the start site as well. To bring acoding sequence “under the control of a promoter, one positions the 5′end of the transcription initiation site of the transcriptional readingframe “downstream” of (i.e., 3′ of) the chosen promoter. The “upstream”promoter stimulates transcription of the DNA and promotes expression ofthe encoded RNA.

The spacing between promoter elements frequently is flexible, so thatpromoter function is preserved when elements are inverted or movedrelative to one another. In the tk promoter, the spacing betweenpromoter elements can be increased to 50 bp apart before activity beginsto decline. Depending on the promoter, it appears that individualelements can function either cooperatively or independently to activatetranscription. A promoter may or may not be used in conjunction with an“enhancer,” which refers to a cis-acting regulatory sequence involved inthe transcriptional activation of a nucleic acid sequence.

A promoter may be one naturally associated with a nucleic acid sequence,as may be obtained by isolating the 5′ non-coding sequences locatedupstream of the coding segment and/or exon. Such a promoter can bereferred to as “endogenous.” Similarly, an enhancer may be one naturallyassociated with a nucleic acid sequence, located either downstream orupstream of that sequence. Alternatively, certain advantages will begained by positioning the coding nucleic acid segment under the controlof a recombinant or heterologous promoter, which refers to a promoterthat is not normally associated with a nucleic acid sequence in itsnatural environment. A recombinant or heterologous enhancer refers alsoto an enhancer not normally associated with a nucleic acid sequence inits natural environment. Such promoters or enhancers may includepromoters or enhancers of other genes, and promoters or enhancersisolated from any other virus, or prokaryotic or eukaryotic cell, andpromoters or enhancers not “naturally occurring,” i.e., containingdifferent elements of different transcriptional regulatory regions,and/or mutations that alter expression. For example, promoters that aremost commonly used in recombinant DNA construction include theβ-lactamase (penicillinase), lactose and tryptophan (trp) promotersystems. In addition to producing nucleic acid sequences of promotersand enhancers synthetically, sequences may be produced using recombinantcloning and/or nucleic acid amplification technology, including PCR™, inconnection with the compositions disclosed herein (see U.S. Pat. Nos.4,683,202 and 5,928,906). Furthermore, it is contemplated the controlsequences that direct transcription and/or expression of sequenceswithin non-nuclear organelles such as mitochondria, chloroplasts, andthe like, can be employed as well. Control sequences comprisingpromoters, enhancers and other locus or transcriptioncontrolling/modulating elements are also referred to as “transcriptionalcassettes”.

Naturally, it will be important to employ a promoter and/or enhancerthat effectively directs the expression of the DNA segment in theorganelle, cell type, tissue, organ, or organism chosen for expression.Those of skill in the art of molecular biology generally know the use ofpromoters, enhancers, and cell type combinations for protein expression,(see, for example Sambrook et al, 2000). The promoters employed may beconstitutive, tissue-specific, inducible, and/or useful under theappropriate conditions to direct high level expression of the introducedDNA segment, such as is advantageous for gene therapy or forapplications such as the large-scale production of recombinant proteinsand/or peptides. The promoter may be heterologous or endogenous.

Use of a T3, T7 or SP6 cytoplasmic expression system is another possibleembodiment. Eukaryotic cells can support cytoplasmic transcription fromcertain bacterial promoters if the appropriate bacterial polymerase isprovided, either as part of the delivery complex or as an additionalgenetic expression construct.

Tables 1 lists non-limiting examples of elements/promoters that may beemployed, in the context of the present invention, to regulate theexpression of a RNA. Table 2 provides non-limiting examples of inducibleelements, which are regions of a nucleic acid sequence that can beactivated in response to a specific stimulus.

TABLE 1 Promoter and/or Enhancer Promoter/Enhancer ReferencesImmunoglobulin Heavy Chain Banerji et al., 1983; Gilles et al., 1983;Grosschedl et al., 1985; Atchinson et al., 1986, 1987; Imler et al.,1987; Weinberger et al., 1984; Kiledjian et al., 1988; Porton et al.;1990 Immunoglobulin Light Chain Queen et al., 1983; Picard et al., 1984T-Cell Receptor Luria et al., 1987; Winoto et al., 1989; Redondo et al.;1990 HLA DQ a and/or DQ β Sullivan et al., 1987 β-Interferon Goodbournet al., 1986; Fujita et al., 1987; Goodbourn et al., 1988 Interleukin-2Greene et al., 1989 Interleukin-2 Receptor Greene et al., 1989; Lin etal., 1990 MHC Class II 5 Koch et al., 1989 MHC Class II HLA-Dra Shermanet al., 1989 β-Actin Kawamoto et al., 1988; Ng et al.; 1989 MuscleCreatine Kinase (MCK) Jaynes et al., 1988; Horlick et al., 1989; Johnsonet al., 1989 Prealbumin (Transthyretin) Costa et al., 1988 Elastase IOmitz et al., 1987 Metallothionein (MTII) Karin et al., 1987; Culotta etal., 1989 Collagenase Pinkert et al., 1987; Angel et al., 1987 AlbuminPinkert et al., 1987; Tronche et al., 1989, 1990 α-Fetoprotein Godboutet al., 1988; Campere et al., 1989 γ-Globin Bodine et al., 1987;Perez-Stable et al., 1990 β-Globin Trudel et al., 1987 c-fos Cohen etal., 1987 c-HA-ras Triesman, 1986; Deschamps et al., 1985 Insulin Edlundet al., 1985 Neural Cell Adhesion Molecule Hirsh et al., 1990 (NCAM)α₁-Antitrypain Latimer et al., 1990 H2B (TH2B) Histone Hwang et al.,1990 Mouse and/or Type I Collagen Ripe et al., 1989 Glucose-RegulatedProteins Chang et al., 1989 (GRP94 and GRP78) Rat Growth Hormone Larsenet al., 1986 Human Serum Amyloid A (SAA) Edbrooke et al., 1989 TroponinI (TN I) Yutzey et al., 1989 Platelet-Derived Growth Factor Pech et al.,1989 (PDGF) Duchenne Muscular Dystrophy Klamut et al., 1990 SV40 Banerjiet al., 1981; Moreau et al., 1981; Sleigh et al., 1985; Firak et al.,1986; Herr et al., 1986; Imbra et al., 1986; Kadesch et al., 1986; Wanget al., 1986; Ondek et al., 1987; Kuhl et al., 1987; Schaffner et al.,1988 Polyoma Swartzendruber et al., 1975; Vasseur et al., 1980; Katinkaet al., 1980, 1981; Tyndell et al., 1981; Dandolo et al., 1983; deVilliers et al., 1984; Hen et al., 1986; Satake et al., 1988; Campbelland/or Villarreal, 1988 Retroviruses Kriegler et al., 1982, 1983;Levinson et al., 1982; Kriegler et al., 1983, 1984a, b, 1988; Bosze etal., 1986; Miksicek et al., 1986; Celander et al., 1987; Thiesen et al.,1988; Celander et al., 1988; Chol et al., 1988; Reisman et al., 1989Papilloma Virus Campo et al., 1983; Lusky et al., 1983; Spandidos and/orWilkie, 1983; Spalholz et al., 1985; Lusky et al., 1986; Cripe et al.,1987; Gloss et al., 1987; Hirochika et al., 1987; Stephens et al., 1987Hepatitis B Virus Bulla et al., 1986; Jameel et al., 1986; Shaul et al.,1987; Spandau et al., 1988; Vannice et al., 1988 Human ImmunodeficiencyVirus Muesing et al., 1987; Hauber et al., 1988; Jakobovits et al.,1988; Feng et al., 1988; Takebe et al., 1988; Rosen et al., 1988;Berkhout et al., 1989; Laspia et al., 1989; Sharp et al., 1989; Braddocket al., 1989 CD11b Hickstein et al., 1992 Gibbon Ape Leukemia VirusHolbrook et al., 1987; Quinn et al., 1989

TABLE 2 Inducible Elements Element Inducer References MT II PhorbolEster (TFA) Palmiter et al., 1982; Haslinger et Heavy metals al., 1985;Searle et al., 1985; Stuart et al., 1985; Imagawa et al., 1987, Karin etal., 1987; Angel et al., 1987b; McNeall et al., 1989 MMTV (mouse mammaryGlucocorticoids Huang et al., 1981; Lee et al., tumor virus) 1981;Majors et al., 1983; Chandler et al., 1983; Lee et al., 1984; Ponta etal., 1985; Sakai et al., 1988 β-Interferon Poly(rI)x Tavernier et al.,1983 Poly(rc) Adenovirus 5 E2 E1A Imperiale et al., 1984 CollagenasePhorbol Ester (TPA) Angel et al., 1987a Stromelysin Phorbol Ester (TPA)Angel et al., 1987b SV40 Phorbol Ester (TPA) Angel et al., 1987b MurineMX Gene Interferon, Newcastle Hug et al., 1988 Disease Virus GRP78 GeneA23187 Resendez et al., 1988 α-2-Macroglobulin IL-6 Kunz et al., 1989Vimentin Serum Rittling et al., 1989 MHC Class I Gene H-2κb InterferonBlanar et al., 1989 HSP70 E1A, SV40 Large T Taylor et al., 1989, 1990a,1990b Antigen Proliferin Phorbol Ester-TPA Mordacq et al., 1989 TumorNecrosis Factor PMA Hensel et al., 1989 Thyroid Stimulating ThyroidHormone Chatterjee et al., 1989 Hormone α Gene

The identity of tissue-specific promoters or elements, as well as assaysto characterize their activity, is well known to those of skill in theart. Non-limiting examples of such regions include the human LIMK2 gene(Nomoto et al, 1999), the somatostatin receptor 2 gene (Kraus et al,1998), murine epididymal retinoic acid-binding gene (Lareyre et al,1999), human CD4 (Zhao-Emonet et al, 1998), mouse alpha2 (XI) collagen(Tsumaki, et al, 1998), D1A dopamine receptor gene (Lee, et al, 1997),insulin-like growth factor II (Wu t al, 1997), and human plateletendothelial cell adhesion molecule-1 (Almendro et al, 1996).

The lentiviral vectors of the present invention are designed, primarily,to transform cells with a therapeutic gene under the control ofregulated eukaryotic promoters. Although the gp91-phox promoter ispreferred, other promoter and regulatory signal elements as described inthe Tables 1 and 2 above may also be used. Additionally anypromoter/enhancer combination (as per the Eukaryotic Promoter Data BaseEPDB) could also be used to drive expression of structural genesencoding the therapeutic gene of interest that is used in context withthe lentiviral vectors of the present invention. Alternatively, atissue-specific promoter for cancer gene therapy or the targeting oftumors may be employed with the lentiviral vectors of the presentinvention for treatment of cancers, especially hematological cancers.

Typically promoters and enhancers that control the transcription ofprotein encoding genes in eukaryotic cells are composed of multiplegenetic elements. The cellular machinery is able to gather and integratethe regulatory information conveyed by each element, allowing differentgenes to evolve distinct, often complex patterns of transcriptionalregulation. Activation or repression of the promoter and enhancerelements may be had through contacting those elements with theappropriate transcriptional activators or repressors, such as thosedescribed in FIG. 1B for the gp91-phox promoter and disclosed in Luo andSkalnik (1996) J. Biol. Chem. 271:18203-210, and Luo and Skalnik (1996)J. Biol. Chem. 271:23445-23451.

With respect to the gp91-phox promoter, the activity of Ihterferon-gammain modulating the transcription and expression of the expressioncassette is an example of how such promoter or enhancer elements and thefactors that interact with them may be employed in the practice of thepresent invention.

Enhancers were originally detected as genetic elements that increasedtranscription from a promoter located at a distant position on the samemolecule of DNA. This ability to act over a large distance had littleprecedent in classic studies of prokaryotic transcriptional regulation.Subsequent work showed that regions of DNA with enhancer activity areorganized much like promoters. That is, they are composed of manyindividual elements, each of which binds to one or more transcriptionalproteins. See, for example, the model for the regulation of thegp91-phox promoter presented in FIG. 1B. Exemplary enhancerscontemplated in the present invention are the DNAase HyperSensitiveelements and their homologs described by Lien L L, Lee Y, Orkin S H,(1997) “Regulation of the myeloid-cell-expressed human gp91-phox gene asstudied by transfer of yeast artificial chromosome clones into embryonicstem cells: suppression of a variegated cellular pattern of expressionrequires a full complement of distant cis elements,” Mol Cell Biol.17(4):2279-90. Under the influence of these enhancer elements, geneexpression may be higher (due to enhancer activity HS) and lessvariegated (due to silencer activity of HS).

Analogs of the HS elements of gp91-phox are active in otherpromoter-enhancer systems. See, for example, May C, Rivella S, CallegariJ, Heller G, Gaensler K M, Luzzatto L, Sadelain M, (2000) Therapeutichaemoglobin synthesis in beta-thalassaemic mice expressinglentivirus-encoded human beta-globin. Nature 406(6791):82-6, whereanalogous beta-globin HS elements were included into lentivectorupstream of beta-globin promoter to drive expression of beta-globincDNA.

Promoters and enhancers have the same general function of activatingtranscription in the cell. They are often overlapping and contiguous,often seeming to have a very similar modular organization. Takentogether, these considerations suggest that enhancers and promoters arehomologous entities and that the transcriptional activator proteinsbound to these sequences may interact with the cellular transcriptionalmachinery in fundamentally the same way. The basic distinction betweenenhancers and promoters is operational. An enhancer region as a wholemust be able to stimulate transcription at a distance; this need not betrue of a promoter region or its component elements. On the other hand,a promoter must have one or more elements that direct initiation of RNAsynthesis at a particular site and in a particular orientation, whereasenhancers lack these specificities. Aside from this operationaldistinction, enhancers and promoters are very similar entities.Constructs of elements that control transcription and expression maytherefore be comprised of various elements arranged so as to providemeans of control of enhanced utility and operation.

A signal that may prove useful is a polyadenylation signal (hGH, BGH,SV40). The use of internal ribosome binding sites (IRES) elements areused to create multigene, or polycistronic, messages. IRES elements areable to bypass the ribosome scanning model of 5′-methylatedcap-dependent translation and begin translation at internal sites(Pelletier and Sonenberg, 1988). IRES elements from two members of thepicornavirus family (polio and encephalomyocarditis) have been described(Pelletier and Sonenberg, 1988), as well as an IRES from a mammalianmessage (Macejak and Sarnow, 1991). IRES elements can be linked toheterologous open reading frames. Multiple open reading frames can betranscribed together, each separated by an IRES, creating polycistronicmessages. By virtue of the IRES element, each open reading frame isaccessible to ribosomes for efficient translation. Multiple genes can beefficiently expressed using a single promoter/enhancer to transcribe asingle message.

In any event, it will be understood that promoters are DNA elements thatwhen positioned functionally upstream of a gene leads to the expressionof that gene. Most transgenes that will be transformed using thelentiviral vectors of the present invention are functionally positioneddownstream of a promoter element.

A specific initiation signal also may be required for efficienttranslation of coding sequences. These signals include the ATGinitiation codon or adjacent sequences. Exogenous translational controlsignals, including the ATG initiation codon, may need to be provided.One of ordinary skill in the art would readily be capable of determiningthis and providing the necessary signals. It is well known that theinitiation codon must be “in-frame” with the reading frame of thedesired coding sequence to ensure translation of the entire insert. Theexogenous translational control signals and initiation codons can beeither natural or synthetic. The efficiency of expression may beenhanced by the inclusion of appropriate transcription enhancerelements.

10. BRIEF DESCRIPTION OF THE SEQUENCE LISTINGS

SEQ ID NO: 1 provides the nucleotide sequence encoding a chimericglycoprotein comprising a cytoplasmic tail domain derived from MLV-A anda transmembrane and extracellular domain derived from feline endogenousvirus RD114.

SEQ ID NO:2 provides the amino acid sequence of the chimericglycoprotein encoded by SEQ ID NO: 1.

SEQ ID NO:3 provides the nucleotide sequence encoding an alternatechimeric glycoprotein.

SEQ ID NO 4 provides the amino acid sequence of the chimericglycoprotein encoded by SEQ ID NO: 3.

11. EXAMPLES

The following examples are included to demonstrate preferred embodimentsof the invention. It should be appreciated by those of skill in the artthat the techniques disclosed in the examples that follow representtechniques discovered by the inventor to function well in the practiceof the invention, and thus can be considered to constitute preferredmodes for its practice. However, those of skill in the art should, inlight of the present disclosure, appreciate that many changes can bemade in the specific embodiments which are disclosed and still obtain alike or similar result without departing from the spirit and scope ofthe invention.

A. Materials and Methodology Employed in Examples 1-10 1. Cells

The 293T human embryo kidney cell line (ATCC CRL-1573) and the TE671human rhabdomyosarcoma cell line (ATCC CRL-8805) were grown in DMEM(Life Technologies, France) supplemented with 10% fetal calf serum(FCS).

Human and cynomolgus macaque (Macaca fascicularis) CD34⁺ cells wereobtained from mobilized blood and bone marrow samples, respectively, asdescribed previously²⁶⁻²⁸. CD34⁺ cells were recovered after Ficoll-Paque(Pharmacia, Sweden) gradient centrifugation and were purified withanti-CD34 M450 Dynabeads (Dynal, Norway). CD34⁺ cell purity was over95%.

Human and cynomolgus macaque peripheral blood mononuclear cells (PBMCs)were separated from fresh blood of healthy donors using aFicoll-Hypaque/Percoll gradient (Pharmacia, Sweden), as describedpreviously²⁹. Peripheral blood lymphocytes (PBLs) were enriched from thePBMC fraction by overnight adherence at 37° C. to remove adherentmonocytes and were monitored for CD3 marker expression (75-85% wereCD3⁺).

2. Antibodies

Anti-RD114 GP (ViroMed Biosafety Labs, USA) was a goat antiserum raisedagainst the RD114 gp70 envelope glycoprotein (SU), used diluted to1/5,000 for Western Blots. Anti-SIV CA (NIH AIDS Research and ReferenceReagent Program, USA) was a mouse monoclonal antibody (2F12) raisedagainst the SIVmac251 ρ27 capsid protein (CA), used diluted to 1/500 forWestern Blots. Anti-MLV CA (ViroMed Biosafety Labs, USA) was a goatantiserum raised against the Rausher leukemia virus (RLV) p30 capsidprotein (CA), used diluted to 1/10,000 for Western Blots.

3. Packaging and Transfer Vector Constructs

The pSIN-12 packaging plasmid (FIG. 1) is a derivative of pSIN8²⁵ andexpresses the SIVmac251 gag-pol genes under control of the hCMV promoterand an HIV-1 rev gene expression unit into which the two exons of revhave been fused and placed under control of the3-hydroxy-3-methylglutaryl co enzyme A reductase (HMG) promoter, HMGintron I and the SV40 polyadenylation sequences. The pSIV-Tl⁺ plasmid³⁰encodes a packaging-competent SIVmac251-based vector that expresses theenhanced green fluorescent protein (GFP) marker gene under control ofthe CMV promoter (FIG. 1).

The pSIV-Tl⁺ plasmid encodes a packaging-competent SIVmac251-basedvector that expresses the enhanced green fluorescent protein (GFP)marker gene under control of the CMN promoter. The pTG5349 murineleukemia virus (MLN) packaging plasmid and the pTG13077 plasmid,encoding an MLN-based vector containing a CMN-GFP internaltranscriptional unit, were kindly provided by Transgene SA (Strasbourg,France).

4. Viral Glycoprotein Expression Constructs

The following plasmids, phCMV-G³¹, EboV-GP (kind gift of V. Volchkov),phCMV-HA³², phCMV-10Al³³ and phCMV-GALV³³ encode the vesicularstomatitis virus (VSV) G protein, the glycoprotein of the Zaire strainof Ebola Virus (EboV), the fowl plague virus (FPV) H7-HA hemagglutinin,the MLV-10A1 and the gibbon ape leukemia virus (GALV) envelopeglycoproteins, respectively. All glycoproteins were expressed undercontrol of the same cis-acting signals: CMV promoter, rabbit β-globinintron II and polyadenylation sequences (FIG. 1).

phCMV-G was used as a backbone to express the glycoproteins derived fromthe feline endogenous virus RD1 14 (Genbank X87829³⁴) and the 4070Astrain of amphotropic MLN (MLN-A³⁵). The phCMN-RD114 expression vector,expressing the RD1 14 virus envelope glycoprotein (RD114 GP), and thephCMN-GALN construct were further modified to express the RD114/TR (FIG.2B) and GALV/TR^(8,13,15) chimeric glycoproteins carrying the MLV-A GPcytoplasmic tail.

The phCMV-RD expression vector, expressing the RD114 virus envelopeglycoprotein (RD114 GP), was further modified to generate a series ofmutants that harbour modifications in the RD114 GP transmembrane domain(TMD) and/or cytoplasmic tail (CT). All subsequent constructs weregenerated by PCR-mediated and oligonucleotide site-directed mutagenesis(details and sequences are available upon request) and cloned in thephCMN-RD plasmid. The amino-acid sequences of the carboxy-terminalportions of the mutant RD114 GPs are shown in FIG. 7.

5. Syncytia Assays

The HeLa cells used for the fusion assay were stable transfectants ofeither a β-galactosidase gene (LacZ) under the control of the HIN-1 longterminal repeat (LTR), whose expression is Tat-dependent (HeLaCD4LTRLacZcells), or were constitutively expressing the Tat protein of HIV-1(Hela-Tat cells), as described previously (9). Envelope-mediated fusionwas quantified essentially as described previously (9, 16). In thisassay, the HIV-1 LTR-driven expression of β-galactosidase istransactivated by the Tat protein upon fusion of envelope-expressingcells with receptor-bearing indicator cells. Twenty-four hours prior totransfection, 5×10⁴ HeLaCD4LTRLacZ cells were seeded per twelve-wellplates. Viral glycoprotein expression constructs were transfected intothe HeLa cells described above using a calcium-phosphate transfectionprotocol (Clontech, France) according to the manufacturer'srecommendations using 1 μg of plasmid. 24 hours post-transfection, 10⁵indicator Hela-Tat cells were cocultivated with the viralglycoprotein-presenting cells for 36 to 48 hours. Cell-cell fusion wasmeasured following fixation with 0.5% (weight/volume) glutaraldehyde inPBS (phosphate buffer saline), washed with PBS, and stained byincubation in a 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal)solution as described previously (9, 16). Blue syncytia, indicatingfusion between the envelope-presenting and Tat-containing indicatorcells, were counted regardless of the number of nuclei per syncytia.

6. Production of Retroviral Vectors

Pseudotyped SIV-derived vectors were generated as previously described²⁵by transient transfection of 293T cells. The pSIV-Tl⁺ vector construct(8.1 μg), the pSIV-12 packaging construct (8.1 μg), and the viralglycoprotein-expression construct (2.7 μg) were used to co-transfect293T cells seeded the day before in 10 cm plates. The medium (12 mlplate) was replaced 16 hrs after transfection, and supernatant washarvested 24 hrs later. Concentration of the vector particles wasperformed by pelleting the virions in 26-ml ultracentrifugation tubes,which were spun for one hr at 32,000 rpm at 4° C. in a 70Ti Beckmanrotor. Viral pellets were resuspended in serum-free DMEM supplementedwith 1% bovine serum albumin (BSA) in 1/100 of the initial volume of theviral supernatant, aliquoted and stored at −80° C.

Pseudotyped MLV-derived vectors were generated in a similar manner bytransient transfection of the pTG5349 MLV packaging construct (8.1 μg),of the pTG13077 MLV vector construct (8.1 μg) and of theglycoprotein-expressing construct (2.7 μg). Plasmid DNAs weretransfected into 2.5×10⁶ 293T cells seeded the day before in 10 cmplates using a calcium-phosphate transfection protocol (Clontech,France) according to the manufacturer's recommendations. The medium (8ml/plate) was replaced 16 hrs after transfection, and supernatant washarvested 24 hrs later and filtered through 0.45 μm-pore-sizedmembranes.

7. Immunoblots and Viral Incorporation of the Glycoproteins

Virus producer cells were lysed in a 20 mM Tris-HCl buffer (pH 6.5)containing 1% Triton-X1OO, 0.05% SDS (sodium dodecyl-sulfate), 5 mg/mlsodium deoxycholate, 150 mM NaCI, and 1 mM PMSF. Lysates were incubatedfor 10 min at 4° C. and were centrifuged for 5 min at 13,000×g to pelletthe nuclei. Supernatants were then frozen at −80° C. until furtheranalysis. Purified virus samples were obtained by ultracentrifugation ofviral supernatants (8 ml) through a 1.5-ml 20% sucrose cushion in a SW41Beckman Rotor (25,000 rpm, 2.5 hrs, 4° C.). Viral pellets were suspendedin 100 μl of PBS, and frozen at −80° C.

Samples (30 μg for cell lysates, or 20 μl for purified viruses) weremixed 5:1 (vol:vol) in a 375 mM Tris-HCl (pH 6.8) buffer containing 6%SDS, 30% β-mercapto-ethanol, 10% glycerol, and 0.06% bromophenol blue,boiled for 5 min, then run on 9% SDS-PAGE. After protein transfer ontonitrocellulose filters, immunostaining was performed in TBS (Tris-basesaline, pH 7.4) with 10% milk powder and 0.1% TWEEN. The blots wereprobed with the relevant antibody and developed using HRPO-conjugated Ig(immunoglobulins) raised against the species of each primary antibody(DAKO, UK) and an enhanced chemiluminescence kit (Amersham LifeScience).

8. Metabolic Labeling and Immunoprecipitation

Twelve hours after transfection with the different onco-retroviral orlentiviral vector component, virus producer cells were starved incysteine- and methionine-free culture medium for 1 h and labeled at 37°C. for 16 hrs in 3 ml of cysteine- and methionine-free DMEM containing100 μCi of ³⁵S-cysteine and ³⁵S-methionine (ICN) per ml and 2% dialysedfetal calf serum. Cells were lysed and immunoprecipitated as previouslydescribed (9) with a goat anti-RD114 SU serum. For analyses of theprocessing of the cytoplasmic tail of the TM GP subunit, the supernatantof virus producer cells were harvested and filtered through a0.45-mm-pore-size filter. Supernatants were ultracentrifuged on a 2-ml20% sucrose cushion for 2 hrs at 30,000 rpm in an SW41 rotor (Beckman).The pellets were lysed by adding 150 ml of lysis buffer (50 mM Tris HCI(pH 7.5), 15 mM NaCI, 5 mM MgCl2, 5 mM KCI, 1% Triton X-100, 0.5% sodiumdeoxycholate). One-fifth of the lysate was preserved and electrophoresedas such for a crude analysis of the virus protein content bywestern-blotting, whereas the remaining lysate was submitted toimmunoprecipitation with anti-RD1 14 SU antibodies, hnmunoprecipitateswere electrophoresed in sodium dodecyl sulfate (SDS)-12% polyacrylamidegels under reducing conditions to dissociate the co-immunoprocipitatedTM GP subunit from the SU.

9. Infection Assays

Determination of transduction efficiencies and infectious titers wasperformed as detailed previously²⁵, using TE671 as target cells.Stability of vector pseudotypes in human or macaque sera was examined bytitrating surviving viral particles after incubation in 1:1 mixtures(volume:volume) of virus preparations with fresh sera for 1 hr at 37°C., as previously described³⁶. Approximately 5×10⁴ GFP infectious unitsof pseudotyped vector particles were used per point. Sera were harvestedfrom healthy blood donors and conditioned as published³⁶. Stability ofvirions was determined as the percentage of infectivity of primateserum-treated viruses versus fetal calf serum-treated viruses.Heat-inactivated sera (56° C., 1 hr) were used as controls.

TE671 target cells were seeded at a density of 3×10⁵ cells per well in6-well plates one day prior transduction. Serial dilutions of vectorpreparations were added to the cells in the presence of 6 μg/ml ofpolybrene, and the cultures were incubated for 4 hrs at 37° C. Thevector-containing medium was then replaced with normal culture mediumand the cells were incubated for 72 hrs at 37° C. The transductionefficiency, determined as the percentage of GFP-positive cells, wasmeasured by FACS analysis following individualisation of the transducedcells in trypsine and their re-suspension in PBS. The infectious titres,provided as infectious units (i.u.)/ml, were calculated by using theformula: Titre=% inf×(3×10⁵/100)×d; where “d” is the dilution factor ofthe viral supernatant and “% inf” is the percentage of GFP-positivecells as determined by FACS analysis using dilutions of the viralsupernatant that transduce between 1% and 5% of GFP-positive targetcells.

10. Transduction of Primary Cells

Purified CD34⁺ cells were incubated overnight in 12-well plates at 2×10⁶cells/well in 2 ml of StemSpan SFEM medium supplemented with antibiotics(StemCell Technologies, Meylan, France) and with 10 ng/ml ofthrombopoietin (TPO; Peprotech Inc, London, UK). Pre-activated CD34+cells were then seeded in 96-well plates (10⁴/well) and were transducedwith the pseudotyped vectors in a total volume of 200 μl StemSpan mediumcontaining TPO and 6 μg/ml of polybrene. Variable multiplicities ofinfection (MOIs), determined using TE671 target cells, were applied tothe target cells and were in the range of 0.5 to 60 infectiousparticles/target cell. Transduction in retronectin-coated wells (CH-296;Takara Shuzo, Japan) was performed using the same protocol in 96-wellplates pre-coated for 2 hrs with 8 μg retronectin/well. After 16 hours,CD34⁺ cells were washed, suspended in 400 μl of StemSpan mediumsupplemented with 10% fetal calf serum (Life Technologies, France), withantibiotics, and with 10 ng/ml of Flt3-L, TPO, and stem cell factor(SCF) for 3 days. GFP expression was analyzed by FACS analysis 5 dayspost-infection.

Human and macaque PBLs were pre-activated for 24 hr before infection asdescribed previously by adding 1 μg of anti-CD3 (HIT3a, Pharmingen) andanti-CD28 (CD28.2, Pharmingen) antibodies to 1 ml of medium containing2×10⁶ human PBLs²⁹ or by adding 5 ng/ml of concanavalin A and 10 ng/mlof IL2 to 2×10⁶ macaque PBLs³⁷. For transduction, 10⁵ activated PBLswere mixed with the pseudotyped vectors in a total volume of 1 ml of PBLmedium supplemented with 6 μg/ml of polybrene, for 4 hrs at 37° C. Afterinfection, cells were washed in PBS and incubated at 37° C. for 5 daysin RPMI-1640 (Life Technologies, France) supplemented with IL2 untiltransduction efficiency was determined by FACS analysis.

B. Examples 1-10 Example 1 Ability of Different Viral Glycoproteins toPseudotype an SIV Vector

We examined a panel of viral glycoproteins (GPs) for their ability topseudotype lentiviral vectors derived from simian immunodeficiency virus(SIVmac251). These glycoproteins were derived from type C mammalianretroviruses, such as the Env GPs of the feline endogenous retrovirusRD114, the amphotropic murine leukemia virus (MLV-A), the MLV-10A1 andthe gibbon ape leukemia virus (GALV), or from membrane-envelopedviruses, such as the fowl plague virus (FPV hemagglutinin—FPV-HA), thelymphocytic choriomeningitis virus (LCMV), Ebola virus (EboV), andvesicular stomatitis virus (VSV) GPs. Pseudotyped SIN vectors weregenerated by transient expression in 293 T cells transfected with threeplasmids (FIG. 1) encoding the SIN viral core proteins, an SIN-basedtransfer vector harboring the GFP marker gene, and the different GPs.Infection assays on TE671 human rhabdomyosarcoma cells indicated thattiters higher than 105 i.u./ml were obtained for vectors generated withthe GPs of VSV, LCMV, MLV-A and MLV-10A1 (FIG. 2A). In contrast, vectorsgenerated with the GPs of EboV and FPV had low titers, of less than5×10³ i.u./ml. SIV vectors generated with the GPs of GALV and RD114 hadintermediate titers, between 10⁴ and 5×10⁴ i.u./ml. These relativedifferences in infectivity of the pseudotyped vectors were reproduced onother target cells such as 293T cells (data not shown), suggesting thatdetermination of the infectious titers on TE671 cells reflected thecapacity of the different GPs to pseudotype SIN cores.

The infectious titers obtained with SIV vectors generated with the GPsof FPN, GALN and RD114 were surprisingly low in comparison to thoseachieved with MLN vectors pseudotyped with the sameglycoproteins^(21,34,38). Since budding of lentiviral core particles isnot dependent on the expression of viral glycoproteins, this suggestedthat the virions could not efficiently incorporate these GPs or,alternatively, that they could not egress from producer cells after GPassembly. Indeed, when vector-producer cells expressing the FPN-HA weretreated with neuraminidase, infectivity of HA-pseudotyped vectors wasstrongly increased by up to 100 fold (FIG. 2A). This enhancementcorrelated with a 50-fold increased production of viral particles in thesupernatant of producer cells (data not shown). This was most likelyinduced by neuraminidase-mediated release of virions from the cellsurface on which they were retained because of binding tosialic-acid-containing cell-surface molecules^(40,41). However, such adefect in virion egress could not explain the lack of infectivity of SIVvectors generated with the GALN and RD114 GPs since the titers of MLNvectors pseudotyped with the latter glycoproteins are generallyhigh^(21,34). This suggested, rather, a defect at the level of GPincorporation on the lentiviral cores. Previous studies have indicatedthat the cytoplasmic tail of mammalian type C retroviruses bearselements that control the formation and/or infectivity of pseudotypeswith primate lentiviruses^(8,13-15). Since the MLN-A GP efficientlypseudotypes lentiviral vectors (FIG. 2A), we hypothesized that itscytoplasmic tail should contain all the elements required for optimal GPincorporation on lentiviral particles. Indeed, replacement of thecytoplasmic tail of RD114 (FIG. 2B) and GALN GPs with that of MLN-A GPresulted in strongly increased incorporation of either glycoprotein onlentiviral cores, as shown in FIG. 2C for the RD114 GP and elsewhere forthe GALN GP^(8,13,15). These chimeric GALN and RD114 GPs, named GALN/TRand RD114/TR, preserved the host-range of the initial glycoproteins, asassessed on receptor-interference assays (data not shown), and conferred25 fold increased titers to the SIV vectors (FIG. 2A).

Example 2 Characterization of Pseudotyped SIV-Based Vector Stocks

We sought to characterize the properties of vectors coated with themodified or unmodified viral glycoproteins that efficiently pseudotypedthe SIV vector particles. The SIN vector pseudotypes were concentratedby ultracentrifugation, re-suspended in a storage buffer containing 1%BSA, aliquoted and stored at −80° C. prior to infection assays. Althoughvectors coated with MLN-10A1 GP had fair titers before concentration,they were not used in the further analyses because they could not beefficiently concentrated (data not shown). In contrast, vectorspseudotyped with FPN-HA, VSV-G or with the GALV/TR, RD114/TR, MLV-A andLCMV glycoproteins were very efficiently concentrated, allowing recoveryof more than 80%, on average, of the infectious particles after a100-fold concentration of the physical particles (data not shown). Asvectors pseudotyped with the FPV-HA and LCMV glycoproteins failed totransduce the primary hematopoietic cells tested here (i.e., PBLs andCD34⁺ cells; data not shown), they were not analyzed further. Infectioustiters of the concentrated stocks of vectors pseudotyped with theremaining glycoproteins (i.e., MLV-A, GALV/TR, RD114/TR and VSV-G) weredetermined using TE671 target cells and were in the range of 5×10⁶ forthe less infectious pseudotypes, obtained with GALV/TR GP, to 1×10⁸i.u./ml for the most infectious one, obtained with VSV-G (FIG. 3A).Similar differences in titers between the vector pseudotypes weredetected on other human adherent cell lines (data not shown). Thisindicated that titer determination using the highly permissive TE671cells reflected the evaluation of the specific infectivity ofpseudotyped vectors. Importantly, the number of infectious particlescorrelated with the presence of physical particles. As shown in FIG. 3B,within a given preparation of pseudotyped vectors, similar amounts ofvirion-associated capsid proteins were detected for the vectorpseudotypes that gave the highest titers (VSV-G and MLV-A or

RD1 14/TR GPs). Lower amounts of physical particles were reproduciblydetected for virions pseudotyped with GALV/TR GPs, in agreement withtheir lower titers (FIG. 3A). However, important differences in theabsolute quantities of virion-associated capsid proteins were noticedwhen two independent vector preparations were compared, despitecomparable infectious titers

(data not shown). Thus, to minimize artifacts due to differences in thequality of vectors stocks, each subsequent evaluation experiment wasconducted using pseudotyped vectors generated concurrently. Moreover,since the detection of virion-associated capsid proteins did not appearto be a valid indicator of infectious particles and precluded comparisonof results, normalization of the pseudotyped vector stocks was performedusing titers determined on TE671 cells.

Example 3 Stability of Vector Pseudotypes in Primate Sera

Vectors suitable for in vivo gene delivery should be stable at 37° C.and should retain high infectivity in primate sera. The stability of thevector pseudotypes was therefore determined by comparing titers of viralparticles incubated for one hour at 37° C. versus 4° C. Lentiviralvectors pseudotyped with RD1 14/TR GP or VSV-G were stable at 37° C.,with more than 85% of the vector particles remaining infectious afterincubation at 37° C. (data not shown). In comparison, vectorspseudotyped with MLV-A and GALV/TR GPs lost more than 75% of infectivityfollowing incubation at 37° C. (data not shown), suggesting that thelatter GPs incorporated into lentiviral core particles weretemperature-sensitive.

The stability of the pseudotyped vectors in human and cynomolgus macaquesera was evaluated. The same quantities of pseudotyped infectiousparticles were mixed with fresh primate sera at a ratio of 50/50 (v/v)and incubated for one hr at 37° C. Heat-inactivated primate sera as wellas fetal calf serum (FCS) were used as controls. The results,represented as the percentages of residual infectivity after incubationin fresh or heat-inactivated primate sera relative to the infectivity ofFCS-incubated virions (100%), are shown in FIG. 4. The VSV-G-pseudotypedvectors were inactivated by both human and macaque sera, resulting inmore than 90% degradation of viral particles. Vectors pseudotyped withthe retroviral glycoproteins were significantly more resistant in humansera, although their levels of resistance were variable according to theserum sample tested and the type of retroviral GP. Vectors pseudotypedwith MLV-A glycoproteins were stable in human serum but were relativelysensitive to inactivation by macaque serum. Vectors coated with GALV/TRGP displayed variable levels of stability in human and macaque sera. Incontrast, lentiviral vectors pseudotyped with the RD114/TR GP exhibitedcomplete stability in all human sera tested (FIG. 4A) and presented goodstability in macaque sera (FIG. 4B).

Example 4 Transduction of Human and Macaque Primary Hematopoietic Cells

We next compared the different vector pseudotypes for their capacity totransduce primary hematopoietic cells such as CD34⁺ cells and PBLs.Human CD34⁺ cells derived from mobilized blood were pre-activatedovernight in serum-free medium supplemented with TPO and were transducedfor 16 hours with a single-hit of SIN vectors pseudotyped with theMLN-A, GALN/TR, RD114/TR or NSN-G glycoproteins. Variable multiplicitiesof infection (MOIs), as determined using infectious titers assessed onTE671 cells, were used to transduce the CD34+ cells. Side-by-sidetransductions experiments were performed in the presence, or in theabsence, of CH-296 retronectin fragment⁴²⁻⁴⁴. After infection, cellswere grown for 5 days in the presence of low concentrations of TPO, SCFand Flt3-L. GFP expression was readily detected in the transduced cellsby flow cytometry, allowing us to evaluate the influence of the MOIs andthe pseudotyping GP on transduction efficiency (FIG. 5A). Fortransduction in the absence of retronectin, the percentage of GFP cellsinitially increased as a direct function of the MOI and the curvesflattened at MOIs comprised between 2 and 20, reaching a maximum of 25%GFP⁺ cells. These moderate transduction efficiencies were likely due tothe sub-optimal infection protocol, and specifically the single andshort incubation of target cells with virions. In these experimentalconditions, the most efficient vectors were those pseudotyped with theVSV-G glycoprotein (mean GFP+ cells: 24.75%±3.23%; n=5), although, atMOIs lower than 2, SIV vectors pseudotyped with GALV/TR and MLV-A GPsexhibited a transduction efficiency higher than that ofVSV-G-pseudotyped vectors (see inset in FIG. 5A). However, at the mostefficient MOIs tested, vectors generated with the MLV-A, GALV/TR andRD114/TR glycoproteins achieved 5 to 12-fold lower transductionefficiencies than VSV-G-pseudotypes (FIG. 5 A). The relatively lowtiters of vectors generated with the GALV/TR GP (FIG. 3A) did not allowtransduction efficiency to be evaluated at high MOIs. Divergent resultswere obtained when infections of CD34⁺ cells were performed onretronectin-coated plates (FIG. 5A). Under these conditions, theVSV-G-pseudotyped vectors retained the same maximal transductionefficiency (24.56%±3.27% GFP+ cells; n=5) than in the absence ofretronectin, in agreement with results of others⁴⁵. In contrast, theRD114/TR-pseudotyped vectors exhibited a 10-fold increased transductionefficiency, reaching up to 65% GFP+ cells (mean: 51.30%±8.74%; n=5),indicating that the combined use of RD114/TR GP and retronectinsynergistically enhanced infection. The retronectin also enhanced thetransduction efficiency of vectors pseudotyped with GALV/TR and MLV-AGPs, yet with a much lower magnitude compared to vectors pseudotypedwith RD114/TR GP (FIG. 5A).

We then transduced macaque CD34⁺ cells derived from bone marrow with thepseudotyped vectors (FIG. 5B). In the absence of retronectin, the bestpseudotyping GP was VSV-G, allowing transduction of up to 26% GFP⁺ cells(21.7%±3.51%; n=5). SIV vectors pseudotyped with the GALV/TR and withthe MLV-A GPs were the less efficient to transduce macaque CD34⁺ cells(maximal transduction efficiency of 3% GFP⁺ cells). Compared to vectorspseudotyped with VSV-G, the RD114/TR GP-pseudotyped vectors resulted inabout 2-fold less efficient transduction (10.12%±1.26%, n=4). Thepresence of retronectin during transduction did not improve theefficiency of transduction by VSV-G-pseudotyped vectors (FIG. 5B).However, in a manner similar to transduction of the human CD34⁺ cells,retronectin enhanced transduction of macaque CD34⁺ cells by lentiviralvectors pseudotyped with MLV-A and RD114/TR GPs. Under these conditions,maximal levels of transduction of up to 30% GFP⁺ cells (24.23%±4.15%,n=5) could be obtained with RD114/TR-pseudotyped vectors (FIG. 5B).

We then determined the transduction efficiencies of the pseudotyped SIVvectors in human and macaque PBLs. PBLs, isolated from fresh blood, wereincubated for 4 hours with the vectors in the absence of retronectin.Pre-activation of the PBLs for 24 hrs with soluble anti-CD3 andanti-CD28 antibodies was necessary for transduction with lentiviralvectors, as previously reported^(26,29,46). As a result of theseexperimental conditions that favored stimulation and survival of CD3+cells, transduction of PBLs was oriented to T cells. GFP expression,determined at 5 days post-infection (FIG. 6), showed that transductionof the PBLs was dependent on the MOI. At low MOIs, the percentages ofGFP⁺ cells steadily increased for the different vector pseudotypes untilreaching plateaus. The MOIs required for reaching these plateaus variedwith the vector pseudotype. The plateaus of transduction were quicklyreached at MOIs of less than 5 infectious particles per cell forlentiviral vectors pseudotyped with VSV-G, with MLV-A GP or with GALV/TRGP (FIG. 6A). In contrast, the threshold MOI necessary to reach aplateau with RD114/TR GP-pseudotyped virions was of about 5-10infectious particles per cell (FIG. 6A). Interestingly, the maximaltransduction levels also varied with the vector pseudotype tested.VSV-G-pseudotyped vectors only transduced a maximum of 10-23% of T cells(mean: 16.87%±6.53%; n=4). This somewhat low level of transduction is inagreement with our previous results26 obtained with a VSV-G-pseudotypedHIV-1-derived vector of the same generation and design as the SIV-T1⁺vector used in this report. In contrast, much higher levels oftransduction, reaching 50-75%, were achieved with vectors pseudotypedwith the RD1 14/TR chimeric GP (55.04%±11.74%; n=4). Maximaltransduction efficiencies obtained with the other pseudotyped vectorsremained low although, as mentioned above, the low titers of vectorscoated with the GALN/TR chimeric GP did not allow us to assay for MOIshigher than 2. Additionally, for some vector preparations, thetransduction efficiency was found to decrease when high MOIs of MLN-A GPor GALN/TR GP-pseudotyped Sr vectors were used to transduce the humanPBLs (FIG. 6A). This effect was probably due to competition for receptorbinding induced by an excess of defective particles or by soluble GP“shed” from viral particles, as suggested in recent studies^(44,47.)

Similar results were obtained for transduction of macaque PBLs, althoughthe threshold MOIs necessary to reach the plateaus of infection seemedhigher than those necessary for human PBLs and the maximal levels oftransduction were lower than those obtained with human PBLs (FIG. 6B).Transduction efficiencies obtained with vector particles pseudotypedwith GALV/TR or MLV-A GPs remained very low (less than 4-12% GFP⁺ cells)and were found to decrease at MOIs higher than 1. In comparison tovectors pseudotyped with these latter GPs or with VSV-G (15.32%)±10.06%;n=4), PBL transduction with RD114/TR GP-pseudotyped vectors wasfacilitated. Up to 40% of GFP⁺ cells could be transduced (26.86%±8.07%;n=4) although higher transduction levels might clearly be expected whenusing MOIs superior to those applied in these experiments.

Altogether these results indicated that the RD114/TR glycoprotein wasparticularly potent to allow transduction of primate CD34⁺ cells andPBLs with pseudotyped SJN vectors, although the RD114/TR GP-pseudotypedSIN vectors required the retronectin CH-296 fragment for optimaltransduction of short-term stimulated CD34⁺ cells.

Example 5 Design of RD1 14 GP Cytoplasmic-Tail Mutants

As determined by the morphology of its intracellular core particle, thefeline endogenous virus RD114 is a type C mammalian retrovirus (32).However its GP is typical of that of simian type D retroviruses (28),with which it shares the same cell surface receptor, RDR (31, 38), andbears significant homology with the GP of MPMN (Mason-Pfizer monkeyvirus), in the TM subunit, in particular (FIG. 7). In a previous report,we have found that the RD1 14 feline endogenous virus glycoprotein didnot allow efficient pseudotype formation with lentiviral cores (35).Here we sought to investigate the determinants of the RD114 GP thatrestrict pseudotyping with lentiviral vectors derived from SIN (simianimmunodeficiency vims).

Recent studies have indicated that the transmembrane domain and/orcytoplasmic tail of mammalian type C retroviruses bear elements thatcontrol formation and/or infectivity of pseudotypes with HIV-1 vectors(4, 34, 36). Such elements might possibly influence the infectivity ofviral particles at different levels: i) cellular co-localisation of theGP and viral cores necessary for viral assembly, ii) GP interactionswith viral core proteins that condition GP incorporation, and iii)activation of GP fusogenicity through cleavage of its cytoplasmic tailby the retroviral protease during or shortly after virion budding. TheGPs of both amphotropic MLN (MLN-A) and RD114 efficiently pseudotypesMLN core particles (6, 39). Therefore, since the GP of MLN-A alsoefficiently pseudotypes SIN viral cores (24, 35), we assumed that itshould contain elements that optimally control the assembly and/orinfectivity of SIN vector pseudotypes, in contrast to those carried bythe RD114 GP. Thus, to define determinants that restrict the capacity ofthe RD114 GP to pseudotype lentiviral core particles, we generated apanel of RD114 GP mutants into which sub-regions derived from itstrans-membrane domain (TMD) and/or its cytoplasmic tail (CT) werereplaced by their counterparts derived from MLN-A GP (FIG. 7B). MutantRD/TR was generated to address the importance of the MLV CT itself.Mutants RD/MTR and RD/eMTR carried the MLV TMD in addition to the MLVCT. The RDRless GP was a truncated version of RD114 GP and was generatedby insertion of a stop codon at a position corresponding to a putativecleavage site of its CT (see below). Mutant RDPrMLV harbored replacementof the putative RD114 CT cleavage site with that of MLV GP. Thecytoplasmic tails of the other mutants, RDPrSIV_(ARLM), RDPrSIV_(RQAG)and RDPrHTV, contained substrates for the SIVmac or HIV-1 coreproteases, which were respectively derived from cleavage sites found inthe Gag proteins of SIVmac251 or of HIV-1. Finally, mutant RDΔYXXL wasdesigned to evaluate the importance of a putative tyrosine endocytosismotif carried by the RD114 CT, which might influence GP localisation,cell-surface expression and/or fusogenicity. The influence of this motifhas been well characterised for other retroviral GPs (1, 13, 19).

Production of all GP mutants was achieved using identicalexpression-vectors under control of a CMV promoter. 293 producer cellswere co-transfected with plasmids encoding the components of vectorparticles, i.e., the viral core proteins, the transfer vector and eitherof the different GPs. No variations in the quantities of either coreproteins or GPs were detected, as monitored by immuno-blotting of celllysates using anti-RD114 SU antibodies (data not shown).

Example 6 Modifications of the RD1 14 GP Cytoplasmic Tail AlterCell-Cell Fusogenicity

Cultures of the GP-expressing cells showed formation of syncytia, whoseincidence was found to depend on the type of mutation introduced in thecytoplasmic tail (FIG. 8). Compared to wild-type MLV-A GP, expression ofthe unmodified RD114 GP itself induced significant syncytia formation.This effect appeared to be caused by an inefficient control of GPfusogenicity by the RD114 CT since its substitution with that of MLV-A(mutants RD/TR, RD/MTR and RD/eMTR) significantly reduced the number ofsyncytia in the transfected cells to the levels detected with wild-typeMLV-A GP (FIG. 8). The other RD114 chimeric GPs induced variable levelsof syncytia. Maximal cytopathic effects were noticed for the RDPrHIV andRDRless mutants. With the exception of mutant RDPrSIV_(ARLM) which wasas fusogenic than the unmodified RD114 GP, the other chimeras (RDAYXXL,RDPrMLV, and RDPrSIV_(RQAG)) induced the formation of syncytia at levelshigher than those obtained with the wild-type RD114 GP (FIG. 8). Alteredcell-cell fusogenicity was intrinsically linked to modifications of theRD114 GP and was not influenced by interaction with the other viralcomponents present in the transfected cells. Indeed the same levels ofsyncytia were detected whether the cells expressed, or not,onco-retroviral or lentiviral core proteins (data not shown). Since novariation in GP-expression could be found for the different RD114 GPchimeras, these results established the role played by the RD114 GPcytoplasmic tail in the control of cell-cell fusogenicity. ThisCT-mediated fusion control was reminiscent of that of other mammaliantype C and D retrovirus GPs, such as MLNs and MPMN (2, 30, 33). Sequencemodification of the cytoplasmic tail of the RD1 14 glycoprotein mostlikely altered its fusion-inhibitory properties, at the instar of MLN-AGP (14, 17, 43). Thus, to minimise the cytopathic effects induced bymodifications of the RD114 GP that could be counter-productive for theformation of viral particles, harvests of virions in the supernatants ofproducer cells were performed shortly, i.e., 36 hrs after transfection.

Example 7 Modifications of the RD114 GP Cytoplasmic Tail ModulatePseudotyping of Lentiviral or Onco-Retroviral Vectors

The capacity of the RD114 GP mutants to pseudotype either SIVmac251- orMLN-based vectors was determined comparatively to wild-type RD114 GP,MLN-A GP and NSV-G. The infectivity of vectors generated in the presenceof the different GPs was assessed using TE671 target cells (FIG. 9).Consistent with our previous results, the unmodified RD114 GP could wellpseudotype MLV-based vectors (6), but not efficiently lentiviral-basedvectors (35). Both SIV and MLV vectors generated with the RDΔYXXL GPmutant had 3 to 4 fold lower titres than vectors pseudotyped withunmodified RD114 GP (FIG. 9). Titres of vectors generated with thehyperfusogenic mutant RDRless were also lower than those generated withwild-type RD114 GP, yet we could not rule out that the particularlystrong cytopathic effect exerted by this mutant (FIG. 8) did notpreclude the optimal formation of vector particles. Importantly, theRD/TR and RD/MTR chimeric GPs efficiently pseudotyped the SIV-basedvectors, hi the case of the RD/TR mutant, this resulted in infectioustitres higher than 10⁶ i.u/ml; i.e., up to 25 fold higher than thoseobtained with the wild-type RD114 GPs, and in the same range, if nothigher, than infectious titres obtained with SIV vectors pseudotypedwith MLV-A GP or VSV-G (FIG. 9B). In contrast, MLV-derived vectorsgenerated with the same chimeric GPs displayed only up to a 2-foldincrease of infectivity compared to vectors pseudotyped with wild-typeRD1 14 GP, whose titres were aheady high (FIG. 9A). Since thecytoplasmic tail was the minimal domain modified in these RD114 GPchimeras that led to increased infectivity of pseudotyped lentiviralvectors, these data therefore suggested that the CT of MLV-A, ratherthan its TMD, harboured a component that facilitated pseudotypeformation with SIV vectors. Investigation of further RD1 14 GP chimeras(FIG. 7B) established that this component was located in a region thatencompassed a putative cleavage site in its cytoplasmic tail.

Viral protease-mediated removal of the C-terminal end from mammaliantype C and D retroviruses TM proteins, called R peptide for MLVs, hasbeen shown to be essential to activate their fusion functions (2,30,33). This carboxy-terminal processing of the TM proteins occurs duringof after budding of the virions. Cleavage of the cytoplasmic tail andsubsequent activation of fusogenicity has not been reported so far forthe RD114 GP. Our results indicate that processing of the RD114 TM isalso likely to be required in order to promote full fusion activity ofthe glycoprotein upon receptor binding. Indeed, truncation of the RD114GP by insertion of a premature stop codon (mutant RDRless) resulted inhigh cell-cell fusogenic activity (FIG. 8), a phenotype similar to thatof the R-truncated GP mutants of either type C or D mammalianretroviruses (2, 10, 30, 33). Moreover sequence alignment of thecytoplasmic tail of RD114 GP with the CTs of several type C and type Dmammalian retroviral GPs allowed to predict the position of a 8amino-acid-long sequence—VHAMVLAQ (SEQ ID NO: 27)—in the cytoplasmictail of the RD114 GP that most likely formed a retroviral proteasecleavage site (FIG. 7A). Interestingly, replacement of this sequence bycleavage sites derived from the MLV CT (mutant RDPrMLV) or from SIV Gagproteins (mutants RDPrSIV_(ARLM) and RDPrSIV_(RQAG)) resulted in up to 7fold increased infectivity of SIV vector pseudotypes (FIG. 9B).Likewise, insertion of a cleavage site derived from HIV-1 Gag proteins(mutant RDPrHIV) selectively increased pseudotype formation withHIV-1-based vectors (data not shown), but not with SIV-derived vectors(FIG. 9B). These results therefore indicated that this 8 amino-acidssequence contains an essential component that modulates pseudotypeformation with lentiviral vector particles. Very different results wereobtained when the latter RD1 14 GP chimeras were used to pseudotype MLNvector particles (FIG. 9A). Although MLN vectors pseudotyped with theRDPrMLV mutant displayed similar or slightly increased infectivitycompared to viral pseudo types formed with the wild-type RD1 14 GP, RD114 chimeric GPs harbouring lentiviral cleavage sites (RDPrSIV_(ARLM),RDPrSIV_(RQAG) and RDPrHIN) dramatically decreased the infectivity ofthe MLN pseudotyped vectors, by up to 20 fold (FIG. 9A). Thus the RD1 14chimeras behaved differentially when they were associated to eitherlentiviral or onco-retroviral cores. Therefore these results stronglysuggested that particular core/CTs interactions occurred in a virustype-specific manner and could control GP incorporation and/orprocessing of the cytoplasmic tail.

Example 8 Modifications of the RD114 GP Cytoplasmic Tail Alter ViralIncorporation

We then sought to determine whether modifications of the RD114glycoprotein might affect its incorporation on viral particles. Theseexperiments were conducted comparatively to unmodified RD114 GP on asubset of the GP mutants, RDPrMLV, RDPrSIV_(ARLM), RDPrSIV_(RQAG) andRD/TR, which did not induce syncytia formation in a too extensive manner(FIG. 8). Indeed, the high cell-cell fusogenic activity of the othermutants (RDPrHIN and RDRless) compromised the quality of the purifiedvirion preparations by releasing cell debris in the producer cellsupernatants (data not shown). Viral particles carrying either SIN orMLN cores were generated with the RD114 GP chimeras and were purified byultracentrifugation through 20% sucrose cushions. Detection andquantification of both viral core proteins and glycoproteins wereperformed by immunoblotting of the purified virions using anti-CA oranti-RD114 GP antibodies and allowed to measure the densities of RD114GP chimeras on the viral particles (FIG. 4). No GP could be detected inthe pellets of ultracentrifuged supernatants from producer cells thatonly expressed the glycoproteins in the absence of viral cores (FIG. 4),thus demonstrating the specificity of the signals obtained with thepurified virions. Compared to wild-type RD114 GP, the RDPrSIV_(ARLM) GPmutant was equally well incorporated on SIV core particles, despite theincreased infectivity conferred by this GP (FIG. 9B). In contrast,incorporation of the RDPrMLV, RDPΓSIV_(RQAG) and RD/TR chimeric GPs onSIV vector particles was increased by 3 to 10 fold (FIG. 4), inagreement with the strongly enhanced titres obtained with these mutantGPs (FIG. 9B). Thus, these results indicated that incorporation of theRD114 GP chimeras on SIV cores particles and infectious titres of thepseudotyped vectors were correlated, although the case of theRDPrSIN_(ARLM) GP mutant ruled out an absolute correlation.

Contrasting results were obtained for incorporation of the same GPchimeras on MLV core particles. Incorporation of the RD/TR GP chimerawas weakly increased, by up to 2 fold (FIG. 4), consistent with theslightly enhanced viral titres obtained with this particular mutant(FIG. 9A). However, compared to unmodified RD114 GP, the RDPrMLV,RDPrSIV_(ARLM) and RDPrSIV_(RQAG) GP mutants had similar densities onMLV particles (FIG. 4), despite the strongly reduced titres of the twolatter GP chimeras on the pseudotyped MLV vectors (FIG. 9A). Therefore,on pseudotyped MLV cores, no correlation could be demonstrated betweenGP incorporation and infectivity.

Example 9 Modifications of the RD114 GP Cytoplasmic Tail Alter itsCleavage in a Viral Core-Dependent Manner

We then investigated whether the cytoplasmic tail of the RD114 GPchimeras was cleaved in pseudotyped MLN or SIV viral core particles.Transfected cells, producing either of the two types of pseudotypedvirons, were radio-labelled with S-methionine and S-cysteine. Lysates ofthe virion-producer cells or of virions purified on 20% sucrose cushionswere incubated with anti-RD114 SU antibodies. After immuno-precipitationof the glycoproteins, samples were reduced and denatured to allowdissociation of the TM proteins for the immuno-precipitated GP complexesand then analysed by SDS-PAGE (FIG. 5). Lysates of virion-producer cellsrevealed similar quantities of both SU and TM glycoproteins, asexpected. All mutant TM glycoproteins had the same electrophoreticmobility on gels (FIGS. 5A and B), indicating that the majority of theCTs of the different TM species were not cleaved inside the producercells. These results also confirmed that the modulation of the cell-cellfusogenicity of the mutant RD1 14 GPs was not dependent on processing oftheir TM proteins (FIG. 8) but, rather, was intrinsically linked toalteration of the structure or conformation of their cytoplasmic tails.

The different RD114 GP chimeras had similar intensities on the purifiedMLV viral cores, for both SU and TM subunits (FIG. 5 A). This resultconfirmed that modification of their cytoplasmic tails did not affecttheir incorporation on onco-retroviral cores (FIG. 4). However,processing of the incorporated TM glycoproteins was detected in a mannerdependent on the type of RD114 GP chimera. Indeed, compared to the sizeof their TM proteins in cell lysates, the TM subunits of the unmodifiedRD114 GP and of the chimeric RDPrMLV and RD/TR chimeras wereapproximately 2 kDa shorter (FIG. 5). This observation directlyconfirmed the genetic evidence for TM processing of the RD114 GP by theviral core protease. In contrast, only unprocessed TMs were detected onMLV cores for the RDPrSIV_(ARLM) and RDPrSIV_(RQAG) GP mutants (FIG. 5A)that harbour lentiviral protease-specific cleavage sites (FIG. 7B).These results were in agreement with the strongly reduced infectivity ofMLV vectors pseudotyped with the latter RD1 14 chimeric GPs (FIG. 9A)and confirmed that cleavage of the cytoplasmic tail of the RD114 GP isrequired to allow virion infection.

In contrast to MLV cores, variable quantities of both SU and TMglycoproteins were detected on SIV core particles (FIG. 5B) and were inagreement with the results of differential GP incorporation into virions(FIG. 4). In the case of the RDPrSIV_(RQAG) and RD/TR GP mutants whoseSUs were readily incorporated on SIV particles, the TM proteins could beobserved (FIG. 5B). Efficient processing of the cytoplasmic tails of thelatter RD114 GP chimeras could be detected, in agreement with theresults of infectivity of the SIV vector pseudotypes (FIG. 9B).

The TM proteins of the unmodified RD114 GP and of the RDPrMLV andRDPrSIV_(ARLM) mutant GPs were not easily detected under normalconditions of exposure of the gels, in agreement with the results ofincorporation (FIG. 9B). Over-exposure of the gels revealed that the TMproteins of the latter GPs were processed (data not shown). This resultexplained the low infectious levels obtained with SIV vector particlesgenerated with these latter GPs (FIG. 9B).

Example 10 Modifications of the RD114 GP Cytoplasmic Tail do not AffectGP Localisation in Lipid Rafts

Recent reports have shown that lentiviruses may assemble and budselectively from lipid rafts (18, 25, 26). Therefore one possibility toexplain the differential incorporation of the RD114 GP mutants onpseudotyped SIN particles could be the variation of co-localisation ofviral core components and glycoproteins at the viral assembly site as aresult of modification of the RD114 GP cytoplasmic tail. Thus weinvestigated whether the RD114 GP might localise to lipid rafts andwhether modification of its cytoplasmic tail may alter cellularlocalisation. Lipid rafts are resistant to nonionic detergents at lowtemperature and can be physically separated from the bulk of solublemembranes by sucrose gradient centrifugation. Membranes of cellstransfected with the different GP mutants were fractionated under theseconditions and the GP content of the membrane fractions was analysed bywestern-blot analysis (FIG. 6). Wild-type RD114 GP as well ascytoplasmic tail mutants appeared in the detergent-resistant fractionsof the lysates of transfected cells, indicating that all GPs weretargeted to rafts.

All of the compositions and/or methods disclosed and claimed herein canbe made and executed without undue experimentation in light of thepresent disclosure. While the compositions and methods of this inventionhave been described in terms of preferred embodiments, it will beapparent to those of skill in the art that variations may be applied tothe compositions and/or methods and in the steps or in the sequence ofsteps of the method described herein without departing from the concept,spirit and scope of the invention. More specifically, it will beapparent that certain agents which are both chemically andphysiologically related may be substituted for the agents describedherein while the same or similar results would be achieved. All suchsimilar substitutes and modifications apparent to those skilled in theart are deemed to be within the spirit, scope and concept of theinvention as defined by the appended claims.

REFERENCES

The following patent and non-patent references, to the extent that theyprovide exemplary procedural or other details supplementary to those setforth herein, are specifically incorporated herein by reference.

-   U.S. Pat. No. 4,682,195-   U.S. Pat. No. 4,683,202-   U.S. Pat. No. 5,466,468-   U.S. Pat. No. 5,645,897-   U.S. Pat. No. 5,686,279-   U.S. Pat. No. 5,705,629-   U.S. Pat. No. 5,846,225-   U.S. Pat. No. 5,846,233-   U.S. Pat. No. 5,925,565-   U.S. Pat. No. 5,928,906-   U.S. Pat. No. 5,935,819-   U.S. Pat. No. 5,994,136-   U.S. Pat. No. 6,013,516-   U.S. Pat. No. 6,136,597-   EP 266,032

SUPERSCRIPT NUMBERED REFERENCES

-   1. Negre D, Duisit G, Mangeot P-E, Moullier P, Darlix J-L, Cosset    F-L. Lentiviral vectors derived from simian immunodeficiency vims    (SIN). In: Trono D, ed. Current Topics in Microbiology and    Immunology. Vol. 261; 2002:53-74-   2. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage F H, Verma    I M, Trono D. In vivo gene delivery and stable transduction of    nondividing cells by a lentiviral vector. Science. 1996; 272:263-267-   3. Blomer U, Naldini L, Kafri T, Trono D, Verma I M, Gage F H.    Highly efficient and sustained gene transfer in adult neurons with a    lentiviral vector. J Virol. 1997; 71:6641-6649-   4. Kafri T, Blomer U, Peterson D A, Gage F H, Verma I M. Sustained    expression of genes delivered directly into liver and muscle by    lentiviral vectors. Nat Genet. 1997; 17:314-317-   5. Naldini L, Blomer U, Gage F H, Trono D, Verma I M. Efficient    transfer, integration, and sustained long-term expression of the    transgene in adult rat brains injected with a lentiviral vector.    Proc Natl Acad Sci USA. 1996; 93:11382-11388-   6. Park F. Efficient lentiviral transduction of liver requires cell    cycling in vivo. Nat Genet. 2000, 24:49-52-   7. Takahashi M, Miyoshi H, Verma D V I, Gage F H. Rescue from    photoreceptor degeneration in the rd mouse by human immunodeficiency    vims vector-mediated gene transfer. J Virol. 1999; 73:7812-7816-   8. Christodoulopoulos I, Cannon P. Sequences in the cytoplasmic tail    of the gibbon ape leukemia virus envelope protein that prevent its    incorporation into lentivirus vectors. J Virol. 2001; 75:4129-4138-   9. Desmaris N, Bosch A, Salaun C, Petit C, Prevost M C, Tordo N,    Perrin P, Schwartz O, deRocquigny H, Heard J M. Production and    neurotropism of lentivims vectors pseudotyped with lyssavirus    envelope glycoproteins. Mol Ther. 2001; 4:149-156-   10. Kobinger G P, Weiner D J, Yu Q C, Wilson J M.    Filovirus-pseudotyped lentiviral vector can efficiently and stably    transduce airway epithelia in vivo. Nat Biotechnol. 2001; 19:225-230-   11. Lewis B C, Chinnasamy N, Morgan R A, Varmus H E. Development of    an Avian Leukosis-Sarcoma Virus Subgroup A Pseudotyped Lentiviral    Vector. J Virol. 2001; 75:9339-9344-   12. Mochizuki H, Schwartz J P, Tanaka K, Brady R O, Reiser J.    High-Titer Human Immunodeficiency Virus Type 1-Based Vector Systems    for Gene Delivery into Nondividing Cells. J. Virol. 1998;    72:8873-8883-   13. Salmon P, Negre D, Trono D, Cosset F-L. A chimeric GALV-derived    envelope glycoprotein harboring the cytoplasmic tail of MLV envelope    efficiently pseudotypes HJN-1 vectors. J Gen Med. 2000; 2 (sup):23-   14. Sandrin V, Boson B, Cosset F-L. Insertion of lentiviral protease    substrates in the cytoplasmic tail of the feline endogenous vims RD1    14 glycoprotein enhances viral incorporation and infectivity of    pseudotyped lentiviral vectors, in preparation. 2001-   15. Stitz J, Buchholz C, Engelstadter M, Uckert W, Bloemer U,    Schmitt I, Cichutek K. Lentiviral vectors pseudotyped with envelope    glycoproteins derived from gibbon ape leukemia vims and murine    leukemia vims 10A1. Virology. 2000; 273:16-20-   16. Gatlin J, Melkus M W, Padgett A, Kelly P F, Garcia J V.    Engraftment of NOD/SCID Mice with Human CD34+ Cells Transduced by    Concentrated Oncoretroviral Vector Particles Pseudotyped with the    Feline Endogenous Retrovirus (RD1 14) Envelope Protein. J. Virol.    2001; 75:9995-9999-   17. Goemer M, Horn P A, Peterson L, Kurre P, Storb R, Rasko J E,    Kiem H P. Sustained multilineage gene persistence and expression in    dogs transplanted with CD34(+) marrow cells transduced by    RD114-pseudotype oncoretrovims vectors. Blood. 2001; 98:2065-2070-   18. Kelly P, Vandergriff J, Nathwani A, Nienhuis A, Vanin E. Highly    efficient gene transfer into cord blood nonobese diabetic/severe    combined immunodeficiency repopulating cells by oncoretroviral    vector particles pseudotyped with the feline endogenous retrovirus    (RD114) envelope protein. Blood. 2000; 96:1206-1214-   19. Marandin A, Dubart A, Pflumio F, Cosset F-L, Cordette V,    Chapel-Fernandes S, Coulombel, L, Vainchenker W, Louache F.    Retroviral-mediated gene transfer into human CD34+/38-primitive    cells capable of reconstituting long-term cultures in vitro and in    nonobese diabetic-severe combined immunodeficiency mice in vivo.    Human Gene Ther. 1998; 9:1497-1511-   20. Movassagh M, Desmyter C, Baillou C, Chapel-Fernandes S, Guigon    M, Klatzmann D, Lemoine F M. High-level gene transfer to cord blood    progenitors using gibbon ape leukemia virus pseudotyped retroviral    vectors and an improved clinically applicable protocol. Hum Gene    Ther. 1998; 9:225-234-   21. Porter C D, Collins M K L, Tailor C S, Parker M H, Cosset F-L,    Weiss R A, Takeuchi Y. Comparison of efficiency of infection of    human gene therapy target cells via four different retroviral    receptors. Human Gene Therapy. 1996; 7:913-919-   22. Peng K W, Pham L, Ye H, Zufferey R, Trono D, Cosset F-L, Russell    S J. Organ distribution of gene expression after intravenous    infusion of targeted and untargeted lentiviral vectors. Gene    Therapy. 2001; 8:1456-1463-   23. Seganti L, Superti F, Girmenia C, Melucci L, Orsi N. Study of    receptors for vesicular stomatitis vims in vertebrate and    invertebrate cells. Microbiologica. 1986; 9:259-267-   24. DePolo N J, Reed J D, Sheridan P L, Townsend K, Sauter S L,    Jolly D J, Dubensky T W. VSV-G pseudotyped lentiviral vector    particles produced in human cells are inactivated by human serum.    Mol Ther. 2000; 2:218-222-   25. Negre D, Mangeot P, Duisit G, Blanchard S, Vidalain P, Leissner    P, Winter A, Rabourdin-Combe C, Mehtali M, Moullier P, Darlix J-L,    Cosset F-L. Characterization of novel safe lentiviral vectors    derived from simian immunodeficiency virus (SINmac251) that    efficiently transduce mature human dendritic cells. Gene Ther. 2000;    7:1613-1623-   26. Salmon P, Kindler N, Ducrey O, Chapuis B, Zubler R H, Trono D.    High-level transgene expression in human hematopoietic progenitors    and differentiated blood lineages after transduction with improved    lentiviral vectors. Blood. 2000; 96:3392-3398-   27. Salmon P, Arrighi J F, Piguet N, Chapuis B, Zubler R H, Trono D,    Kindler N. Transduction of CD34+ cells with lentiviral vectors    enables the production of large quantities of transgene-expressing    immature and mature dendritic cells. J Gene Med. 2001; 3:311-320-   28. Thiebot H, Louache F, Naslin B, Revel Td, Neildez O, Larghero J,    Nainchenker W, Dormont D, Grand R L. Early and persistent bone    marrow hematopoiesis defect in simianhuman immunodeficiency    vims-infected macaques despite efficient reduction of viremia by    highly active antiretroviral therapy during primary infection. J    Nirol. 2001; 75:11594-11602-   29. Maurice M, Nerhoeyen E, Salmon P, Trono D, Russell S J, Cosset    F-L. Efficient gene transfer into human primary blood lymphocytes by    surface-engineered lentiviral vectors that display a T    cell-activating polypeptide. Blood. 2002; 99: in press-   30. Mangeot P-E, Negre D, Dubois B, Winter A J, Leissner P, Methali    M, Kaiserlian D, Cosset, F-L, Darlix J-L. Development of minimal    lentiviral vectors derived from simian immunodeficiency vims    (SIVmac251) and their use for the gene transfer in human dendritic    cells. J Virol. 2000; 74:8307-8315-   31. Yee J K, Friedmann T, Burns J C. Generation of high-titer    pseudotyped retroviral vectors with very broad host range. Methods    Cell Biol. 1994; 43:99-112-   32. Hatziioannou T, Valsesia-Wittmann S, Russell S, Cosset F-L.    Incorporation of fowl plague virus hemagglutinin into murine    leukemia virus particles and analysis of the infectivity of the    pseudotyped retroviruses. J Virol. 1998; 72:5313-5317-   33. Collins M K L, Weiss R A, Takeuchi Y, Cosset F-L. Expression    systems. PCT/GB96/02061. WO 97/08330. 1996-   34. Cosset F-L, Takeuchi Y, Battini J, Weiss R, Collins M. High    titer packaging cells producing recombinant retroviruses resistant    to human serum. J. Virol. 1995; 69:7430-7436-   35. Ott D, Friedrich R, Rein A. Sequence analysis of amphotropic and    10A1 murine leukemia vims: close relationship to mink cell focus    forming viruses. J Virol. 1990; 64:757-766-   36. Takeuchi Y, Cosset F L, Lachmann P J, Okada H, Weiss R A,    Collins M K L. Type C retrovirus inactivation by human complement is    determined by both the viral genome and producer cell. J. Virol.    1994; 68:8001-8007 37. Matheux F, Lauret E, Rousseau V, Larghero J,    Boson B, Vaslin B, Cheret A, DeMaeyer E, Dormont D, LeGrand R.    Simian immunodeficiency vims resistance of macaques infused with    interferon beta-engineered lymphocytes. J Gen Virol. 2000;    81:2741-2750-   38. Hatziioannou T, Delahaye E, Martin F, Russell S J, Cosset F-L.    Retroviral display of functional binding domains fused to the    amino-terminus of influenza haemagglutinin. Human Gene Therapy.    1999; 10:1533-1544-   39. Freed E O. HIV-1 gag proteins: diverse functions in the vims    life cycle. Virology. 1998; 251:1-15-   40. Bosch V, Kramer B, Pfeiffer T, Starck L, Steinhauer D A.    Inhibition of release of lentivims particles with incorporated human    influenza vims haemagglutinin by binding to sialic acid-containing    cellular receptors. J Gen Virol. 2001; 82:2485-2494-   41. Wagner R, Wolff T, Herwig A, Pleschka S, Klenk H D.    Interdependence of hemagglutinin glycosylation and neuraminidase as    regulators of influenza vims growth: a study by reverse genetics. J    Virol. 2000; 74:6316-6323-   42. Carstanjen D, Dutt P, Moritz T. Heparin inhibits retrovirus    binding to fibronectin as well as retrovirus gene transfer on    fibronectin fragments. J Virol. 2001; 75:6218-6222-   43. Moritz T, Dutt P, Xiao X, Carstanjen D, Vik T, Hanenberg H,    Williams D A. Fibronectin improves transduction of reconstituting    hematopoietic stem cells by retroviral vectors: evidence of direct    viral binding to chymotryptic carboxy-terminal fragments. Blood.    1996; 88:855-862-   44. Relander T, Brim A, Hawley R G, Karlsson S, Richter J.    Retroviral transduction of human CD34+ cells on fibronectin fragment    CH-296 is inhibited by high concentrations of vector containing    medium. J Gene Med. 2001; 3:207-218-   45. Haas D L, Case S S, Crooks G M, Kohn D B. Critical factors    influencing stable transduction of human CD34(+) cells with    HIV-1-derived lentiviral vectors. Mol Ther. 2000; 2:71-80-   46. Dardalhon V, Herpers B, Noraz N, Pflumio F, Guetard D, Leveau C,    Dubart-kupperschmitt, A, Charneau P, Taylor N. Lentivirus-mediated    gene transfer in primary T cells is enhanced by a central DNA flap.    Gene therapy. 2001; 8:190-198-   47. Slingsby J H, Baban D, Sutton J, Esapa M, Price T, Kingsman S M,    Kingsman A J, Slade A. Analysis of 4070A envelope levels in    retroviral preparations and effect on target cell transduction    efficiency. Hum Gene Ther. 2000; 11:1439-1451-   48. Ott D E. Cellular proteins in HIV virions. Rev Med Virol. 1997;    7:167-180 49. Swanstrom R, Wills J W. Synthesis, assembly, and    processing of viral proteins. In: Coffin J M, Hughes S H, Varmus H    E, eds. Retroviruses. New York, USA: Cold Spring Harbor Laboratory    Press; 1997:263-334-   50. Takeuchi Y, Simpson G, Vile R, Weiss R, Collins M. Retroviral    pseudotypes produced by rescue of moloney murine leukemia vims    vector by C-type, but not D-type, retroviruses. Virology. 1992a;    186:792-794-   51. Pickl W F, Pimentel-Muinos F X, Seed B. Lipid rafts and    pseudotyping. J Virol. 2001; 75:7175-7183-   52. Cosson P. Direct interaction between the envelope and matrix    proteins of HIV-1. The Embo J. 1996; 15:5783-5788-   53. Murakami T, Freed E O. Genetic evidence for an interaction    between human immunodeficiency vims type 1 matrix and alpha-helix 2    of the gp41 cytoplasmic tail. J Virol. 2000; 74:3548-3554-   54. Vincent M J, Melsen L R, Martin A S, Compans R W. Intracellular    interaction of simian immunodeficiency vims Gag and Env proteins. J    Virol. 1999; 73:8138-8144-   55. Wyma D J, Kotov A, Aiken C. Evidence for a stable interaction of    gp41 with Pr55(Gag) in immature human immunodeficiency vims type 1    particles. J Virol. 2000; 74:9381-9387-   56. Brody B A, Rhee S S, Hunter E. Postassembly cleavage of a    retroviral glycoprotein cytoplasmic domain removes a necessary    incorporation signal and activates fusion activity. J Virol. 1994;    68:4620-4627-   57. Ragheb J A, Anderson W F. pH-independent murine leukemia vims    ecotropic envelope-mediated cell fusion: Implications for the role    of the R peptide and p12E TM in viral entry. J Virol. 1994;    68:3220-3231-   58. Rein A, Mirro J, Haynes J G, Ernst S M, Nagashima K. Function of    the cytoplasmic domain of a retroviral transmembrane protein:    p15E-p2E cleavage activates the membrane fusion capability of the    murine leukemia vims env protein. J Virol. 1994; 68:1773-1781-   59. Galili U, Shohet S B, Kobrin E, Stults C L, Macher B A. Man,    apes, and Old World monkeys differ from other mammals in the    expression of alpha-galactosyl epitopes on nucleated cells. J Biol    Chem. 1988; 263:17755-17762-   60. Rother R P, Fodor W L, Springhorn J P, Birks C W, Setter E,    Sandrin M S, Squinto S P, Rollins S A. A novel mechanism of    retrovirus inactivation in human serum mediated by    anti-alpha-galactosyl natural antibody. J Exp Med. 1995;    182:1345-1355-   61. Takeuchi Y, Porter C, Strahan K, Preece A, Gustafsson K, Cosset    F-L, Weiss R, Collins M. Sensitisation of cells and retroviruses to    human serum by alpha(1-3) galactosyltransferase. Nature. 1996;    379:85-88-   62. Takeuchi Y, Liong S H, Bieniasz P D, Jager U, Porter C D,    Friedman T, McClure M O, Weiss R A. Sensitization of rhabdo-,    lenti-, and spumaviruses to human serum by    galactosyl(alpha1-3)galactosylation. J Virol. 1997; 71:6174-6178-   63. DePolo N J, Harkleroad C E, Bodner M, Watt A T, Anderson C G,    Greengard J S, Murthy K K, Jr T W D, Jolly D J. The resistance of    retroviral vectors produced from human cells to serum inactivation    in vivo and in vitro is primate species dependent. J Virol. 1999;    73:6708-6714-   64. Montefiori D C, Cornell R J, Zhou J Y, Zhou J T, Hirsch V M,    Johnson P R. Complement control proteins, CD46, CD55, and CD59, as    common surface constituents of human and simian immunodeficiency    viruses and possible targets for vaccine protection. Virology. 1994;    205:82-92-   65. Lavillette D, Russell S J, Cosset F-L. Retargeting gene delivery    by surface-engineered retroviral vector particles. Current Opinion    in Biotechnology. 2001; 12:461-466-   66. Russell S J, Cosset F-L. Modifying the Host Range Properties of    Retroviral Vectors. Journal of Gene Medicine. 1999; 1:300-311-   67. Donahue R E, Sorrentino B P, Hawley R G, An D S, Chen I S,    Wersto R P. Fibronectin fragment CH-296 inhibits apoptosis and    enhances ex vivo gene transfer by murine retrovirus and human    lentivirus vectors independent of viral tropism in nonhuman primate    CD34+ cells. Mol Ther. 2001; 3:359-367-   68. Pizzato M, Marlow S A, Blair E D, Takeuchi Y. Initial binding of    murine leukemia vims particles to cells does not require specific    Env-receptor interaction. J Virol. 1999; 73:8599-8611-   69. Barnett A L, Cunningham J M. Receptor binding transforms the    surface subunit of the mammalian C-type retrovirus envelope protein    from an inhibitor to an activator of fusion. J Virol. 2001;    75:9096-9105-   70. Lavillette D, Ruggieri A, Boson B, Maurice M, Cosset F-L.    Structural inter-relations between subdomains of the SU that    regulate receptor-mediated transition between the fusion-inhibited    and fusion-active conformations of the MLV glycoprotein. submitted.    2002 71. Jinno-Oue A, Oue M, Ruscetti S K. A unique heparin-binding    domain in the envelope protein of the neuropathogenic PVC-211 murine    leukemia virus may contribute to its brain capillary endothelial    cell tropism. J Virol. 2001; 75:12439-12445-   72. Klimstra W B, Heidner H W, Johnston R E. The furin protease    cleavage recognition sequence of Sindbis vims PE2 can mediate virion    attachment to cell surface heparan sulfate. J Virol. 1999;    73:6299-6306-   73. Uckert W, Willimsky G, Pedersen F S, Blankenstein T, Pedersen L.    RNA levels of human retrovirus receptors Pit1 and Pit2 do not    correlate with infectibility by three retroviral vector pseudotypes.    Hum Gene Ther. 1998; 9:2619-2627-   74. Lavillette D, Boson B, Russell S, Cosset F-L. Membrane fusion by    murine leukemia viruses is activated in cis or in trans by    interactions of the receptor-binding domain with a conserved    disulfide loop at the carboxy-terminus of the surface glycoproteins.    J of Virol. 2001; 75:3685-3695-   75. Rodrigues P, Heard J M. Modulation of Phosphate Uptake and    Amphotropic Murine Leukemia Vims Entry by Posttranslational    Modifications of PIT-2. J. Virol. 1999:3789-3799

NUMBERED REFERENCES IN PARENTHESES

-   1. Berlioz-Torrent, C, B. L. Shacklett, L. Erdtmann, L.    Delamarre, I. Bouchaert, P. Sonigo, M. C. Dokhelar, and R.    Benarous 1999. Interactions of the cytoplasmic domains of human and    simian retroviral transmembrane proteins with components of the    clathrin adaptor complexes modulate intracellular and cell surface    expression of envelope glycoproteins J Virol. 73:1350-1361.-   2. Brody, B. A., S. S. Rhee, and E. Hunter 1994. Postassembly    cleavage of a retroviral glycoprotein cytoplasmic domain removes a    necessary incorporation signal and activates fusion activity J    Virol. 68:4620-4627.-   3. Brody, B. A., S. S. Rhee, M. A. Sommerfelt, and E. Hunter 1992. A    viral protease-mediated cleavage of the transmembrane glycoprotein    of Mason-Pfizer monkey vims can be suppressed by mutations within    the matrix protein Proc Natl Acad Sci USA. 89:3443-7.-   4. Christodoulopoulos, I., and P. Cannon 2001. Sequences in the    cytoplasmic tail of the gibbon ape leukemia vims envelope protein    that prevent its incorporation into lentivims vectors J Virol.    75:4129-38.-   5. Collawn, J. F., A. Lai, D. Domingo, M. Fitch, S. Hatton,    and I. S. Trowbridge 1993. YTRF is the conserved internalization    signal of the transferrin receptor, and a second YTRF signal at    position 31-34 enhances endocytosis J Biol Chem. 268:21686-21692.-   6. Cosset, F.-L., Y. Takeuchi, J. Battini, R. Weiss, and M.    Collins 1995. High titer packaging cells producing recombinant    retrovimses resistant to human serum J. Virol. 69:7430-7436.-   7. Cosson, P. 1996. Direct interaction between the envelope and    matrix proteins of HFV-1 The Embo J. 15:5783-5788.-   8. Delamarre, L., C. Pique, A. R. Rosenberg, V. Blot, M. P.    Grange, I. L. Blanc, and M. C. Dokhelar 1999. The Y-S-L-I    tyrosine-based motif in the cytoplasmic domain of the human T-cell    leukemia vims type 1 envelope is essential for cell-to-cell    transmission. J Virol. 73:9659-9663.-   9. Denesvre, C, C. Carrington, A. Corbin, Y. Takeuchi, F.-L.    Cosset, T. Schulz, M. Sitbon, and P. Sonigo 1996. TM domain swapping    of murine leukemia vims and human T-cell leukemia virus envelopes    confers different infectious abilities despite similar incorporation    into virions J. Virol. 70:4380-4386.-   10. Fielding, A., S. Chapel-Fernandes, M. Chadwick, F. Bullough,    F.-L. Cosset, and S. Russell 2000. A hyperfusogenic Gibbon ape    leukemia virus envelope glycoprotein: targeting of a cytotoxic gene    by ligand display Human Gene Therapy. 11:817-826.-   11. Freed, E. 0. 1998. HIV-1 gag proteins: diverse functions in the    vims life cycle Virology. 251:1-15.-   12. Freed, E. O., and M. A. Martin 1995. Virion incorporation of    envelope glycoproteins with long but not short cytoplasmic tails is    blocked by specific, single amino acid substitutions in the human    immunodeficiency vims type 1 matrix J Virol. 69:1984-1989.-   13. Grange, M., V. Blot, L. Delamarre, I. Bouchaert, A. Rocca, A.    Dautry-Varsat, and M. Dokhelar 2000. Identification of two    intracellular mechanisms leading to reduced expression of    oncoretrovims envelope glycoproteins at the cell surface J Virol.    74:11734-11743.-   14. Januszeski, M. M., P. M. Cannon, D. Chen, Y. Rozenberg,    and W. F. Anderson 1997. Functional analysis of the cytoplasmic tail    of Moloney murine leukemia vims envelope protein J Virol. 71:3613-9.-   15. Kiernan, R. E., and E. O. F. EO 1998. Cleavage of the murine    leukemia vims transmembrane env protein by human immunodeficiency    vims type 1 protease: transdominant inhibition by matrix mutations J    Virol. 72:9621-7.-   16. Kim, F. J., I. Seiliez, C. Denesvre, D. Lavillette, F.-L.    Cosset, and M. Sitbon 2000. Definition of an amino-terminal domain    of the human T-cell leukemia vims type 1 envelope surface unit which    extends the fusogenic range of an ecofropic murine leukemia vims    Journal of Biological Chemistry. 275:23417-20.-   17. Li, M., C. Yang, and R. W. Compans 2001. Mutations in the    cytoplasmic tail of murine leukemia virus envelope protein suppress    fusion inhibition by R peptide J Virol. 75:2337-44.-   18. Lindwasser, O. W., and M. D. Resh 2001. Multimerization of human    immunodeficiency vims type 1 Gag promotes its localization to    barges, raft-like membrane microdomains J Virol. 75:7913-24.-   19. Lodge, R., L. Delamarre, J. P. Lalonde, J. Alvarado, D. A.    Sanders, M. C. Dokhelar, E. A. Cohen, and G. Lemay 1997. Two    distinct oncomavirases harbor an intracytoplasmic tyrosine-based    basolateral targeting signal in their viral envelope glycoprotein J    Virol. 71:5696-702.-   20. Mangeot, P.-E., D. Negre, B. Dubois, A. J. Winter, P.    Leissner, M. Methali, D. Kaiserlian, F.-L. Cosset, and J.-L.    Darlix 2000. Development of minimal lentiviral vectors derived from    simian immunodeficiency virus (SINmac251) and their use for the gene    transfer in human dendritic cells J Virol. 74:8307-8315.-   21. Murakami, T., and E. O. Freed 2000. Genetic evidence for an    interaction between human immunodeficiency vims type 1 matrix and    alpha-helix 2 of the gp41 cytoplasmic tail J Virol. 74:3548-54.-   22. Naldini, L., U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. H.    Gage, I. M. Verma, and D. Trono 1996. In vivo gene delivery and    stable transduction of nondividing cells by a lentiviral vector    Science. 272:263-267.-   23. Negre, D., G. Duisit, P.-E. Mangeot, P. Moullier, J.-L. Darlix,    and F.-L. Cosset 2002. Lentiviral vectors derived from simian    immunodeficiency vims (SIV), p. 53-74. In D. Trono (ed.), Current    Topics in Microbiology and Immunology, vol. 261.-   24. Negre, D., P. Mangeot, G. Duisit, S. Blanchard, P. Vidalain, P.    Leissner, A. Winter, C. Rabourdin-Combe, M. Mehtali, P. Moullier,    J.-L. Darlix, and F.-L. Cosset 2000. Characterization of novel safe    lentiviral vectors derived from simian immunodeficiency vims    (STVmac251) that efficiently transduce mature human dendritic cells    Gene Ther. 7:1613-1623.-   25. Nguyen, D. H., and J. E. Hildreth 2000. Evidence for budding of    human immunodeficiency vims type 1 selectively from    glycolipid-enriched membrane lipid rafts J Virol. 74:3264-72.-   26. Ono, A., and E. O. Freed 2001. Plasma membrane rafts play a    critical role in HIN-1 assembly and release PNAS. 98:13925-13930.-   27. Ott, D., R. Friedrich, and A. Rein 1990. Sequence analysis of    amphotropic and 10A1 murine leukemia vims: close relationship to    mink cell focus forming viruses. J Nirol. 64:757-766.-   28. Overbaugh, J., A. D. Miller, and M. V. Eiden 2001. Receptors and    Entry Cofactors for Retrovimses Include Single and Multiple    Transmembrane-Spanning Proteins as well as Newly Described    Glycophosphatidylinositol-Anchored and Secreted Proteins Microbiol    Mol Biol Rev. 65:371-89.-   29. Pickl, W. F., F. X. Pimentel-Muinos, and B. Seed 2001. Lipid    rafts and pseudotyping J Virol. 75:7175-83.-   30. Ragheb, J. A., and W. F. Anderson 1994. pH-independent murine    leukemia vims ecofropic envelope-mediated cell fusion: Implications    for the role of the R peptide and p12E TM in viral entry. J Virol.    68:3220-3231.-   31. Rasko, J. E., J. L. Battini, R. J. Gottschalk, I. Mazo,    and A. D. Miller 1999. The RD114/simian type D retrovims receptor is    a neutral amino acid transporter Proc Natl Acad Sci USA.    96:2129-2134.-   32. Reeves, R. H., and S. J. O'Brien 1984. Molecular genetic    characterisation of the RD1 14 gene family of endogenous feline    retroviral sequences J. Nirol. 52:164-171.-   33. Rein, A., J. Mirro, J. G. Haynes, S. M. Ernst, and K.    Nagashima 1994. Function of the cytoplasmic domain of a retroviral    transmembrane protein: p15E-p2E cleavage activates the membrane    fusion capability of the murine leukemia virus env protein J Virol.    68:1773-1781.-   34. Salmon, P., D. Negre, D. Trono, and F.-L. Cosset 2000. A    chimeric GALV-derived envelope glycoprotein harboring the    cytoplasmic tail of MLV envelope efficiently pseudotypes HIV-1    vectors J Gen Med. 2 (sup):23.-   35. Sandrin, V., B. Boson, P. Salmon, W. Gay, D. Negre, R. L.    Grand, D. Trono, and F.-L. Cosset 2002. Lentiviral vectors    pseudotyped with a modified RD1 14 envelope glycoprotein show    increased stability in sera and augmented transduction of primary    lymphocytes and CD34+ cells derived from human and non-human    primates Blood, in press.-   36. Stitz, J., C. Buchholz, M. Engelstadter, W. Uckert, U.    Bloemer, I. Schmitt, and K. Cichutek 2000. Lentiviral vectors    pseudotyped with envelope glycoproteins derived from gibbon ape    leukemia vims and murine leukemia vims 10A1 Virology. 273:16-20.-   37. Swanstrom, R., and J. W. Wills 1997. Synthesis, assembly, and    processing of viral proteins, p. 263-334. In J. M. Coffin, S. H.    Hughes, and H. E. Varmus (eds), Retro viruses. Cold Spring Harbor    Laboratory Press, New York, USA.-   38. Tailor, C. S., A. Nouri, Y. Zhao, Y. Takeuchi, and D.    Kabat 1999. A sodium-dependent neutral-amino-acid transporter    mediates infections of feline and baboon endogenous retroviruses and    simian type D retro viruses J Virol. 73:4470-4474.-   39. Takeuchi, Y., F. L. Cosset, P. J. Lachmann, H. Okada, R. A.    Weiss, and M. K. L. Collins 1994. Type C retrovirus inactivation by    human complement is determined by both the viral genome and producer    cell J. Virol. 68:8001-8007.-   40. Takeuchi, Y., R. G. Vile, G. Simpson, B. O'Hara, M. K. L.    Collins, and R. A. Weiss 1992b. Feline leukemia vims subgroup B uses    the same cell surface receptor as gibbon ape leukemia vims J Virol.    66:1219-1222.-   41. Vincent, M. J., L. R. Melsen, A. S. Martin, and R. W.    Compans 1999. Intracellular interaction of simian immunodeficiency    vims Gag and Env proteins J Virol. 73:8138-44.-   42. Wyma, D. J., A. Kotov, and C. Aiken 2000. Evidence for a stable    interaction of gp41 with Pr55(Gag) in immature human    immunodeficiency vims type 1 particles J Virol. 74:9381-7.-   43. Yang, C, and R. W. Compans 1997. Analysis of the murine leukemia    vims R peptide: delineation of the molecular determinants which are    important for its fusion inhibition activity J Virol. 71:8490-8496.-   43. Yee, J. K., T. Friedmann, and J. C. Burns 1994. Generation of    high-titer pseudotyped retroviral vectors with very broad host range    Methods Cell Biol. 43:99-112.

ADDITIONAL REFERENCES

-   Akkina, Walton, Chen, Li, Planelles, Chen, “High-efficiency gene    transfer into CD34+ cells with a human immunodeficiency vims type    1-based retroviral vector pseudotyped with vesicular stomatitis vims    envelope glycoprotein G,” J Virol, 70:2581-2585, 1996.-   Almendro et al, “Cloning of the human platelet endothelial cell    adhesion molecule-1 promoter and its tissue-specific expression.    Structural and functional characterization,” J. Immunol,    157(12):5411-5421, 1996.-   An, Wersto, Agricola, Metzger, Lu, Amado, Chen, Donahue, “Marking    and gene expression by a lentivirus vector in transplanted human and    nonhuman primate CD34(+) cells,” J. Virol, 74:1286-1295, 2000.-   Angel, Bauman, Stein, Delius, Rahmsdorf, and Herrlich,    “12-0-tetradecanoyl-phorbol-13-acetate Induction of the Human    Collagenase Gene is Mediated by an Inducible Enhancer Element    Located in the 5′ Flanking Region,” Mol. Cell. Biol, 7:2256, 1987a.-   Angel, hnagawa, Chiu, Stein, hnbra, Rahmsdorf, Jonat, Herrlich, and    Karin, “Phorbol Ester-hiducible Genes Contain a Common cis Element    Recognized by a TPA-Modulated Trans-acting Factor,” Cell, 49:729,    1987b-   Arrighi, Hauser, Chapuis, Zubler, Kindler, “Long-term culture of    human CD34(+) progenitors with FLT3-ligand, thrombopoietin, and stem    cell factor induces extensive amplification of a CD34(−)CD14(−) and    CD34(−)CD14(+) dendritic cell precursor,” Blood, 93:2244-2252, 1999.-   Atchison and Perry, “Tandem Kappa Immunoglobulin Promoters are    Equally Active in the Presence of the Kappa Enhancer: Implications    for Model of Enhancer Function,” Cell, 46:253, 1986.-   Atchison and Perry, “The Role of the Kappa Enhancer and its Binding    Factor NF-kappa B in the Developmental Regulation of Kappa Gene    Transcription,” Cell, 48:121, 1987.-   Banerji et al, “Expression of a Beta-Globin Gene is Enhanced by    Remote SV40 DNA Sequences,” Cell, 27:299, 1981.-   Banerji, Olson, and Schaffher, “A lymphocyte-specific cellular    enhancer is located downstream of the joining region in    immunoglobulin heavy-chain genes,” Cell, 35:729, 1983.-   Berkhout, Silverman, and Jeang, “Tat Trans-activates the Human    Immunodeficiency Vims Through a Nascent RNA Target,” Cell, 59:273,    1989.-   Bhatia, Bonnet, Kapp, Wang, Murdoch, Dick, “Quantitative analysis    reveals expansion of human hematopoietic repopulating cells after    short-term ex vivo culture,” J. Exp. Med., 186:619-624, 1997.-   Blanar, Baldwin, Flavell, and Sharp, “A gamma-interferon-induced    factor that binds the interferon response sequence of the MHC class    I gene, H-2 Kb,” EMBO J., 8:1139, 1989. Blomer, Naldini, Kafri,    Trono, Verma, Gage, “Highly efficient and sustained gene transfer in    adult neurons with a lentivirus vector,” J Virol, 71:6641-6649,    1997.-   Bodine and Ley, “An enhancer element lies 3′ to the human a gamma    globin gene,” EMBO J, 6:2997, 1987.-   Boshart, Weber, Jahn, Dorsch-Hasler, Fleckenstein, and Schaffher, “A    very strong enhancer is located upstream of an immediate early gene    of human cytomegalo virus,” Cell, 41:521, 1985.-   Bosze, Thiesen, and Chamay, “A transcriptional enhancer with    specificity for erythroid cells is located in the long terminal    repeat of the friend murine leukemia vims,” EMBO J., 5:1615, 1986.-   Braddock, Chambers, Wilson, Esnouf, Adams, Kingsman, and Kingsman,    “HIV-I Tat activates presynthesized RNA in the nucleus,” Cell,    58:269, 1989.-   Bray, Prasad, Dubay, Hunter, Jeang, Rekosh, Hammarskjold, “A small    element from the Mason-Pfizer monkey vims genome makes human    immunodeficiency vims type 1 expression and replication    Rev-independent,” Proc. Natl. Acad. Sci. 91:1256-60, 1994.-   Brown, Tiley, Cullen, “Efficient polyadenylation within the human    immunodeficiency vims type 1 long terminal repeat requires flanking    U3-specific sequences,” J. Virol, 65:3340-3343, 1991.-   Bulla and Siddiqui, “The hepatitis B vims enhancer modulates    transcription of the hepatitis B vims surface-antigen gene from an    internal location,” J. Virol, 62:1437, 1986.-   Campbell and Villarreal, “Functional analysis of the individual    enhancer core sequences of polyoma virus: cell-specific uncoupling    of DNA replication from transcription,” Mol. Cell. Biol, 8:1993,    1988.-   Campere and Tilghman, “Postnatal repression of the alpha-fetoprotein    gene is enhancer independent,” Genes and Dev., 3:537, 1989.-   Campo, Spandidos, Lang, Wilkie, “Transcriptional control signals in    the genome of bovine papilloma vims type 1,” Nature, 303:77, 1983.-   Carbonelli et al. “A plasmid vector for isolation of strong    promoters in E. coli,” FEMS Microbiol Lett. 177(1):75-82, 1999.-   Case, Price, Jordan, Yu, Wang, Bauer, Haas, Xu, Stripecke, Naldini,    Kohn, Crooks, “Stable transduction of quiescent CD34(+)CD38(−) human    hematopoietic cells by HIN-1 based lentiviral vectors,” Proc. Natl.    Acad. Sci. USA, 96:2988-2993, 1999.-   Celander and Haseltine, “Glucocorticoid Regulation of Murine    Leukemia Vims Transcription Elements is Specified by Determinants    Within the Viral Enhancer Region,” J. Virology, 61:269, 1987.-   Celander, Hsu, and Haseltine, “Regulatory Elements Within the Murine    Leukemia Vims Enhancer Regions Mediate Glucocorticoid    Responsiveness,” J Virology, 62:1314, 1988.-   Chandler, Maler, and Yamamoto, “DNA Sequences Bound Specifically by    Glucocorticoid Receptor in vitro Render a Heterlogous Promoter    Hormone Responsive in vivo,” Cell, 33:489, 1983.-   Chandler et al, “RNA splicing specificity determined by the    coordinated action of RNA recognition motifs in SR proteins,” Proc    Natl Acad Sci USA. 94(8):3596-3601, 1997. Chang, Erwin, and Lee,    “Glucose-regulated Protein (GRP94 and GRP78) Genes Share Common    Regulatory Domains and are Coordinately Regulated by Common    Trans-acting Factors,” Mol. Cell. Biol, 9:2153, 1989.-   Chameau, Mirambeau, Roux, Paulous, Buc, Clavel, “HIV-1 reverse    transcription: a termination step at the center of the genome,” J.    Mol. Biol. 241:651-662, 1994.-   Chatterjee, Lee, Rentoumis, and Jameson, “Negative Regulation of the    Thyroid-Stimulating Hormone Alpha Gene by Thyroid Hormone: Receptor    Interaction Adjacent to the TATA Box,” Proc Natl. Acad Sci. U.S.A.,    86:9114, 1989.-   Chen and Okayama, “High-efficiency transformation of mammalian cells    by plasmid DNA,” Mol. Cell. Biol. 7:2745-2752, 1987-   Cherrington and Ganem, “Regulation of polyadenylation in human    immunodeficiency vims (HIV): contributions of promoter proximity and    upstream sequences,” Embo. J., 11:1513-1524, 1992.-   Choi, Chen, Kriegler, and Roninson, “An altered pattern of    cross-resistance in multi-drag-resistant human cells results from    spontaneous mutations in the mdr-1 (p-glycoprotein) gene,” Cell,    53:519, 1988.-   Cocea, “Duplication of a region in the multiple cloning site of a    plasmid vector to enhance cloning-mediated addition of restriction    sites to a DNA fragment,” Biotechniques, 23:814-816, 1997.-   Cohen, Walter, and Levinson, “A Repetitive Sequence Element 3′ of    the Human c-Ha-rasl Gene Has Enhancer Activity,” J. Cell. Physiol.,    5:75, 1987.-   Corbeau, et al, PNAS (U.S.A.) 93(24): 14070-14075, 1996.-   Costa, Lai, Grayson, and Darnell, “The Cell-Specific Enhancer of the    Mouse Transthyretin (Prealbumin) Gene Binds a Common Factor at One    Site and a Liver-Specific Factor(s) at Two Other Sites,” Mol. Cell.    Biol, 8:81, 1988.-   Cripe, Haugen, Turk, Tabatabai, Schmid, Durst, Gissmann, Roman, and    Turek, “Transcriptional Regulation of the Human Papilloma Vims-16    E6-E7 Promoter by a Keratinocyte-Dependent Enhancer, and by Viral E2    Trans-Activator and Repressor Gene Products: Implications for    Cervical Carcinogenesis,” EMBO J., 6:3745, 1987.-   Culotta and Hamer, “Fine Mapping of a Mouse Metallothionein Gene    Metal-Response Element,” Mol. Cell. Biol, 9:1376, 1989.-   Dandolo, Blangy, and Kamen, “Regulation of Polyma Viras    Transcription in Murine Embryonal Carcinoma Cells,” J. Virology,    47:55, 1983.-   Das, Klayer, Klasens, van Wamel, “A conserved hairpin motif in the    R-U5 region of the human immunodeficiency viras type 1 RNA genome is    essential for replication,” J Virol. 71:2346-2356.-   Dao, Hannum, Kohn, Nolta, “FLT3 ligand preserves the ability of    human CD34+ progenitors to sustain long-term hematopoiesis in    immune-deficient mice after ex vivo retroviral-mediated    transduction,” Blood, 89:446-456, 1997.-   Dao, Hashino, Kato, Nolta, “Adhesion to fibronectin maintains    regenerative capacity during ex vivo, culture and transduction of    human hematopoietic stem and progenitor cells,” Blood, 92:4612-4621,    1998.-   Deschamps, Meijlink, and Verma, “Identification of a Transcriptional    Enhancer Element Upstream From the Proto-Oncogene Fos,” Science,    230:1174, 1985.-   De Villiers, Schaffher, Tyndall, Lupton, and Kamen, “Polyoma Vims    DNA Replication Requires an Enhancer,” Nature, 312:242, 1984.-   DeZazzo, Kilpatrick, Imperiale, “Involvement of long terminal repeat    U3 sequences overlapping the transcription control region in human    immunodeficiency virus type 1 mRNA 3′ end formation;’ Mol. Cell.    Biol, 11:1624-1630, 1991.-   Donello, Loeb, Hope, “Woodchuck hepatitis viras contains a    tripartite posttranscriptional regulatory element,” J Virol,    72:5085-5092, 1998.-   Dorrell, Gan, Pereira, Hawley, Dick, “Expansion of human cord blood    CD34(+)CD38(−) cells in ex vivo culture during retroviral    transduction without a corresponding increase in SCID repopulating    cell (SRC) frequency: dissociation of SRC phenotype and function,”    Blood, 95:102-110, 2000.-   Dull, Zufferey, Kelly, Mandel, Nguyen, Trono, Naldini, “A third    generation lentivims vector with a conditional packaging system,” J.    Virol, 72:8463-8471, 1998.-   Edbrooke, Burt, Cheshire, and Woo, “Identification of cis-acting    sequences responsible for phorbol ester induction of human serum    amyloid a gene expression via a nuclear-factor-kappa β-like    transcription factor,” Mol. Cell. Biol, 9:1908, 1989.-   Edlund, Walker, Barr, and Rutter, “Cell-specific expression of the    rat insulin gene: evidence for role of two distinct 5′ flanking    elements,” Science, 230:912, 1985.-   Fechheimer, Boylan, Parker, Sisken, Patel and Zimmer, “Transfection    of mammalian cells with plasmid DNA by scrape loading and sonication    loading,” Proc Nat'l Acad. Sci. USA 84:8463-8467, 1987-   Feng and Holland, “HTV-I Tat Trans-Activation Requires the Loop    Sequence Within Tar,” Nature, 334:6178, 1988. Firak and Subramanian,    “Minimal Transcription Enhancer of Simian Viras 40 is a 74-Base-Pair    Sequence that Has Interacting Domains,” Mol. Cell. Biol, 6:3667,    1986.-   Foecking and Hofstetter, “Powerful and Versatile Enhancer-Promoter    Unit for Mammalian Expression Vectors,” Gene, 45(1):101-105, 1986.-   Froehler, Ng, Matteucci, “Synthesis of DNA via deoxynucleoside    H-phosphonate intermediates.” Nuc. Acids Res. 14:5399-407, 1986.-   Fujita, Shibuya, Hotta, Yamanishi, and Taniguchi, “Interferon-Beta    Gene Regulation: Tandemly Repeated Sequences of a Synthetic 6-bp    Oligomer Function as a Vims-Inducible Enhancer,” Cell, 49:357, 1987.-   Gilles, Morris, Oi, and Tonegawa, “A tissue-specific transcription    enhancer element is located in the major intron of a rearranged    immunoglobulin heavy-chain gene,” Cell, 33:717, 1983.-   Gilmartin, Fleming, Oetjen, “Activation of HIN-1 pre-mRNA 3′    processing in vitro requires both an upstream element and TAR,”    Embo. J., 11:4419-4428, 1992.-   Gloss, Bernard, Seedorf, and Klock, “The Upstream Regulatory Region    of the Human Papilloma Vims-16 Contains an E2 Protein-Independent    Enhancer Which is Specific for Cervical Carcinoma Cells and    Regulated by Glucocorticoid Hormones,” EMBO J., 6:3735, 1987.-   Godbout, Ingram, and Tilghman, “Fine-Structure Mapping of the Three    Mouse Alpha-Fetoprotein Gene Enhancers,” Mol. Cell. Biol, 8:1169,    1988.-   Goodbourn, Burstein, and Maniatis, “The Human Beta-hiterferon Gene    Enhancer is Under Negative Control,” Cell, 45:601, 1986.-   Goodbourn and Maniatis, “Overlapping Positive and Negative    Regulatory Domains of the Human β-Interferon Gene,” Proc. Natl.    Acad. Sci. USA, 85:1447, 1988.-   Gopal, “Gene transfer method for transient gene expression, stable    transformation, and cotransformation of suspension cell cultures,”    Mol. Cell. Biol. 5:1188-1190, 1985.-   Gossen and Bujard, Proc. Natl. Acad. Sci., 89:5547-5551, 1992.-   Graham and Nan Der Eb, “A new technique for the assay of infectivity    of human adenovims 5 DNA,” Virology 52:456-467, 1973-   Greco and Dachs, “Gene directed enzyme/prodrug therapy of cancer:    historical appraisal and future prospectives,” J Cell. Phys. 187:    22-36, 2001 Greene, Bohnlein, and Ballard, “HIV-1, and Normal T-Cell    Growth: Transcriptional Strategies and Surprises,” Immunology Today,    10:272, 1989-   Grosschedl and Baltimore, “Cell-Type Specificity of Immunoglobulin    Gene Expression is Regulated by at Least Three DNA Sequence    Elements,” Cell, 41:885, 1985.-   Haslinger and Karin, “Upstream Promoter Element of the Human    Metallothionein-II Gene Can Act Like an Enhancer Element,” Proc    Natl. Acad. Sci. U.S.A., 82:8572, 1985.-   Hauber and Cullen, “Mutational Analysis of the    Trans-Activiation-Responsive Region of the Human Immunodeficiency    Vims Type I Long Terminal Repeat,” J. Virology, 62:673, 1988.-   Hen, Borrelli, Fromental, Sassone-Corsi, and Chambon, “A Mutated    Polyoma Vims Enhancer Which is Active in Undifferentiated Embryonal    Carcinoma Cells is not Repressed by Adenovirus-2 El A Products,”    Nature, 321:249, 1986.-   Hensel, Meichle, Pfizenmaier, and Kronke, “PMA-Responsive 5′    Flanking Sequences of the Human TNF Gene,” Lymphokine Res., 8:347,    1989.-   Herr and Clarke, “The SV40 Enhancer is Composed of Multiple    Functional Elements That Can Compensate for One Another,” Cell,    45:461, 1986.-   Hirochika, Browker, and Chow, “Enhancers and Trans-Acting E2    Transcriptional Factors of Papilloma Viruses,” J. Virol, 61:2599,    1987.-   Hirsch, Gaugler, Deagostini-Bauzin, Bally-Cuif, and Gordis,    “Identification of Positive and Negative Regulatory Elements    Governing Cell-Type-Specific Expression of the    Neural-Cell-Adhesion-Molecule Gene,” Mol. Cel Biol., 10:1959, 1990.-   Holbrook, Gulino, and Ruscetti, “cis-Acting Transcriptional    Regulatory Sequences in the Gibbon Ape Leukemia Viras (GALV) Long    Terminal Repeat,” Virology, 157:211, 1987.-   Horlick and Benfield, “The upstream muscle-specific enhancer of the    rat muscle creatine kinase gene is composed of multiple elements,”    Mol. Cell. Biol, 9:2396, 1989.-   Huang, Ostrowski, Berard, and Hagar, “Glucocorticoid regulation of    the ha-musv p21 gene conferred by sequences from mouse mammary tumor    vims,” Cell, 27:245, 1981.-   Hug, Costas, Staeheli, Aebi, and Weissmann, “Organization of the    Murine Mx Gene and Characterization of its Interferon- and    Vims-Inducible Promoter,” Mol. Cell. Biol, 8:3065, 1988.-   Hwang, Lim, and Chae, “Characterization of the S-Phase-Specific    Transcription Regulatory Elements in a DNA-Replication-Independent    Testis-Specific H2B (TH2B) Histone Gene,” M?/. Cell. Biol, 10:585,    1990.-   Imagawa, Chiu, and Karin, “Transcription Factor AP-2 Mediates    induction by Two Different Signal-Transduction Pathways: Protein    Kinase C and cAMP,” Cell, 51:251, 1987.-   Imbra and Karin, “Phorbol Ester Induces the Transcriptional    Stimulatory Activity of the SV40 Enhancer,” Nature, 323:555, 1986.-   Imler, Lemaire, Wasvlyk, and Waslyk, “Negative Regulation    Contributes to Tissue Specificity of the Immunoglobulin Heavy-Chain    Enhancer,” Mol. Cell. Biol, 7:2558, 1987.-   Imperiale and Nevins, “Adeno virus 5 E2 Transcription Unit: an El    A-hiducible Promoter with an Essential Element that Functions    Independently of Position or Orientation,” Mol. Cell. Biol, 4:875,    1984.-   Jakobovits, Smith, Jakobovits, and Capon, “A Discrete Element 3′ of    Human Immunodeficiency Viras 1 (HJV-1) and HJN-2 mRNA Initiation    Sites Mediates Transcriptional Activation by an HIN    Trans-Activator,” Mol. Cell. Biol, 8:2555, 1988.-   Jameel and Siddiqui, “The Human Hepatitis B Virus Enhancer Requires    Transacting Cellular Factor(s) for Activity,” Mol. Cell. Biol,    6:710, 1986.-   Jaynes, Johnson, Buskin, Gartside, and Hauschka, “The Muscle    Creatine Kinase Gene is Regulated by Multiple Upstream Elements,    Including a Muscle-Specific Enhancer,” Mol. Cell. Biol, 8:62, 1988.-   Johnson, Wold, and Hauschka, “Muscle creatine kinase sequence    elements regulating skeletal and cardiac muscle expression in    transgenic mice,” Mol. Cell. Biol, 9:3393, 1989.-   Kadesch and Berg, “Effects of the Position of the Simian Viras 40    Enhancer on Expression of Multiple Transcription Units in a Single    Plasmid,” Mol. Cell. Biol, 6:2593, 1986.-   Kafri, et al, “Sustained expression of genes delivered directly into    liver and muscle by lentiviral vectors,” Nat. Genetics, 17:314-317,    1997.-   Karin, Haslinger, Heguy, Dietlin, and Cooke, “Metal-Responsive    Elements Act as Positive Modulators of Human Metallothionein-IIA    Enhancer Activity,” Mol. Cell. Biol, 7:606, 1987.-   Katinka, Yaniv, Vasseur, and Blangy, “Expression of Polyoma Early    Functions in Mouse Embryonal Carcinoma Cells Depends on Sequence    Rearrangements in the Beginning of the Late Region,” Cell, 20:393,    1980.-   Kawamoto, Makino, Niw, Sugiyama, Kimura, Anemura, Nakata, and    Kakunaga, “Identification of the Human Beta-Actin Enhancer and its    Binding Factor,” Mol. Cell. Biol, 8:267, 1988.-   Kiledjian, Su, Kadesch, “Identification and characterization of two    functional domains within the murine heavy-chain enhancer,” Mol.    Cell. Biol., 8:145, 1988.-   Klages, Zufferey, Trono, “A stable system for the high-titer    production of multiply aattenuated lentiviral vectors,” Mol. Ther.    2:170-176, 2000.-   Klamut, Gangopadyhay, Worton, and Ray, “Molecular and Functional    Analysis of the Muscle-Specific Promoter Region of the Duchenne    Muscular Dystrophy Gene,” Mol. Cell. Biol, 10:193, 1990.-   Klein et al, “High-velocity microprojectiles for delivering nucleic    acids into living cells,” Nature, 327:70-73, 1987.-   Koch, Benoist, and Mathis, “Anatomy of a new β-cell-specific    enhancer,” Mol. Cell. Biol, 9:303, 1989.-   Kohn, Nolta, Weinthal, Banner, Yu, Lilley, Crooks, “Toward gene    therapy for Gaucher disease,” Hum. Gene Ther., 2:101-105, 1991.-   Kotsopoulou, Kim, Kingsman, Kingsman, Mitrophanous. “A    Rev-independent human immunodeficiency virus type 1 (HTV-1)-based    vector that exploits a codon-optimized HIV-1 gag-pol gene,” J.    Virol. 74:4839-52, 2000.-   Kraus et al, “Alternative promoter usage and tissue specific    expression of the mouse somatostatin receptor 2 gene,” FEBS Lett.,    428(3):165-170, 1998.-   Kriegler and Botchan, “A retrovirus LTR contains a new type of    eukaryotic regulatory element,” In: Eukaryotic Viral Vectors,    Gluzman (ed.), Cold Spring Harbor, Cold Spring Harbor Laboratory,    NY, 1982.-   Kriegler et al, “Promoter substitution and enhancer augmentation    increases the penetrance of the sv40 a gene to levels comparable to    that of the harvey murine sarcoma virus ras gene in morphologic    transformation,” In: Gene Expression, Alan Liss (Ed.), Hamer and    Rosenberg, New York, 1983.-   Kriegler et al, “Viral Integration and Early Gene Expression Both    Affect the Efficiency of SV40 Transformation of Murine Cells:    Biochemical and Biological Characterization of an SV40 Retrovirus,”    In: Cancer Cells 2/Oncogenes and Viral Genes, Van de Woude et al.    (eds), Cold Spring Harbor, Cold Spring Harbor Laboratory, 1984.-   Kriegler, Perez, Defay, Albert and Liu, “A Novel Form of    TNF/Cachectin Is a Cell-Surface Cytotoxix Transmembrane Protein:    Ramifications for the Complex Physiology of TNF,” Cell, 53:45, 1988.-   Kuhl, De La Fuenta, Chaturvedi, Parinool, Ryals, Meyer, and    Weissman, “Reversible Silencing of Enhancers by Sequences Derived    From the Human IFN-alpha Promoter,” Cell, 50:1057, 1987.-   Kunz, Zimmerman, Heisig, and Heinrich, “Identification of the    Promoter Sequences Involved in the Interleukin-6-Dependent    Expression of the Rat Alpha-2-Macroglobulin Gene,” Nucl. Acids Res.,    11:1121, 1989.-   Lareyre et al, “A 5-kilobase pair promoter fragment of the murine    epididymal retinoic acid-binding protein gene drives the    tissue-specific, cell-specific, and androgen-regulated expression of    a foreign gene in the epididymis of transgenic mice,” J Biol Chem.,    274(12):8282-8290, 1999.-   Larsen, Harney, and Moore, “Repression medaites cell-type-specific    expression of the rat growth hormone gene,” Proc Natl. Acad. Sci.    USA., 83:8283, 1986.-   Laspia, Rice, and Mathews, “HIV-1 Tat protein increases    transcriptional initiation and stabilizes elongation,” Cell, 59:283,    1989.-   Latimer, Berger, and Baumann, “Highly conserved upstream regions of    the alpha. sub.1-antitrypsin gene in two mouse species govern    liver-specific expression by different mechanisms,” Mol. Cell. Biol,    10:760, 1990.-   Lee, Mulligan, Berg, and Ringold, “Glucocorticoids Regulate    Expression of Dihydrofolate Reductase cDNA in Mouse Mammary Tumor    Viras Chimaeric Plasmids,” Nature, 294:228, 1981-   Lee et al, “Activation of beta3-adrenoceptors by exogenous dopamine    to lower glucose uptake into rat adipocytes,” j Auton Nery Syst.    74(2-3): 86-90, 1997.-   Levenson et al, “Internal ribosomal entry site-containing retroviral    vectors with green fluorescent protein and drug resistance markers,”    Human Gene Tlierapy, 9:1233-1236, 1998.-   Levinson, Khoury, VanDeWoude, and Grass, “Activation of SV40 Genome    by 72-Base-Pair Tandem Repeats of Moloney Sarcoma Viras,” Nature,    295:79, 1982. Lewis and Emerman, “Passage through mitosis is    required for oncoretrovirases but not for the human immunodeficiency    virus,” J. Virol, 68:510-516, 1994.-   Lin, Cross, Halden, Dragos, Toledano, and Leonard, “Delineation of    an enhancerlike positive regulatory element in the interleukin-2    receptor .alpha.-chain gene,” Mol. Cell. Biol, 10:850, 1990.-   Luria, Gross, Horowitz, and Givol, “Promoter Enhancer Elements in    the Rearranged Alpha-Chain Gene of the Human T-Cell Receptor,” EMBO    J., 6:3307, 1987.-   Lusky, Berg, Weiher, and Botchan, “Bovine Papilloma Virus Contains    an Activator of Gene Expression at the Distal End of the Early    Transcription Unit,” Mol. Cell. Biol. 3:1108, 1983.-   Lusky and Botchan, “Transient Replication of Bovine Papilloma Vims    Type 1 Plasmids: cis and trans Requirements,” Proc Natl. Acad. Sci.    U.S.A., 83:3609, 1986.-   Majors and Varmus, “A Small Region of the Mouse Mammary Tumor Vims    Long Terminal Repeat Confers Glucocorticoid Hormone Regulation on a    Linked Heterologous Gene,” Proc. Natl. Acad. Sci. U.S.A., 80:5866,    1983.-   Marthas et al. J. Virol, 67:6047-6055, 1993.-   Mazurier, Moreau-Gaudry, Maguer-Satta, Salesse, Pigeonnier-Lagarde,    Ged, Belloc, Lacombe, Mahon, Reiffers, de Vemeuil, “Rapid analysis    and efficient selection of human transduced primitive hematopoietic    cells using the humanized S65T green fluorescent protein,” Gene    Ther., 5:556-562, 1998.-   McNeall, Sanchez, Gray, Chesterman, and Sleigh, “Hyperinducible Gene    Expression From a Metallotionein Promoter Containing Additional    Metal-Responsive Elements,” Gene, 76:81, 1989.-   Miksicek, Heber, Schmid, Danesch, Posseckert, Beato, and Schutz,    “Glucocorticoid Responsiveness of the Transcriptional Enhancer of    Moloney Murine Sarcoma Viras,” Cell, 46:203, 1986.-   Miyoshi, Smith, Mosier, Verma, Torbett, “Transduction of human CD34+    cells that mediate long-term engraftment of NOD/SCID mice by HIV    vectors,” Science, 283:682-686, 1999.-   Mizushima and Nagata, “pEF-BOS, a powerful mammalian expression    vector,” Nucleic Acids Res., 18:5322, 1990.-   Mordacq and Linzer, “Co-localization of Elements Required for    Phorbol Ester Stimulation and Glucocorticoid Repression of    Proliferin Gene Expression,” Genes and Dev., 3:760, 1989.-   Moreau, Hen, Wasylyk, Everett, Gaub, and Chambon, “The SV40    base-repair repeat has a striking effect on gene expression both in    sv40 and other chimeric recombinants,” Nucl Acids Res., 9:6047,    1981.-   Muesing et al, Cell, 48:691, 1987.-   Naldini, Blomer, gallay, Ory, Mulligan, Gage, Verma, Trono, “In vivo    gene delivery and stable transduction of nondividing cells by a    lentiviral vector,” Science, 212:263-261, 1996a. Naldini, Blomer,    Gage, Trono, Verma, “Efficient transfer, integration, and sustained    long-term expression of the transgene in adult rat brains injected    with a lentiviral vector,” Proc. Natl. Acad. Sci. USA,    93:11382-11388, 1996b.-   Naldini, “Lentiviruses as gene transfer agents for delivery to    non-dividing cells,” Curr. Opin. Biotechnol 9:457-463, 1998.-   Ng, Gunning, Liu, Leavitt, and Kedes, “Regulation of the Human    Beta-Actin Promoter by Upstream and Intron Domains,” Nuc. Acids    Res., 17:601, 1989.-   Nomoto et al, “Cloning and characterization of the alternative    promoter regions of the human LIMK2 gene responsible for alternative    transcripts with tissue-specific expression,” Gene, 236(2):259-271,    1999.-   Omitz, Hammer, Davison, Brinster, and Palmiter, “Promoter and    enhancer elements from the rat elastase i gene function    independently of each other and of heterologous enhancers,” Mol.    Cell. Biol. 7:3466, 1987.-   Ondek, Sheppard, and Herr, “Discrete Elements Within the SV40    Enhancer Region Display Different Cell-Specific Enhancer    Activities,” EMBO J, 6:1017, 1987.-   Ory et al, Proc. Natl. Acad. Sci., 93:11400-11406, 1996.-   Palmiter, Chen, and Brinster, “Differential regulation of    metallothionein-thymidine kinase fusion genes in transgenic mice and    their offspring,” Cell, 29:701, 1982.-   Pech, Rao, Robbins, and Aaronson, “Functional identification of    regulatory elements within the promoter region of platelet-derived    growth factor 2,” Mol. Cell. Biol, 9:396, 1989.-   Perez-Stable and Constantini, “Roles of fetal γ-globin promoter    elements and the adult β-globin 3′ enhancer in the stage-specific    expression of globin genes,” Mol. Cell. Biol, 10:1116, 1990.-   Piacibello, Sanavio, Severino, Dane, Gammaitoni, Fagioli,    Perissinotto, Cavalloni, Kollet Lapidot, Aglietta, “Engraftment in    nonobese diabetic severe combined immunodeficient mice of human    CD34(+) cord blood cells after ex vivo expansion: evidence for the    amplification and self-renewal of repopulating stem cells,” Blood,    93:3736-3749, 1999. Picard and Schaffner, “A Lymphocyte-Specific    Enhancer in the Mouse Immunoglobulin Kappa Gene, Nature, 307:83,    1984.-   Pinkert, Omitz, Brinster, and Palmiter, “An albumin enhancer located    10 kb upstream functions along with its promoter to direct    efficient, liver-specific expression in transgenic mice,” Genes and    Dev., 1:268, 1987.-   Ponta, Kennedy, Skroch, Hynes, and Groner, “Hormonal Response Region    in the Mouse Mammary Tumor Vims Long Terminal Repeat Can Be    Dissociated From the Proviral Promoter and Has Enhancer Properties,”    Proc. Natl. Acad. Sci. U.S.A., 82:1020, 1985. Porton, Zaller,    Lieberson, and Eckhardt, “Immunoglobulin heavy-chain enhancer is    required to maintain transfected .gamma.2a gene expression in a    pre-b-cell line,” Mol. Cell. Biol, 10:1076, 1990.-   Potter et al, “Enhancer-dependent expression of human k    immunoglobulin genes introduced into mouse pre-B lymphocytes by    electroporation,” Proc Nat'l Acad. Sci. USA, 81:7161-7165, 1984.-   Queen and Baltimore, “Immunoglobulin Gene Transcription is Activated    by Downstream Sequence Elements,” Cell, 35:741, 1983.-   Quinn, Farina, Gardner, Krutzsch, and Levens, “Multiple components    are required for sequence recognition of the apl site in the gibbon    ape leukemia virus enhancer,” Mol. Cell. Biol, 9:4713, 1989.-   Redondo, Hata, Brocklehurst, and Krangel, “A T-Cell-Specific    Transcriptional Enhancer Within the Human T-Cell Receptor .delta.    Locus,” Science, 247:1225, 1990.-   Resendez Jr., Wooden, and Lee, “Identification of highly conserved    regulatory domains and protein-binding sites in the promoters of the    rat and human genes encoding the stress-inducible 78-kilodalton    glucose-regulated protein,” Mol. Cell. Biol, 8:4579, 1988.-   Reisman and Rotter, “induced Expression From the Moloney Murine    Leukemia Viras Long Terminal Repeat During Differentiation of Human    Myeloid Cells is Mediated Through its Transcriptional Enhancer,”    Mol. Cell. Biol, 9:3571, 1989.-   Remington's Pharmaceutical Sciences, 15th Ed., pages 1035-1038 and    1570-1580.-   Ripe, Lorenzen, Bremier, and Breindl, “Regulatory elements in the 5′    flanking region and the first intron contribute to transcriptional    control of the mouse alpha-1-type collagen gene,” Mol. Cell. Biol,    9:2224, 1989.-   Rippe, Brenner and Leffert, “DNA-mediated gene transfer into adult    rat hepatocytes in primary culture,” Mol. Cell Biol, 10:689-695,    1990.-   Rittling, Coutinho, Amarm, and Kolbe, “AP-1/jun-binding Sites    Mediate Serum Inducibihty of the Human Vimentin Promoter,” Nuc.    Acids Res., 17:1619, 1989.-   Roe, Reynolds, Yu, Brown, “Integration of murine leukemia viras DNA    depends on mitosis,” Embo. J., 12:2099-2108, 1993.-   Rosen, Sodroski, and Haseltine, “The location of cis-acting    regulatory sequences in the human t-cell lymphotropic viras type III    (HTLV-11 1/LAV) long terminal repeat,” Cell, 41:813, 1988.-   Sakai, Helms, Carlstedt-Duke, Gustafsson, Rottman, and Yamamoto,    “Hormone-Mediated Repression: A Negative Glucocorticoid-Response    Element From the Bovine Prolactin Gene,” Genes and Dev., 2:1144,    1988.-   Sambrook, Fritsch, Maniatis, In: Molecular Cloning: A Laboratory    Manual 2 rev. ed., Cold Spring Harbor, Cold Spring Harbor Laboratory    Press, 1(77): 19-17.29, 1989.-   Satake, Furukawa, and Ito, “Biological activities of ohgonucleotides    spanning the f9 point mutation within the enhancer region of polyoma    vims DNA,” J. Virology, 62:970, 1988.-   Scharfmann, Axelrod, Nerma, “Long-term in vivo expression of    retrovirus-mediated gene transfer in mouse fibroblast implants,”    Proc. Natl. Acad. Sci. USA, 88:4626-4630, 1991.-   Schaffher, Schirm, Muller-Baden, Wever, and Schaffher, “Redundancy    of Information in Enhancers as a Principle of Mammalian    Transcription Control,” J. Mol. Biol, 201:81, 1988.-   Schmid, Uittenbogaart, Keld, Giorgi, “A rapid method for measuring    apoptosis and dual-color immunofluorescence by single laser flow    cytometry,” J. Immunol. Methods, 170:145-157, 1994.-   Searle, Stuart, and Palmiter, “Building a metal-responsive promoter    with synthetic regulatory elements,” Mol. Cell. Biol, 5:1480, 1985.-   Sharp and Marciniak, “HIN Tar: an RNA Enhancer?,” Cell, 59:229,    1989.-   Shaul and Ben-Levy, “Multiple Nuclear Proteins in Liver Cells are    Bound to Hepatitis B Vims Enhancer Element and its Upstream    Sequences,” EMBO J., 6:1913, 1987.-   Sherman, Basta, Moore, Brown, and Ting, “Class II Box Consensus    Sequences in the HLA-DR.alpha. Gene: Transcriptional Function and    interaction with Nuclear Proteins,” Mol. Cell. Biol., 9:50, 1989.-   Sleigh and Lockett, “SN40 Enhancer Activation During Retinoic-Acid-h    duced Differentiation of F9 Embryonal Carcinoma Cells,” J. EMBO,    4:3831, 1985.-   Spalholz, Yang, and Howley, “Transactivation of a Bovine Papilloma    Virus Transcriptional Regulatory Element by the E2 Gene Product,”    Cell, 42:183, 1985.-   Spandau and Lee, “Trans-Activation of Viral Enhancers by the    Hepatitis B Vims X Protein,” J. Virology, 62:427, 1988.-   Spandidos and Wilkie, “Host-Specificities of Papilloma Virus,    Moloney Murine Sarcoma Virus and Simian Viras 40 Enhancer    Sequences,” EMBO J., 2:1193, 1983.-   Stephens and Hentschel, “The Bovine Papilloma Virus Genome and its    Uses as a Eukaryotic Vector,” Biochem. J., 248:1, 1987.-   Stuart, Searle, and Palmiter, “Identification of Multiple Metal    Regulatory Elements in Mouse Metallothionein-I Promoter by Assaying    Synthetic Sequences,” Nature, 317:828, 1985. Sullivan and Peterlin,    “Transcriptional Enhancers in the HLA-DQ Subregion,” Mol. Cell.    Biol, 7:3315, 1987.-   Sutton, Reitsma, Uchida, Brown, “Transduction of human progenitor    hematopoietic stem cells by human immunodeficiency viras type    1-based vectors is cell cycle dependent,” J. Virol, 73:3649-3660,    1999.-   Sutton, Wu, Rigg, Bohnlein, Brown, “Human immunodeficiency viras    type 1 vectors efficiently transduce human hematopoietic stem    cells,””/. Virol, 72:5781-5788, 1998.-   Swartzendruber and Lehman, “Neoplastic Differentiation: Interaction    of Simian Viras 40 and Polyoma Virus with Murine Teratocarcinoma    Cells,” J. Cell. Physiology, 85:179, 1975. Takebe, Seiki, Fujisawa,    Hoy, Yokota, Arai, Yoshida, and Arai, “SRalpha. Promoter: An    Efficient and Versatile Mammalian cDNA Expression System Composed of    the Simian Virus 40 Early Promoter and the R-U5 Segment of Human    T-Cell Leukemia Viras Type 1 Long Terminal Repeat,” Mol. Cell. Biol,    8:466, 1988.-   Taylor and Kingston, “EIA Trans-Activation of Human HSP70 Gene    Promoter Substitution Mutants is Independent of the Composition of    Upstream and TATA Elements,” Mol. Cell. Biol, 10:176, 1990.-   Taylor and Kingston, “Factor Substitution in a Human HSP70 Gene    Promoter: TATA-Dependent and TAT A-Independent Interactions,” Mol.    Cell Biol, 10:165, 1990.-   Taylor, Solomon, Weiner, Paucha, Bradley, and Kingston, “Stimulation    of the Human Heat-Shock Protein 70 Promoter in vitro by Simian Vims    40 Large T Antigen,” J. Biol. Chem., 264:15160, 1989.-   Tavemier, Gheysen, Duerinck, Can Der Heyden, and Fiers, “Deletion    Mapping of the Inducible Promoter of Human IFN-beta Gene,” Nature,    301:634, 1983.-   Thiesen, Bosze, Henry, and Chamay, “A DNA Element Responsible for    the Different Tissue Specificities of Friend and Moloney Retroviral    Enhancers,” J. Virology, 62:614, 1988. Tranche, Rollier, Bach,    Weiss, and Yaniv, “The Rat Albumin Promoter: Cooperation with    Upstream Elements is Required When Binding of APF/HNF 1 to the    Proximal Element is Partially impaired by Mutation or Bacterial    Methylation,” Mol. Cell. Biol, 9:4759, 1989. Tranche, Rollier,    Herbomel, Bach, Cereghini, Weiss, and Yaniv, “Anatomy of the Rat    Albumin Promoter,” Mol. Biol. Med., 7:173, 1990.-   Tmdel and Constantini, “A 3′ Enhancer Contributes to the    Stage-Specific Expression of the human Beta-Globin Gene,” Genes and    Dev., 6:954, 1987.-   Tsumaki et al, “Modular arrangement of cartilage- and neural    tissue-specific cis-elements in the mouse alpha2(XI) collagen    promoter,” j Biol Chem. 273(36):22861-22864, 1998.-   Tur-Kaspa, Teicher, Levine, Skoultchi and Shafritz, “Use of    electroporation to introduce biologically active foreign genes into    primary rat hepatocytes,” Mol. Cell Biol, 6:116-718, 1986.-   Tyndall, La Mantia, Thacker, Favaloro, and Kamen, “A Region of the    Polyoma Vims Genome Between the Replication Origin and Late    Protein-Coding Sequences is Required in cis for Both Early Gene    Expression and Viral DNA Replication,” Nuc. Acids. Res., 9:6231,    1981.-   Uchida, Sutton, Friera, He, Reitsma, Chang, Veres, Scollay,    Weissman, “HIV, but not murine leukemia viras, vectors mediate high    efficiency gene transfer into freshly isolated G0/G1 human    hematopoietic stem cells,” Proc. Natl. Acad. Sci. USA,    95:11939-11944, 1998. Ueda, Tsuji, Yoshino, Ebihara, Yagasaki,    Hisakawa, Mitsui, Manabe, Tanaka, Kobayashi, Ito, Yasukawa,    Nakahata, “Expansion of human NOD/SCID-repopulating cells by stem    cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble    IL-6 receptor,” J. Clin. Invest, 105:1013-1021, 2000.-   Unutmaz, Kewal, Ramani, Marmon, Liftman, “Cytokine signals are    sufficient for HIV-1 infection of resting human T lymphocytes,” J    Exp. Med., 189:1735-1746, 1999.-   Valsamakis, Schek, Alwine, “Elements upstream of the AAUAAA within    the human immunodeficiency viras polyadenylation signal are required    for efficient polyadenylation in vitro;’ Mol. Cell Biol,    12:3699-3705, 1992.-   Valsamakis, Zeichner, Carswell, Alwine, “The human immunodeficiency    viras type 1 polyadenylylation signal: a 3′ long terminal repeat    element upstream of the AAUAAA necessary for efficient    polyadenylylation,” Proc. Natl. Acad. Sci. USA, 88:2108-2112, 1991.-   Vannice and Levinson, “Properties of the Human Hepatitis B Viras    Enhancer: Position Effects and Cell-Type Nonspecificity,” J.    Virology, 62:1305, 1988.-   Vasseur, Kress, Montreau, and Blangy, “Isolation and    Characterization of Polyoma Viras Mutants Able to Develop in    Multipotential Murine Embryonal Carcinoma Cells,” Proc Natl. Acad.    Sci. U.S.A., 77:1068, 1980.-   Wang and Calame, “SV40 enhancer-binding factors are required at the    establishment but not the maintenance step of enhancer-dependent    transcriptional activation,” Cell, 47:241, 1986.-   Watanabe et al, “Gene transfection of mouse primordial germ cells in    vitro and analysis of their survival and growth control,    Experimental Cell Research, 230:76-83, 1997.-   Weber, De Nilliers, and Schaffher, “An SN40 Enhancer Trap”    Incorporates Exogenous Enhancers or Generates Enhancers From its Own    Sequences,” Cell, 36:983, 1984.-   Weinberger, Jat, and Sharp, “Localization of a Repressive Sequence    Contributing to B-cell Specificity in the Immunoglobulin Heavy-Chain    Enhancer,” Mol. Cell. Biol, 8:988, 1984.-   Winoto and Baltimore, “αβ-lineage-specific Expression of the α    T-Cell Receptor Gene by Nearby Silencers,” Cell, 59:649, 1989.-   Wu et al, “Promoter-dependent tissue-specific expressive nature of    imprinting gene, insulin-like growth factor II, in human tissues,”    Biochem Biophys Res Commun. 233(1):221-226, 1997.-   Wu, Wakefield, Liu, Xiao, Kralovics, Prchal, Kappes, “Development of    a novel trans-lentiviral vector that affords predictable safety,”    Mol. Ther. 2:47-55, 2000.-   Yang, Burkholder, Roberts, Martinell and McCabe, “In vivo and in    vitro gene transfer to mammalian somatic cells by particle    bombardment,” Proc Natl Acad Sci. USA, 87:9568-9572, 1990.-   Yutzey, Kline, and Konieczny, “An Internal Regulatory Element    Controls Troponin I Gene Expression,” Mol. Cell. Biol, 9:1397, 1989.-   Zennou, Petit, Guetard, Nerhbass, Mantagnier, Chameau, “HIN-1 genome    nuclear import is mediated by a central DNA flap,” Cell 101:173-185,    2000.-   Zhao-Emonet et al, “The equine herpes viras 4 thymidine kinase is a    better suicide gene than the human herpes virus 1 thymidine kinase,”    Gene Ther. 6(9): 1638-1642, 1999.-   Zufferey, Nagy, Mandel, Naldini, Trono, “Multiply attenuated    lentiviral vector achieves efficient gene delivery in vivo” Nat.    Biotechnol, 15:871-875, 1997.-   Zufferey, Dull, Mandel, Bukovsky, Quiroz, Naldini, Trono,    “Self-inactivating lentivirus vector for safe and efficient in vivo    gene delivery,” J. Virol, 72:9873-9880, 1998.-   Zufferey, Donello, Trono, Hope, “Woodchuck hepatitis viras    posttranscriptional regulatory element enhances expression of    transgenes delivered by retroviral vectors,” J. Virol, 73:2886-2892,    1999.-   Zufferey and Trono, Current Protocols in Neuroscience: unit 4.21:    “High-titer production of lentiviral vectors,” John Wiley & Sons,    New York, 2000.

We claim:
 1. A method for producing a recombinant pseudotyped viralvector particle comprising: (a) transfecting a cell with: (i) at leastone vector construct comprising the sequence of at least one transgene;(ii) at least one packaging construct; and (iii) an expression constructencoding the chimeric glycoprotein encoded by the nucleic acidcomprising the sequence of SEQ ID NO: 1 to yield a producer cell; (b)culturing the producer cell in a medium; and (c) separating the producercell from the medium to recover the recombinant viral vector particlefrom the medium.
 2. A method for transducing a cell in vitro comprisingcontacting the cell with a vector particle made in accordance with claim1 and under conditions to effect the transduction of the cell by therecombinant vector, wherein the transgene is expressed.
 3. The method ofclaim 2, wherein the cell is a human cell.
 4. The method of claim 3,wherein the cell is a hematopoietic stem cell.
 5. The method of claim 4,wherein the cell is a human CD34+ cell.
 6. The method of claim 4,wherein the cell is cultured in the presence of Flt3-L, TPO, and SCF. 7.The method of claim 2, wherein the transduced cell is introduced into ananimal subject.
 8. The method of claim 7, wherein the subject is a humansubject.